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ABSTRACT 
Research in pharmaceutical process development has gained a lot of interest over the last years. 
Long development times, increasing R&D costs, increasing competition, and short patent 
duration are some of the driving forces for the increased research efforts in the field. Increased 
process understanding of the pharmaceutical process has resulted in major improvements in the 
field. Process systems engineering (PSE) approaches, which have been successfully applied in 
the design, analysis and optimization of chemical and petrochemical processes, might be also 
important for the improvement of pharmaceutical processes by providing systematic and 
structured solutions for the stages of the pharmaceutical process development.  
In this PhD thesis, the objective is to systematize the pharmaceutical process development in 
order to enhance process understanding by creating a data-rich environment and to 
investigate/evaluate opportunities for continuous operation. To achieve the mentioned 
objectives the use of an integrated framework based on systematic model-based methods and 
tools is proposed. Computer-aided methods and tools are used to generate process knowledge 
and to evaluate different operational scenarios.  
The developed framework is divided into four main sections: the reaction pathway, reaction 
analysis, separation synthesis and process evaluation-operation based on evaluation. In the first 
section, the selection of the reaction pathway to produce a desired active ingredient is examined. 
A reaction database for small pharmaceutical molecules, including information for reactions, 
the solvent role and processing information, has been developed to assist the reaction pathway 
selection. In the second section, the reaction analysis, the identified individual reactions during 
the reaction pathway selection are analysed. The objective of the reaction analysis section is to 
collect reaction data and by using model-based methods to investigate possibilities of reaction 
improvement by evaluating the reaction conditions, the operating mode, the solvent role, and 
the reactor design. In the third section, alternatives for the separation of the reaction mixture 
are generated based on the driving force principles and evaluated based on performance criteria, 
such as mass and energy utilization. Finally, the overall process is simulated and evaluated in 
terms of productivity and environmental impact. Process optimization studies are performed by 
defining optimization target based on the process analysis. 
The application of the developed integrated framework is highlighted through four case studies. 
In the first case study, the overall use of the framework is highlighted using the synthesis of 
ibuprofen as a motivating example. The second case study focuses on the application of the 
developed solvent selection methodology for solvent swap problems. The third case study 
focused on multiphase reaction systems and improvements through the combination of 
reaction-separation. Finally, model-based analysis-design is performed for the operation 
improvement of a glucose isomerization plant.   
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RESUME PÅ DANSK 
Forskning i farmaceutisk procesudvikling har opnået meget interesse i de seneste år. Lange 
udviklingstider, øgende F&U-omkostninger, øget konkurrence og korte patentvarigheder er 
nogle af de drivende kræfter for den øget forskningsindsats på området. Øget procesforståelse 
af den farmaceutiske proces har resulteret i de store forbedringer på området. Proces 
systemteknik (engelsk: PSE) fremgangsmåder, som er blevet anvendt med succes i design, 
analyse og optimering af kemiske og petrokemiske processer, kan også være vigtig for 
forbedringen af de farmaceutiske processer ved at give systematiske og strukturerede løsninger 
til faserne af den farmaceutiske procesudvikling. 
De centrale mål i denne afhandling er at systematisere den farmaceutiske procesudvikling for 
at forbedre forståelsen af processerne ved at skabe et data-rigt miljø og at undersøge / vurdere 
mulighederne for kontinuerlig drift. For at nå de nævnte mål foreslås en integreret systematisk 
platform baseret på systematiske modelbaserede metoder og værktøjer. Computerbaserede 
metoder og værktøjer bruges til at generere procesviden og/eller at anvende allerede 
tilgængelige viden til generering af data. Når detaljerede oplysninger for processen er til 
rådighed, kan ændringer forstås og knyttes til procesparametre og endelig forbundet med 
produktkvalitet og / eller andre procesydelseskriterier relateret til at omkostninger, 
bæredygtighed og energi. 
Platformen er opdelt i fire hovedafsnit, reaktionsstien, reaktionsanalyse, separationssyntese og 
processimulering / -evaluering og drift. I det første afsnit, er forbedringer relateret til valget af 
reaktionsveje. En database af reaktioner for små farmaceutiske molekyler, herunder 
oplysninger om reaktionerne, solventrolle og behandling af oplysninger, er blevet udviklet for 
at lette valget reaktionsvej. I det andet afsnit er procesforbedringerne relateret til de enkelte 
reaktioner, som kan forbedres ved at evaluere reaktionsbetingelserne, driftsform, og 
opløsningsmidlets rolle. I tredje afsnit, er alternativer til separationen af reaktionsblandingen 
genereret baseret på den drivkraft principper og evalueres baseret på ydeevne kriterier såsom 
masse og energiudnyttelse. Endelig bliver den samlede proces simuleret og evalueret med 
hensyn til produktivitet og miljøpåvirkning. Procesoptimeringsstudier kan blive udført ved at 
definere optimeringsmålene, som er baseret på procesanalysen. 
Anvendelsen af den udviklede integreret platform er fremhævet i fire forskellige casestudier. I 
det første casestudie, er den samlede brug af platformen fremhævet ved syntese ibuprofen som 
eksempel. Det andet casestudie fokusere på anvendelsen af den udviklede metode til valg af 
opløsningsmidler i et problem om ombytning af opløsningsmidler. Det tredje case studie 
fokuserer på flerfase reaktionssystemer og forbedringer gennem en kombination af reaktion-
separation. Endelig blev en modelbaseret analyse-design metode brugt til driftsforbedringer af 
en reaktor. 
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1 INTRODUCTION 
1.1 Background and Motivation  
Research in the field of pharmaceutical process development for the production of active 
pharmaceutical ingredients (APIs) and drug products has gained a lot of interest over the last 
years, leading to significant advances in science, technology, and engineering. Long 
development times, increasing R&D costs, increasing competition, and short patent duration 
are some of the driving forces for the increased research efforts in the field. The scientific 
community has demonstrated that lower production times, reduced environmental impact and 
increased process safety, while maintaining or increasing the required product quality, can be 
achieved through detailed understanding of the phenomena taking place in the system [1],[2]. 
Implementation of advanced process analytical technologies (PAT) through better process 
understanding has led to improved optimization of pharmaceutical processes [2],[3]. 
Introduction of new processing technologies, the “design space” concept as well as the adoption 
of quality-by-design (QbD) principles have also contributed to pharmaceutical process 
improvements [1],[2],[4].  
The development of pharmaceutical processes starts with the identification of the synthesis 
route that leads to the production of the desired active ingredient. Improvements in the selection 
of the chemical/biochemical pathway might lead to improvements related to the total number 
of reactive steps, the overall reaction yield, reaction selectivity, operation time, waste 
generation, product quality, scalability, separation process, process safety, and economics [5]. 
The improvement in reaction pathway is usually related to the application of different chemistry 
that enables the synthesis of the main product through more efficient synthesis routes. Changes 
in reaction chemistry related to the reagents such as the reducing agent and the solvent, might 
be beneficial for the reaction performance [6], [7]. Other changes related to the catalysts (e.g.  
biocatalysis and biotechnology) can improve the conversion and increase the selectivity 
towards the desired product [5], [6], [7]. Finally, the implementation of new technologies, such 
as flow chemistry and new heating techniques can improve the overall reaction performance in 
terms of operation time, energy required, waste generated and productivity [8]. Given an 
improved chemistry, the reaction process can be further improved through optimization of the 
operating conditions, such as temperature, pressure, stoichiometry, and flowrate [9], [10], [11]. 
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Additionaly, different reactor configurations or reactor types (e.g. continuous microflow) can 
offer significant advantages in the improvement of the reaction processes in terms of 
productivity, process safety, and cost [12]. 
Usually, processes for APIs manufacturing involve many reaction steps [7]. Separation is often 
required between the reaction steps to separate the reaction product from the impurities and 
other reaction compounds (e.g. catalyst, promoters). Selection of the separation tasks and 
sequence of separation task might also offer significant improvements in terms of number of 
unit operations [13], operation time, product quality, sustainability, and energy and solvent 
requirements [14]. 
Batch processing is often applied in pharmaceutical processes due to the slow reaction and 
purification steps using crystallization [2], [15]. In addition batch processes are flexible and 
multipurpose in multiproduct production facilities [1]. However, moving from a batch-wise 
production to continuous pharmaceutical manufacturing can lead to significant process 
improvements as the production can be obtained at lower operational costs, lower energy 
requirements, reduced waste and emissions and in general, lower environmental footprint.  The 
performance of some reactive systems might benefit from the implementation of continuous 
processing as heat and mass transfer limitations, which are crucial for the reaction, might be 
improved [3, 9]. The potential risks of large volumes of hazardous materials (e.g.  volatile 
reactants or solvents) can be avoided using continuous equipment as the reactor head space is 
eliminated [12] and the amount of hazardous materials present in reaction remains low. Another 
important aspect of the implementation of continuous manufacturing is the obtained product 
quality, which does not depend on process dynamics and the differences in product quality 
between batches is minimized [16]. Process variables (e.g.  Temperature, pressure) that are 
directly connected to important process parameters and affect the product quality, can be 
precisely controlled leading thereby to a consistent steady state operation compared to 
uncertainties in batch operations. Regardless of the numerous advantages of continuous 
processing over batch manufacturing, there are some operational challenges related to clogging 
and equipment failure during startups and shutdowns that need to be addressed prior to the 
implementation of continuous manufacturing [7].  
The multistep processes employed to produce pharmaceutical ingredients consists of a 
collection of operational tasks including reactions, separations and purification and most of 
these tasks require the use of solvent or a mixture of solvents to enhance process performance 
[17]. Despite the fact that the use of solvents improve the process performance in terms of yield 
and time, they have the largest contribution to the total used mass per kg of product per 
processing step (process mass intensity metric, PMI), which is translated to large amounts of 
generated waste and high energy requirement for solvent handling [7], [14]. Therefore, during 
the solvent selection needs to consider minimization of solvent minimization, opportunities for 
solvent recycle and improvement of the system needs to be taken into consideration, while for 
the selected solvent, the system performance in terms of yield and operation time [12, 13]. In 
this way, the overall sustainability of the process operation can be improved as the solvent use 
would be minimized, resulting in less energy intensive operations and less waste generation 
[7], [20], [21]. Solvent selection, is therefore, an important part of the pharmaceutical process 
development and different processing concerns for the involved process unit need to be taken 
into account, as the solvent use directly affects the overall process performance in terms of 
economics, sustainability and yield. 
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Process intensification systems that combine reaction and separation steps might have 
significant benefits in the development of pharmaceutical processes in terms of solvent use and 
product loss and ability to operate in the continuous mode [7]. In addition, hybrid operations, 
which facilitate in-situ product (or by-product) removal to shift the reaction equilibrium 
towards the product site, can also be beneficial for the  reactive system as the selectivity towards 
the desired product is increased [22], [23]. Both intensified and hybrid operations have been 
considered in literature, however, the implementation of such new technologies might be 
difficult in a pharmaceutical process because of the high investment risk and the possibility of 
short product lifetime. Nevertheless, investigation to identify possibilities of implementing 
process intensification/hybrid operations and to evaluate different intensified/hybrid operations 
are required to demonstrate their benefit in pharmaceutical product manufacturing. 
The evaluation of pharmaceutical processes in terms of sustainability, energy consumption and 
economics gives useful insights and a better understanding of the operation issues of 
pharmaceutical processes [14]. This evaluation enables the comparison of different reaction 
pathways [24], different unit operations for the same separation task and technologies [25], 
employing different chemistries, processing steps and reagents [6]. 
Process systems engineering (PSE) approaches, which have been widely used in other 
industries for process development, can assist in the development, analysis, design, evaluation, 
and optimization of pharmaceutical processes [26]. The adoption of PSE approaches can be 
very useful in assisting with the complex problem of pharmaceutical process development by 
decomposing the problem into smaller sub-problems that are easier to solve. The obtained 
knowledge from the solution of the individual problems is usually used to supplement 
experimental data in order to improve the decision-making process or to shift the direction of 
experimental studies in order to reduce their overall time and cost required [26],[27].  
1.2 Objectives 
The objectives of this PhD thesis are to: 
 Develop an integrated systematic framework that creates a data-rich environment to 
enhance the process understanding and to investigate opportunities for implementation of 
continuous manufacturing in the pharmaceutical processes. The objective of the developed 
framework is to improve the development of primary pharmaceutical processes for the 
production of small pharmaceutical molecules in terms of overall process performance, product 
quality and sustainability using systematic model-based methods.  
 Analyse each step of pharmaceutical process development starting from the selection 
of the synthesis path, to the analysis of each individual reaction, the development of the 
separation process and overall process evaluation/optimization.  
 Develop systematic methods and tools to support the framework for process knowledge 
generation.  
 Highlight the applicability of the developed framework through different case studies 
representing different problems that are found in pharmaceutical processes such as reaction 
pathway selection, reaction analysis, and solvent selection, batch to continuous, separation 
process development, process intensification, process evaluation, and operation.  
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1.3 Thesis Structure 
The thesis has been divided into 6 main chapters: 
Chapter 1. Introduction 
Provides the main motivation, the background and the main objectives of this project. 
Chapter 2. State-of-the-art pharmaceutical process development 
Provides a review of the state-of-art for pharmaceutical process development. The chapter 2 is 
divided in three main sections: process modelling in pharmaceutical process, process synthesis 
of pharmaceutical process and batch to continuous processing. At the end of the chapter 2 
conclusions are made to identify the research gaps in the field of pharmaceutical process 
development.  
Chapter 3. Framework for pharmaceutical process development: methodology 
Proposes a systematic integrated framework with the objective to assist the pharmaceutical 
process development by enhancing the process understanding at early stage of API 
development. The framework is a step-by-step procedure that assists to solve different 
synthesis/design problems by using systematic model-based methods. 
Chapter 4. Framework for pharmaceutical process development: supporting methods and tools 
Describes the methods and tools that are necessary for each step of the framework. Methods 
and tools that have been developed in this work are discussed in detail while other methods and 
tools that have been developed by other researchers are briefly described.  
Chapter 5. Case studies 
Describes the applications of the framework to four case studies. The first case study is focused 
on the application and verification of the developed framework through the conceptual example 
of the ibuprofen synthesis. In the second case study, a solvent selection problem is considered, 
solvent swap selection in pharmaceutical processes, where the application of the developed 
solvent swap methods has been highlighted through different examples. The third case study 
deals with reaction analysis and reaction-separation intensification of an enzymatic process and 
finally, the last case study deals with process improvement of a biochemical process using 
model-based methods.  
Chapter 6. Conclusion and future perspectives  
Describes the main conclusions and achievements of this project and give the future 
perspectives of this work. 
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2 STATE-OF-THE-ART: PHARMACEUTICAL 
PROCESS DEVELOPMENT 
The main research advances in the field of pharmaceutical process development are related to: 
development of new reaction paths (which enable continuous flow synthesis), development of 
new technologies (to support the implementation of the continuous manufacturing), 
implementation of model-based approaches for analysis and system evaluation, the adoption of 
quality-by-design (QbD) paradigm for pharmaceutical development and the advances in 
process analytical technology (PAT) for design, analysis, and control. This chapter focuses on 
reviewing the state-of-art of pharmaceutical process development and covers key subject areas 
such as process modelling, process synthesis and batch to continuous manufacturing. At the 
end of the chapter, conclusions for the key research areas are made. 
2.1 Review on process development-pharmaceutical processes 
The chemical production, including agrochemical, biochemical, fine chemical and 
pharmaceuticals products is based on multistage-multipurpose batch/continuous production 
systems that involve multiple processing steps [25]. During early stages of the process 
development, processes have to be analysed and understood in order perform improvements in 
terms of productivity, time, cost, energy, safety, product quality, and sustainability. 
In this project, the focus is shifted towards the process development of active pharmaceutical 
ingredients (APIs and NCEs (new chemical entities) small molecules MW<1000) during early 
stage of drug/process development which are produced via chemical or biochemical synthesis. 
In Figure 2.1, a simple process diagram for a pharmaceutical manufacturing process is 
illustrated. The process has two main parts: the primary production, where the API is 
synthesized and isolated in high purity and the second part, the secondary production, where 
the API is mixed with the excipient to formulate the final drug product (e.g.  tablets or liquid). 
During the primary production, operations such as reactions, separations, and product 
purification steps are taking place. The reaction pathway (chemical and/or biological) from 
commercially available reagents to an API might require multiple reaction steps, from which, 
all or some of them might require separation (such as distillation, liquid-liquid extraction, 
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filtration, or membrane separation), and purification steps (such as crystallization and drying) 
[7]. Each production step during primary production might require different compounds such 
as organic solvents and catalysts [6]. The secondary pharmaceutical production consists of unit 
operations such as blending, granulation, and drying and drug formulation of the final product 
[28].  
 
 
Figure 2.1. A typical process diagram for the manufacturing of pharmaceutical products. Process 
representation was inspired by Cervera et al. [26]. 
 
In this chapter, the state-of-art for key aspects of pharmaceutical process development such as 
process modelling, process synthesis, and batch to continuous manufacturing are described in 
detail. Then, common process synthesis/design problems of interest for pharmaceutical process 
are further identified and discussed. Finally, the implementation of a systematic model-based 
systematic approach as a solution approach is presented. 
2.2 Process modelling in pharmaceutical processes  
Mathematical models of different types and forms have an important role in process/product 
development, process design and operation, evaluation, and analysis. Models can improve the 
process understanding, supplement the available knowledge with new data and reduce the time 
of expensive experiments and the cost for development of a new products [27] [29]. Gernaey 
and Gani [27] presented a model-based systematic approach where the need of integrated 
model-based methods are needed in pharmaceutical process/product development is 
highlighted. This approach requires the use of tools such as databases (database of model 
parameters and database of chemicals), model library with predictive and process models, 
modelling tools to solve mathematical models and simulation tools for product and process 
design. Mathematical models, which are dynamic, can be efficiently used to capture the process 
behaviour in different operational strategies and to assist the implementation of the control 
strategy with the minimum requirements of resources. Process modelling has been applied to a 
Reaction (i) Work up (i) Isolation (i)
Drug 
formulationRaw Materials
Drug substance 
synthesis (API) Final Product
Blending Granulation Drying Milling Tablet compaction/ coating
Excipients
i: denotes the number of synthesis steps of a multistep reaction 
Typical pharmaceutical  manufacturing process
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large number of examples related to pharmaceutical production [30]. These modelling efforts 
have been reviewed with respect to different unit operations involved in pharmaceutical 
processes.  
2.2.1 Primary production 
2.2.1.1 Reaction operations 
The chemical synthesis of pharmaceutical active ingredients is a complex process, which 
depends on the operation reaction conditions such as pressure and temperature that have been 
selected in a way such that the reaction performance is optimized. The optimization and the 
design of the reaction process requires detailed understanding of the phenomena, which govern 
the process. To enhance the reaction process understanding and to improve systematically the 
reactions, mathematical models that can capture the important phenomena in the reactive 
system can be used. For modelling the reaction, a model for the reaction mechanism as well as 
a model for the reaction kinetics needs to be developed. In the literature, many kinetic studies 
have been published for different reaction mechanisms and processes. Recently, Grom et al. 
[31] developed a kinetic model for the production of Lorcaserin from 1-(2-bromoethyl)-4-
chlorobenzene and allylamine via a two-step benzapine heterocyclic synthesis. The study 
considers other reactions that take place in parallel with the main reaction and are the sources 
of by-products and impurities. Based on the kinetic model, process optimization was performed 
with the objective to improve the reaction and the separation/purification performance [31].  
The kinetics of hydrogenation of 4-isobutylacetophenone to produce p-isobutyl phenyl ethanol 
(an intermediate of ibuprofen synthesis) has been widely studied to optimize the reaction 
variables to improve the selectivity of the reaction towards the desired product by several author 
considering different type of catalysts, Ru/Al2O3 [32], Pd/SiO2 [33], [34], and 10%Ni/Y (Y: 
zeolite catalyst) [35]. Many more studies involving the development and the use of kinetic 
models to improve the reaction performance have been reported in the literature: models for 
carbonylation of p-isobutyl phenyl ethanol to ibuprofen [36]-[37]; for multiphase reactions 
[38]-[39] , biocatalytic processes [40]–[43]. The comparison of continuous and batch reactors 
employing model-based methods has been studied. Tadepalli et al. [44], has compared the 
performance of a catalytic reactor for the hydrogenation of o-nitroanisole in microreactor and 
semi-batch reactor. The purpose of the study was to investigate the kinetics of the two systems 
and to determine the mass transfer coefficients. Based on the analysis, a guide to determine the 
type of reactor for the kinetic study has been proposed [44], [45].   
2.2.1.2 Crystallization operation 
Crystallization is a very common operation in pharmaceutical processes during the primary 
production as it is designed to obtain crystals of high purity, with controlled shape, size, and 
polymorphic form. Model-based methods have been developed and validated by several 
researchers considering different operational scenarios and applications with the objective to 
optimize the variables related to product quality. Samad et al. [46] developed a general 
systematic model-based framework for study of batch cooling crystallization processes. The 
developed framework allows the study of different chemical systems and different crystallizer 
operation phases considering different phenomena taking place in the system. Aamir et al. [47] 
proposed a hybrid model-based approach for the design and control of batch cooling 
crystallization operation. Through the validated population balance model, the effect of the seed 
recipe on the crystal size distribution (CSD) has been quantified. Therefore, desired crystal 
shape distributions can be predicted  by identifying the optimal seed recipe for batch cooling 
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crystallization operation using model-based optimization [48]. Alvarez et al. [49] investigated 
the size distribution of crystals of different APIs in a continuous plug flow crystallization 
operation to evaluate the mixing effect as a function of the number of the antisolvent addition 
points in the crystallizer. Su et al. [50] applied a systems approach for the optimal design of 
antisolvent addition point in a continuous plug flow crystallizer as a function of crystal size 
distribution. A population balance (PBE) model was developed for the plug-flow crystallization 
process considering the kinetic expressions for crystal growth, nucleation, and mass balances. 
The process parameters were regressed using available experimental data and the model 
validated [49], [50]. Quon et al. [51] experimentally studied a reactive mixed suspension mixed 
product removal (MSMPR) crystallizer for the production of aliskiren hemifumarate. A 
population balance model including growth and nucleation kinetics and mass balance equation 
was also developed and validated. Further, the model has been used for purity and yield 
optimization studies of crystallization operation where the crystallizer is a part of a continuous 
pharmaceutical drug manufacturing pilot plant. Ferguson et al. [52] compared the performance 
of batch crystallizers, MSMPR, and MSMPR by incorporating a membrane, which selectively 
concentrates the API in the mother liquor after the first stage of the MSMPR operation during 
crystallization of cyclosporine. The use of a hybrid configuration improved the performance of 
the process in terms of yield and purity compared to the batch operation and at the same time 
possibilities of product contamination were minimized [52]. Zhang et al. [53], investigated the 
effect of the antisolvent addition on final crystal properties in a two stages MSMPR crystallizer 
by developing a PBE model based on the experimental data to optimize the crystal purity and 
yield with respect the operation conditions (temperature and residence time). The developed 
crystallization models have been used in many application, such as, use of predictive control of 
the polymorphism phenomenon during the batch crystallization operation [54], to investigate 
scale-up aspects of continuous and batch crystallization operation [55], and for the evaluation 
of batch to continuous (MSMPR) crystallization operation with respect to their design (start up, 
superasutration) and control [56]. In Figure 2.2, different types of crystallizers are illustrated, 
the traditional cooling batch crystallizer (Figure 2.2a), the plug flow crystallizer with multiple 
antisolvent point addition (Figure 2.2b),  a two stages mixed suspension mixed product removal 
(MSMPR) crystallizer without recycle (Figure 2.2c) and an oscillatory baffled crystallizer. 
 
(a)  
(b)
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(c) 
(d)  
Figure 2.2 Different operational crystallzation modes published in literature. (a) Batch cooling 
crystallizer [46], (b) plug flow crystallizer [49], (c) mixed suspension mixed product removal 
(MSMPR) crystallizer without recycle [57] and (d) oscillatory baffeled crystallizer [58].  
 
2.2.1.3 Property prediction models 
Property prediction models are required for the prediction of pure compound properties and 
mixture properties of compounds and mixtures. For the prediction of pure compound 
properties, group contribution models [59], [60] are employed, while for the prediction of the 
VLE and LLE mixture properties UNIFAC [61] model can be used. For solubility or SLE 
calculations, models such as NRTL-SAC [62] and PC-SAFT [63] can be used. The 
thermodynamic models are important for the analysis and design of the unit operations. For 
example, to design a solvent-based crystallization unit, solubility calculations are needed to 
evaluate the crystallization performance for different solvents. Therefore, predictive models are 
useful for synthesis and design of pharmaceutical processes as different process alternatives 
can be evaluated without the need for extensive experimental work [20], [64], [65] . 
2.2.2 Secondary production 
2.2.2.1 Blending operation 
Adam et al. has shown that high process understanding can be achieved by using discrete 
element method (DEM) for blending operations [66]. Boukouvala et al. investigated the 
blending process by using PBE/DEM and data driven models and showed that these models 
can be used for process synthesis, optimization and control of a continuous blending process 
[67]. Barrasso et al. developed a PBE model validated with experimental data for mixing 
operation in order to predict the quality of the final product [68]. 
2.2.2.2 Drying operation 
The drying operation is usually performed after the wet granulation step to remove the solvent 
from the wet granules. The selection of the drying process can affect the properties of the 
powder product, such as, porosity, density and shape distribution [69]. Drying technologies are 
classified in terms of supply of the thermal heat to the system, such as convection, conduction 
and vacuum. Fluidized bed drying (convection drying technique) has been modelled as a 
motionless droplet consisting of two parts, a wet porous particle surrounded by a water layer at 
the surface and a crust region when the water has been removed from the droplet [70]. A 
theoretical model has been developed by Mezchericher et al. [70] and it has been used by 
Mortier et al. [71] for model identification/discrimination. In comparison of microwave-
vacuum drying to fluidized bed drying, the granules had lower level of porosity, higher bulk 
and tapped density, retained the spherical shape, and the mean particle size was lower for longer 
Modeling and synthesis of pharmaceutical process: moving from batch to continuous 
 
28 
 
operation time. Overall the performance of these two different operation techniques is 
comparable [72].  
2.2.2.3 Tablet compaction  
Boukouvala et al. [73] developed a dynamic model for continuous pharmaceutical tablet 
manufacturing through a continuous wet granulation process. The total model of the process 
was based on a combination of mechanistic models, population balance models, empirical 
models and correlations along with the available process knowledge. The models, which 
described each operation in the process, were combined in a process line, which was simulated 
for different design scenarios and disturbances. Boukouvala et al. [74] conducted a model based 
study of continuous table manufacturing in two different cases studies: direct compaction and 
dry granulation. The simulation of both cases studies was coupled with sensitivity analysis to 
identify the important process parameters [74]. The same authors also investigated the 
possibility of simultaneous simulation and optimization combined with black-box feasibility 
analysis of the continuous tablet manufacturing with direct compaction [75]. 
2.2.3 Plant-wide models 
Plant wide dynamics models are also necessary for the study of batch and continuous 
pharmaceutical processes, in order to deal with operational issues such as process evaluation 
for different operational scenario, solvent integration and optimization [20] start-up, shut down, 
changing in production lines and dealing with arising problems [26]. A plant-wide steady state 
model containing micro-reaction and micro-separation has been introduced by Gerogiorgis and 
Barton [76]. The proposed model describes a process consisting of four reactive steps and three 
separation steps where economics and the environmental aspect were evaluated and compared 
with a conventional batch process [76]. Barton et al. [16] developed a plant wide control 
strategy based on a plant-wide dynamic model [77] for a continuous pharmaceutical pilot plant 
that has been used to investigate the parametric sensitivities for the evaluation of control 
structures. The developed dynamic model describes the production of API in two reactors, the 
purification of API (liquid-liquid extraction, crystallization, reactive crystallization, wash-
filtration, flash evaporator) and the production of the final drug (mixer, dilution, absorption and 
drying) [77]. Plant-wide steady state simulations have been performed by Jolliffe and 
Gerogiorgis [78], [79] to evaluate process performances of ibuprofen and artemisinin flow 
synthesis. The process development involves kinetic analysis, solvent selection for the 
purification step, and process evaluation in terms of economics [80] and environmental impact 
(E-factor) [78]. A dynamic plant-wide model of an integrated plant describing a purification 
step (API crystallization), followed by filtration and drying process, combined with a powder 
mixing unit has been investigated by Sen et al. [81], the analysis has shown the effect of 
crystallization temperature on the final tablet properties [74]. The analysis can be used to relate 
the critical process parameters of the primary production to the secondary production leading 
to improved integrated process development.  
2.3 Process synthesis in pharmaceutical processes  
For pharmaceutical processes, the process synthesis problem can be classified as reaction 
pathway identification, unit operation selection and sequence, solvent selection and process 
evaluation.  
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2.3.1 Reaction Synthesis  
Organic chemistry has an important role to play in development of synthetic routes for drug 
development during early stage of process development. To pursue chemical research at high 
level, access to chemical information is needed and this can be provided by using knowledge 
databases, experience, literature review and/or computer-aided tools [5], [82]. The retrieved 
data is used for similarity search, reaction data retrieval, synthesis route planning, drug 
discovery and prediction of physicochemical properties [83]. The development of methods, 
algorithms and tools to systematize the data collection and the data retrieval of chemical 
information and to assist the solution to many problems related to the synthesis problem in 
organic chemistry has been started a long time back, around 1970s. The methods and tools for 
reaction synthesis are based on retrieving chemical information organized in chemical reaction 
databases where data for individual reactions and molecular structural information for 
compounds involved in the reactions are stored. 
Computer-aided tools have been developed to solve problems related to “synthesis” and 
“retrosynthesis”. The focus of these tools is to generate a number of possible chemical synthesis 
paths for possible precursors (synthesis tree) to achieve the synthesis of a given target 
compound. In retrosynthesis, the process of generating the possible pathways starts from the 
given target compound, and by going backwards the reactions needed to synthesize the target 
compound are identified. In addition, the reactions needed to produce the reactants of identified 
reactions are generated. The process is continued until commercial available reactants are 
identified. These approaches are based on heuristics and logical rules and all of them rely on 
knowledge databases [84]–[88]. Recently, computer-aided tools that are based on algorithmic 
approaches have been developed, such as The Route Designer, [10] which automatically 
extracts rules that capture the essence of the reactions in the chemical reaction database [89]. 
The tool ICSYNTH utilizes a graph-based approach with available data from literature to 
generate the reaction rules [90]. Many other computer-aided methods and tools for reaction 
synthesis have already been developed with different characteristics [89], [90]. For example, 
tools to perform combinatorial searches, to screen generated alternatives based on information 
retrieved from knowledge databases and to perform extensive reaction assessment calculations 
[91]–[95] 
Searching for reactions and retrieving relevant information is a complex problem because it 
involves searching for chemical structures (complete or partial), transformation information 
(reaction centers), description of the reactions (reaction type, general comments) and numerical 
data such as experimental reaction data (including conversion, yield, selectivity, reaction 
conditions etc.). Reaction databases help to organize, store and retrieve data continue to be 
developed since the beginning of the 20th century (Houben-Weyl [96] and Theillheimer [97]). 
Since then, the field of reaction databases has evolved and databases such as CASREACT [98], 
ChemReact [97] and REAXYS (previously Beilstein plus Reactions) [99] are well-known 
[100]. 
General Databases: In this type of databases, the information included is dedicated to organic 
reactions and synthetic methods in general. 
 
The CASREACT reaction database [98] started in 1840 and since then more than 74.9 million 
reactions have been added and it is updated daily. The information is related to organic 
synthesis, including organometallics, total synthesis of natural products and biocatalytic 
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(biotransformation) reactions. This database can be used to provide information on different 
ways to produce the same product (single step or multi-step reactions, uses or applications of a 
particular catalyst and many ways to carry out specific functional group transformations. The 
REAXYS reaction database [99], which is based on data from Elsevier’s industry leading 
chemistry databases (CrossFire Beilstein, CrossFire Gmelin and Patent Chemistry Database), 
includes more than 40.7 million reactions from 1771 to the present. It includes a huge number 
of compounds (organic, inorganic and organometallic) and experimental facts (yield, solvents 
etc.). It is searchable for reactions, substances, formulas, medical chemistry, literature, and data 
such as physico-chemical data, spectra, natural product, and is searchable. Finally, the 
REAXYS database can be used for synthesis route planning. The Current Chemical Reaction 
(CCR) database [101] includes over one million organic reactions together with reaction 
diagrams, critical conditions and bibliographic data. The Reference library of synthetic 
methodology (RefLib) covers reaction data from 1946 to 1992. The database contains 
information from different sources and the latest version has a comprehensive heterocyclic 
chemistry database [97].  
The ChemReact reaction database [97] is a closed database that covers time period from 1974-
1998 and includes over 3.5 million reactions. It is searchable for reaction types and provides 
information for the reaction transformation classified by type of reaction and relevant data 
(bibliographic, spectra and yield). Chemogenesis is a web-book [102], dealing with chemical 
reactions and chemical reactivity. It examines the rich science between the periodic table and 
the established disciplines of inorganic and organic chemistry. The Organic Synthesis database 
[103], includes more than 6,000 organic reactions, and is searchable by reaction type or the 
structure of the compounds and it provides information for single and multi-step organic 
reaction together with reaction compound, conditions and description. The Reaction database-
Chemical Synthesis [104] enables the user to find reactions related to reagents or target products 
and it also provides information with necessary details for the reagents. The Synthetic Pages 
reaction database [105], covers 292 reactions and provides information for the optimized 
reaction procedure. It is searchable by reaction type and/or the structure of the reagent or the 
target product. The Chemical Thesaurus reaction database [106] contains 4,000 reactions 
classified as organic, inorganic, organometallic, transition metal and biochemical. 
The WebReaction reaction database [107] covers over 400,000 reactions, it can be searched by 
defining the structure of the reactant and the product and it performs search based on the 
reaction similarity with focus on reaction center. The Science of Synthesis database (previously 
Houben-Weyl) [96] contains information for organic and organometallic reactions with 
detailed experimental procedures, methodology evaluation and discussion of the field. Finally, 
the SPRESI reaction database [108] covers 4.6 million reactions and it enables searching of 
structures, references and reactions. 
The Synthetic Reaction Updated (previously Methods in Organic Synthesis) covers many 
organic reactions (in graphical form) and is searchable by reaction type [109]. 
 
Specialized databases: Databases, which are specialized in one class of reaction types. 
 
The ChemInform reaction database [100], includes more than 2 million reactions, including 
organic, enzymatic and microbial reactions. The available data in the database can be used for 
the application of new reagent and catalysts as well as for the preparation of natural and 
pharmaceutical products. Other aspects that are covered from the ChemInform database include 
synthetic procedures, enantio-and diasteroselective syntheses and new protection/de-protection 
procedures. The Biotage Pathfinder reaction database [110] is specialized in the verified 
methods for microwave synthesis.  
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The e-EROS (Encyclopedia of Reagents for Organic Synthesis) [111] focuses on the reagents 
and catalyst use in organic synthesis. The FlowReact Search [112] covers a range of over 2000 
flow chemistry reactions adapted from publications on pharmaceutical, fine chemical and 
biotech companies. The Protecting Groups reaction database [113] provides information for the 
protecting, de-protection and trans-protection methods, stability, liability and reaction 
conditions and includes up-to-date information. Recently, a reaction library focused on generic 
reactions (88 reactions, ~ 20,000 reactants) with high reliability and reasonable yield has been 
developed by Masek et al. [114]. The objective of this library is to provide information for 
synthetically feasible design ideas for de novo drug design. 
Representing chemical reactions in a structured way is a complex task. The reaction information 
contained in a database needs to fulfil several criteria and needs to be categorized with respect 
to their searchable reaction information. The criteria that a reaction database should fulfill are 
[97]: 
i. Each reactions is an individual record in the database (detailed and graphical) 
The reaction must be able to be retrieved from the database as a detailed record (reagents, 
products, stoichiometry etc.). It can also be extracted as a graphical representation where the 
reaction scheme is shown. In many databases, the reaction has been presented in a graphical 
form. 
ii. Structure information for target product as well as substrates 
iii. Reaction centers  
The reaction center of a reaction is the collection of atoms and bonds that are changed during 
the reaction [83] 
iv. Reaction compound must be searchable 
Information for the compound involved in reactions such as reagent, catalysts, solvents etc.  
v. Multistep reactions  
In case of multistep reactions, all reactions (individual and whole pathway) must be searchable 
vi. Reaction conditions 
Conditions such as pH, temperature, pressure etc. should be searchable by exact and a suitable 
range of values 
vii. Reaction classification  
The type of reaction (e.g.  esterification) should be searchable 
viii. Post-processing of the database contents 
Export of the retrieved reaction data in other tools (e.g.MS Excel) 
 
In Table 2.1, existing reaction databases are listed and have been classified based on the 
different criteria, also the number of reactions, as well as online sources have been listed. 
Table 2.1 Database review, all the databases have been summarized with respect to the number of 
reactions and the focus of the database. The database information has been retrieved in July 2016.  
Database Number of reaction  Criteria [97] Reference 
CASREACT >74.9 million (1840-present) i, iv, v, vi [98] 
REAXYS ( previously 
CrossFire Beilstein) 
40.7 million (1771-present) i, ii, iv, vii  [99] 
Theilheimer >72200 (1946-1980) i, v, vi, vii  [115] 
ChemInform RX >2 million (since 1990-present) i, iv, vi,  [100] 
Current Chemical 
reactions 
1,083,758 
(1840-present) 
i, vi [101] 
Methods in Organic 
synthesis 
33,000 (1999-2014) i, vii [109] 
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Reference library of 
synthetic methodology 
209.800 (1946-2001) i [97] 
ChemReact 3.5 million reactions (1974-
1998) 
i, vii [97] 
Chemogenesis - ii, iii [102] 
Organic synthesis  >6000 (1921-present) i, ii, v, vi, vii [103] 
Reaction Database-
Chemical Synthesis 
- i, ii,  [104] 
Synthetic Pages 292 i, ii, vi, vii [105] 
The chemical thesaurus  4,000 i, ii [106] 
WebReactions >400,000 i, ii, iii [107] 
Biotage Pathfinder  >1,000 i, vi, vii, viii 
(reaction 
assisted with 
microwave 
technology) 
[110] 
e-EROS Encyclopedia of 
Reagents for Organic 
Synthesis 
>70,000 (4,000*) i, ii [111] 
FlowReact Search  >2000 i (reaction in 
flow) 
[112] 
Protecting groups - i [113] 
Science of Synthesis ( 
previously Houben-
Weyl) 
240,000 
(early 1800s-present) 
i, ii, iii [96] 
SPRESI  4.6 million i, ii, iii [108] 
 
Many reaction databases have been developed over time, some of them have a large number of 
reactions available and others smaller number; some of the databases cover the whole range of 
the organic and/or inorganic reactions; but also there are reaction databases that cover 
additional specialized reactions such as solid reactions, flow reaction etc. It can also be seen, 
that most of the databases cover the most important criteria as they have been defined by Zass 
[97] such as the need for individual reaction records (criterion i, in Table 2.1) and other criteria.  
2.3.2 Unit operation selection and sequence  
For the development of pharmaceutical processes, decisions in the early stage of their 
development that establish an appropriate synthetic route for an API is an important feature for 
industrial-scale process [5]. However, once the synthesis route has been established and 
reaction optimization has been performed, the type and the sequence of unit operations have to 
be determined for efficient production of the APIs. Not many studies in the literature are dealing 
with the generation of separation alternatives in pharmaceutical processes as the focus is usually 
on the synthesis pathway development. However, many studies have been published dealing 
with improvements on separation techniques for certain mixtures. Recently, Cervera-Pardell et 
al. [116], proposed a framework based on PSE methods and tools to retrofit batch 
pharmaceutical processes and to convert them to the continuous mode with special emphasis 
on solvent selection, reactor design and separation processes. In this study, a liquid-liquid 
separation operation of a biphasic mixture was replaced by a hydrophobic membrane, which 
demonstrated better process performance. The membrane operation indicated that the driving 
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force for the separation is based on surface tension. Therefore, by the use of the identified 
membrane it was possible to separate two phases continuously and to reduce the number of the 
unit operations. A solvent exchange, a solvent-based crystallization and a drying operation were 
avoided due to the improved liquid-liquid separation [13]. A synthesis tool for separation 
processes based on heuristics and simulation information developed by Morao et al., was used 
to generate separation alternatives for the purification of an API [117]. Wong et al. [118] 
summarized the design approaches for continuous cooling crystallization processes with 
recycle for cyclosporine and a continuous antisolvent-cooling crystallization process for 
deferasirox. A continuous crystallization model based flow-sheet was simulated by Hsieh et al. 
in order to reduce the mean size of API crystals [119]. Moreover, the recovery of isoflavones 
via absorption and membrane-based separation was simulated by Kawachale et al. [120]. The 
simulations were based on published experimental data and different scenarios were tested and 
economic evaluation was performed for each scenario [120]. The purification of API and the 
mixing with the excipient(s) was investigated by Sen et al., the operations: crystallization, 
filtration, drying, and mixing represented the process. DEM and PBM were coupled in order to 
describe the process, and the process was optimized in order to identify the optimal operation 
conditions [81], [121]. Synthesis of a batch process for tablet manufacturing was also studied 
by Papavasileiou et al. [122].  
2.3.3 Solvent Selection  
Pharmaceutical products are usually produced via multistep organic reactions where in most 
cases the use of solvents is required to improve the reaction efficiency [123] and to assist with 
separation and final purification of the product [7]. The importance of solvent selection for 
multistep organic reaction systems for greener manufacturing is indicated by Foli et al. [124] 
and Gani et al. [125] where reaction tasks are employed to convert specific raw materials to 
desired products (for example, active ingredients or intermediates) through defined reactions. 
Solvents have an important role to play in reaction tasks as they can promote the reactions in 
terms of yield, selectivity, and mass efficiency. For example, solvents can serve as reaction 
mediums, as carriers for the solute, as creators of phase splits, as cooling/heating agents [126]. 
Solvents are also usually employed for the purification and recovery steps of the APIs 
(crystallization task). Here also, solvents have an important role to play as the selection of an 
appropriate solvent can define the success of the crystallization task. For example, solvents can 
be made to affect the solid solubility curves such that the product recovery is increased [127] 
or to obtain the shape of the solid crystals [128]–[130]. The extraction tasks are usually 
performed after a single-phase reaction task when two phases are created by the addition of a 
solvent to separate a product from the reactants or to recover the product from another solvent 
in cases of temperature sensitive solutes. Therefore, solvents are used in the extraction tasks to 
enhance the partitioning of compounds between two phases and thereby increase the product 
yield. Finally, the washing tasks are applied to remove water-soluble impurities (e.g. salts). 
Here solvents that can dissolve the solute but are immiscible with water are used to trigger a 
phase split with an aqueous (reaction) phase. 
A general systematic procedure for solvent selection to identify solvents for different unit 
operations has been proposed by Gani et al. [17].  
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2.3.4 Process Evaluation 
Energy optimization during early stage design has been highlighted by Jimenez-Gonzalez and 
Overcash [14] by demonstrating the potential benefits on the operating cost and environmental 
impact during early stage design of the process to produce steraline. The process to produce the 
steraline consists of four steps and two steps using different solvents were considered [14]. 
Economic analysis of a batch and alternative continuous processes for the production of an API 
in pilot scale was performed by Schaber et al. [131]. The economic analysis was based on 
different scenarios including intermediate cost, different configuration of the continuous 
process, recycle loops and different ways for tablet compaction (roller or direct). The economic 
analysis had shown that in most of the cases, continuous processing is more profitable (up to 
44% depending on the operational scenario) compared to batch process [131]. 
Sustainability evaluation must be performed during early stages of process development [132] 
and before the approval of the regulatory bodies as the re-approval of the process can be a very 
expensive process [116]. Constable et al. [133] reviewed the possible use of “green” metrics in 
order to enhance the awareness of the generated wastes from reaction and to identify 
opportunities for further improvement.  
Recently, life cycle assessment (LCA) for evaluation of the environmental aspects of 
pharmaceutical processes and identification of optimization and intensification targets have 
been used for pharmaceutical processes. Kressirer et al. [134] investigated the green process 
design for Kolbe-Schmitt synthesis using life cycle assessment. The authors considered many 
process alternatives including different energy sources, process conditions, reactive media, 
operation modes, and work up techniques[134]. Ott et al. [135] investigated an API process at 
Sanofi, which involves, two reactions, filtration, washing, a solvent swap and drying 
operations. The authors considered different batch and continuous processing alternatives based 
on optimization targets identified by analysis of the base case. Similar to their previous work, 
Ott et al. [24] have performed life cycle assessment comparing different reaction pathways for 
the synthesis of Rufinamide and demonstrated that process improvements are achieved by 
implementation of continuous manufacturing and solvent integration. Recently, Theoh et al. 
[136] evaluated a pharmaceutical process that involves a two-phase reactive system considering 
three alternatives for the final separation step: a solid-liquid batch operation, a liquid-liquid 
batch operation, and a liquid-liquid continuous operation [136]. The process alternatives have 
been evaluated through experimental procedures and compared in terms of several performance 
criteria such as raw material consumption, waste generation, energy requirements, capital and 
operation cost. It was concluded that continuous processing has demonstrated higher energy 
efficiency, lower VOC emission, better volume efficiency, smaller processing inventory, 
smaller equipment footprint, lower product loss through waste and lower operating cost [136]. 
The development of sustainable greener processes is a challenge for pharmaceutical industries 
[8, 66]. The use of biocatalysis and biotechnology for the production of pharmaceutical 
products seems to be promising [134], [138]. Biosynthetic production of insulin was 
investigated by Petrides et al. [139], batch process was developed following the principles of 
conceptual process design, the process was economically evaluated and a sensitivity analysis 
was performed. Process considerations for the asymmetric synthesis of chiral amines via bio-
catalysis were recently reviewed by Tufvesson et al. [40]. Chiral amines are widely used as 
building block for pharmaceuticals (APIs and NCEs) and they can be produced by chemical 
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and biocatalytic synthesis, however the chemical routes are not efficient enough. On the other 
hand, the biocatalytic synthesis has gained much attention, and the authors describe the process, 
identify the process challenges and describe the strategies used to overcome these challenges 
and describes the thermodynamic, biocatalyst, solubility limitations [40]. Carbamazepine (API) 
crystals were produced via electro-spraying for continuous manufacturing, the study shows that 
the electrospray technology can help in the intensification of pharmaceutical processes and it 
might be able to produce pharmaceutical dosage forms [140]. The concept of microfluids was 
applied by Benasker et al. [141] in order to produce fine chemicals (2 cases studies – chemicals 
produced by batch processes). Different scenarios were tested experimentally and an economic 
evaluation was performed for each one to identify the most economical feasible configuration 
[141]. 
2.4 Batch to continuous processing 
The advantages of continuous manufacturing against batch manufacturing had been extensively 
reviewed by several authors [9]. Several examples of converting batch processes to continuous 
manufacturing have been published and they can be classified in terms of three research areas: 
APIs synthesis, purification of APIs, downstream processes to produce the final form of the 
drug. 
Cervera-Pardell et al. [15] demonstrated the use of a systematic approach how to retrofit a batch 
process for production of API into a continuous process. The study emphasized the importance 
of solvent selection and replacement, reactor design and separation process design. The 
systematic framework guides the process developer to follow a step-by-step procedure that also 
provides the necessary information and the associated methods/tools for decision-making in the 
early stages of process design [15]. The obtained process is then evaluated with respect to its 
efficiency, time, cost, and environmental factors. Then the process can be optimized and 
intensified in order to reduce the cost, the manufacturing time and to increase the productivity 
and the final process flowsheets can be validated either through experiments or simulations. 
Cervera-Pardell et al. converted partially a batch process for the production of an API 
(Zuchlopentixol) to a continuous process [15]. The synthesis pathway consists of four reactive 
steps, a Grignard reaction, a hydrolysis step followed by liquid –liquid extraction, then solvent 
swap from THF to ethanol/water mixture, a crystallization step followed by drying, a hydration 
reactive step, and finally a hydroamination step. The first reactive step was successfully 
converted to a continuous process using a continuous filter reaction [142], [143] to separate the 
formed solids from the liquid reaction mixture. A tubular reactor was used together with a 
liquid-liquid membrane separation to replace the batch reaction and the batch liquid-liquid 
separation. The use of the membrane made it possible to improve the separation performance 
and obtain an organic phase, which does not need further separation/purification [13]. By using 
the membrane operation, the unit operation reduced by three: a solvent swap operation, a 
crystallization operation and a drying operation [15] were no longer needed. The 3rd reactive 
step was accelerated by optimizing the reaction conditions through a kinetic study and 
converted to flow reactor [144]. The final reactive step was accelerated by performing kinetic 
analysis in solvent-free environment and by optimizing the reaction temperature and 
stoichiometry. After the kinetic analysis, the reaction was completed in 4hr instead of 24hr [10]. 
The hydroamination reaction (4th step) was also accelerated using microwave assisted organic 
synthesis resulting in slightly better reaction performance, although the capital and operating 
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cost of microwave equipment is too high [10]. The final process design was validated by 
experiments [116], [10].  
Mascia et al. [145] presented a fully integrated continuous manufacturing plant for the 
production of a pharmaceutical product (API: aliskiren hemifumarate). The integrated 
continuous process contains lower number of unit operations compared to the conventional 
batch process and the overall residence time was one order of magnitude lower in the 
continuous process (47hr) than in the traditional batch-wise process (300 hr) [145]. The process 
integrates the chemical synthesis, purification, formulation and tableting steps, and, the product 
quality was maintained by using an automated control system [145].  
Laporte et al. [12] reported the conversion of 6-Hydroxybuspirone from batch to continuous 
manufacturing. The reaction consists of two steps, a deprotonation step where an enolate is 
formed, and an oxidation step where the 6-hydroxybuspirone is formed. The main driving force 
to convert the batch reaction system to continuous was the extremely low temperatures required 
for the safe operation and high reaction performance. The reaction is taken place at temperature 
below <-25oC as the intermediate product degrades fast in temperatures above the -25oC.  The 
main concern was that the oxidation step is moderate exothermic and it might increase the 
adiabatic temperature by 68oC, which might be dangerous during the operation as a flammable 
solvent and oxygen are involved. A solution to minimize the potential process risks was to use 
a microreactor for the oxidation step because of smaller hold up times, and more efficient heat 
removal. Single-stage and two-stages microreactors were evaluated resulting in conversions of 
65-70% in 2-3min and 85-92% in 5-6min. The productivity of the system was not suitable for 
the scale up [12]. Another system, involving an enolation continuous reactor and counter-
current flow trickled bed reactor was used resulting in higher conversions and lower residence 
times (1 min and 3.5-4 min, respectively). The process was operated in lower temperature 
increasing the process safety and it was possible to scale up by numbering up [12].  
A continuous trickled-bed reactor was also used by Shen et al. [146] to convert the batch 
dehydrogenation of tetrahydrocarbazole in continuous operation. Continuous synthesis was 
enabled in many cases by modifying the chemistry of the pathway (Ibuprofen [147], [148]),  
and using microfluid technologies or by introducing new technologies (photochemical 
transformation, Artemisinin [149]). Many other reaction systems have been used to convert 
batch to continuous reaction systems such as membrane reactors for Heck reaction [150] and 
transamination reactions [151]–[153], fixed bed catalytic reactors for amination reactions 
[154], continuous microreactor for protection reactions [155], azide synthesis reactions [156] 
and synthesis oxindoles reactions[157].  
Mixed suspension mixed product removal (MSMPR) crystallizer [53], [56], [118], [158]–[160], 
oscillatory baffled crystallizer [58], [161], [162] and plug flow crystallizer [49], [50]  have been 
mainly used to convert batch crystallization operations to continuous one.   
2.5 Conclusions  
2.5.1 Synthesis route 
The pharmaceutical process development starts with the selection and development of the 
synthesis route to produce high quality active pharmaceutical ingredients (APIs) that is 
environmental benign, economic viable and has high product yield. The design of the synthesis 
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routes, usually starts from a given target compound and by going backwards, reactions are 
generated until commercially available compounds are identified (retrosynthesis). To assist the 
chemical synthesis problem, detailed reaction databases and computer-aided tools are required 
to create a data-rich environment. With detailed information for different processes available, 
the procedure to identify and optimize the reaction route becomes faster. In addition, process 
knowledge assists with troubleshooting during the development. The connection to parameters 
such as reaction conditions, experimental data and models of criteria like scalability, cost, 
expected yield, green chemistry metrics [133], number of reaction steps, easy of separation, 
safety, can further improve the process understanding and the decision making process. 
2.5.2 Reaction analysis/improvement 
The core of any pharmaceutical process development is the complex chemical transformation 
under specified conditions lead in the synthesis of the active ingredients from commercially 
available compounds. Therefore, the improvement of the individual reactive step is important 
for the overall process performance as it can reduce the operation time, the required separation 
steps, the complexity of the separation steps, the environmental impact and the overall 
operating costs. Different designs (e.g. solvent, solvent role), technologies (e.g. microwaves), 
reactor types (continuous/batch) and operation conditions (e.g. P, T) can be evaluated using 
kinetic studies (experimental- and/or model-based methods) and to assist the decision making 
process such as selection of reaction conditions and operation mode.   
2.5.3 Separation analysis/improvement 
Improvements in the separation process can lead to significant improvements in the operational 
time, mass and energy intensity, the number of unit operations, the operational cost, and the 
environmental impact. Analysis of the mixture to be separated based on thermodynamic 
insights to identify the separation tasks with the maximum driving force and to determine the 
separation sequence [163],[164] is required. Mixture analysis using detailed thermodynamic 
models is necessary to obtain the separation factors, determine the operating conditions and 
finally, to evaluate the process performance of different generated separation alternatives using 
model-based or experimental methods. 
2.5.4 Batch to continuous  
Batch-wise processes are multipurpose and flexible operation, and allow analysing the product 
quality at discrete times. However, as it has been discussed above, implementation of 
continuous manufacturing might be highly beneficial for the overall process performance as it 
might reduce the potential risks, increase the volume process productivity and improve the 
performance of unit operations in terms of time, operation cost, and resources. In 
pharmaceutical processes, the reaction and the purification (crystallization) operations are often 
operated in a batch mode due to slow reactions and high residence times. Therefore, reaction 
and crystallization operations should be analysed in a way to investigate whether or not a 
continuous operation is beneficial and feasible and finally propose a continuous design that 
might be feasible. Then mechanistic dynamic models or experimental studies should be 
performed to investigate the viability of the proposed designs, to evaluate the overall operation 
including startups and the shutdowns and finally propose an efficient control strategy.  
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2.5.5 Solvent selection  
In pharmaceutical processes, solvents have a multipurpose role since different solvents can be 
used in different processing steps, such as chemical reactions, separation and purification, 
during synthesis of active pharmaceutical ingredients (APIs), including its  
purification/isolation. The solvent selection for the individual synthesis, multistep reaction 
steps and separation/purification steps has been widely investigated in literature. In 
pharmaceutical processes, very often, a reaction may take place in solvent-1 (S1) and the next 
processing step (e.g. reaction, crystallization, extraction, or washing) may require a different 
solvent-2 (S2) because the process performance is better in S2 than in S1. Therefore, solvent 
swap (or solvent exchange) is a common and important task in API production line within 
pharmaceutical industry. The solvent selection and analysis for the individual processing 
operation have already been well defined and established by Gani et al. [17], however, a method 
for solvent selection of swap solvents and analysis of their performance has not yet been 
proposed. 
2.5.6 Process evaluation  
The main driving force of pharmaceutical process development is the production of products 
in high purity and high yields, although, process evaluation with respect to energy consumption 
[14], evaluation of environmental metrics [133], life cycle assessment [24], [135] has only been 
applied, to our knowledge, in few examples [136]. The integration of process evaluation 
methods during early pharmaceutical process development different alternatives related to the 
potential synthesis routes, solvent use, operation modes, process flowsheets (or state-task 
networks) and different designs of unit operations can be evaluated. Optimization targets can 
be identified and optimization studies can be performed in a systematic manner. Despite the 
overall process improvement, which can be achieved through evaluation of different 
operational scenarios of a particular process, process evaluation needs to be performed at the 
early stages before the process approval from the regulatory bodies as the re-approval of a 
modified process can be an expensive process.
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3 FRAMEWORK FOR PHARMACEUTICAL 
PROCESS DEVELOPMENT: METHODOLOGY  
In this chapter, the overall integrated framework is presented, highlighting the main objectives 
and the main steps needed for application of the framework. Secondly, the detailed work- and 
data-flows are presented and, finally, each step of the framework is explained in detail. 
3.1 Framework objective 
The objective of the proposed framework is to assist in the development of pharmaceutical 
processes by providing detailed process understanding and identifying opportunities where 
continuous manufacturing might be an option. The developed framework aims at improvements 
in the following areas: reaction pathway selection, reaction analysis, separation synthesis, and 
finally, process simulation/evaluation and optimization. Systematic model-based methods and 
tools are applied in each step of the framework in order to create a data-rich environment that 
is a requirement for enhanced process understanding and finally, [5] to assist in the decision 
making process in each case. The expected outcome of this framework is a sustainable process 
with high product quality and low risk within a design space. An overview of the developed 
framework is illustrated in Figure 3.1 
3.2 Framework architecture 
The framework (Figure 3.1) follows the process development cycle during the early stage of 
drug and process development. It is based on systematically efficient acquisition of process 
knowledge that is generated by the use of systematic model-based methods and tools to provide 
complementary data to the experimental data and/or to assist the experimental studies when 
they are necessary. The developed framework focuses on the process 
development/improvement for the production of small molecules active pharmaceutical 
ingredients (APIs). The process flowsheet (or state-task network) can be developed for new 
APIs where information about the production process is unknown or for APIs that have 
produced before with known or unknown process flowsheet (or state-task network).  
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Figure 3.1 Integrated systematic framework to assist the pharmaceutical process development. 
3.3 Work-flow and data-flow 
Here, the work-flow and the data-flow for each section of the framework are presented and 
explained. The presentation of each section is given as follows: 
1. The overall objective of the section and the reasoning why the specific section is 
needed.  
2. The objective of each step for each section and the reasoning why the step is needed.  
3. The required data for each step.  
4. The generated information after successful implementation of the specific step of the 
framework. 
5. The methods and tools that are required to generate information are explained. 
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3.3.1 Section A: Reaction pathway  
Section Objective: To identify, to design or to propose a reaction pathway that can be used to 
synthesise the desired product (API or an intermediate). 
The reaction pathway is the core of the process development for the pharmaceutical processes 
as it can affect important criteria for the manufacturing process in terms of scalability, 
production time, ease of manufacturing, produced waste, product quality, yield, and cost. The 
detailed work-flow of the section A is illustrated in Figure 3.2.  
Step A.1. Select API or intermediate 
Step Objective: To identify the compound of interest.  
For known compounds, the name and the molecular structure is to be provided, for unknown 
compounds, the molecular structure with the necessary functional groups need to be provided.  
Step A.2. Reaction synthesis pathway 
Step Objective: To identify the reaction pathway. 
During the development of the synthetic routes for the production of an API, chemical 
information is needed which can be provided by reaction databases, experience, literature 
and/or computer-aided tools [5]. The obtained information is used for similarity searching, 
reaction retrieval, synthesis route planning, drug discovery and prediction of physicochemical 
properties [83]. The chemical information is organized in chemical reaction databases where 
information for individual reactions and structural information for different component 
involved in reaction is available. An early evaluation of sustainability metrics [165] (see Table 
4.7), process performance in terms of yield, cost, scalability [12] and/or life cycle assessment 
[24] can be used for the selection of the chemical route.  
 
Figure 3.2 Work-flow, methods and tools and data flow corresponding to Section A for the reaction 
pathway identification. 
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Information obtained: Reaction pathway, Reaction pathway evaluation 
Methods and Tools: Reaction database, literature review, experimentation, LCA tools, and 
sustainability metrics (see Table 4.7). 
3.3.2 Section B: Reaction analysis  
Section objective: To perform reaction analysis for each reaction step in order to enhance the 
reaction understanding and improve the individual reaction performance, to investigate 
possibilities of performing the reaction in continuous mode, to propose the design of the 
reactive system and to define the objectives of the separation if needed (Section B is illustrated 
in Figure 3.3).  
Step B.1. Reaction data collection 
Step objective: To collect all the relevant reaction data in terms of reaction type, compounds 
involved in reaction (e.g. reactants, products, and catalyst), reaction phases and solvent use and 
role, reaction conditions, available data and models, and scale.  
The data is collected to preliminary investigate the compound and the reaction conditions where 
the reaction performance is high. In this step, the solvent role in reaction step is investigated in 
terms of reaction improvements such as productivity, operation time, or post-processing. 
Available data (e.g. experimental points, dynamic data, and kinetic models) are collected to be 
used later to enhance the understanding of the reaction by associating the changes in the 
variables with the reaction performance. 
Required Data: Reactions 
Information obtained:  Reaction compounds (e.g. reactants, catalyst, solvents etc.), reaction 
products, available experimental data. 
Methods and Tools: Reaction type database, experimentation. 
Step B.2. Perform Kinetic Study 
Step Objective: To identify mass and heat transfer limitations, reaction control mechanism, and 
kinetic model. 
Reactions often have limitations such as heat and mass transfer limitation or equilibrium 
limitations. The identification of these limitation help to improve the reaction understanding 
and to identify possible challenges for further improvement of the reaction performance. In this 
step, a kinetic model, if available, can also be used to fit and validate experimental 
measurements. The kinetic model is often retrieved from a model library, but it can also be 
developed considering the phenomena taking place and available experimental data.  
Required Data: Reaction information. 
Information obtained:  Mass and heat transfer limitations, Reaction class, and Reaction control 
mechanism, kinetic model. 
Methods and Tools: Reaction type database, Roberge et al. [166] reaction classification, model 
libraries, modelling methods and tools. 
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Step B.3. Evaluate reaction variables 
Step objective: To evaluate and identify the reaction variables such as temperature, pressure, 
stoichiometry, solvent, which might improve the reaction performance in terms of product 
selectivity, yield, conversion, reaction time, and byproduct formation.  
The reaction variables can be evaluated for different operational scenario. Validated kinetic 
models or experimentation procedures are employed for collecting necessary data and 
understanding the effect of reaction variables to the reaction performance. The solvent use is 
also evaluated in this step, where an optimal solvent can be selected based on the desired 
properties using the solvent selection methods developed by Gani et al. [17]. 
Methods and tools: Reaction type database, kinetic models, model libraries, model 
development methods, experimentation, design of experiments and solvent selection/analysis 
and design methods and tools.  
Required data: Reaction models, kinetic model, experimental data. 
Information obtained:  Reaction conditions, yield, conversion, selectivity, reaction time (or 
residence time), solvent and impurities. 
Step B.4. Batch or continuous operation?  
Step objective: Investigate opportunities for continuous operation. 
In this step, an evaluation based on the information obtained in steps B.1-B.3 is performed to 
identify possibilities for reaction operation in continuous mode. Information obtained for the 
reaction limitations during the implementation of step B.2, together with the reaction evaluation 
results obtained from step B.3 and available knowledge is utilized to investigate possibilities 
for continuous operation.  
Methods and tools:  Unit operation database. 
Required data: Reaction information, mass and heat transfer limitations, kinetics and reaction 
concerns.  
Information obtained:  Benefits of continuous mode, and decisions. 
Step B.5. Reactor design  
Step objective: To provide the reactor design  
The reactor design is a function of the reactor type that has been decided to be used in step B.4, 
for example, if batch reactor has been selected, the volume of the reactor based on the reaction 
conditions to achieve the desired reaction performance is to be calculated. Other concerns such 
as safety, product quality, material, controllability must be also considered in this step. 
Opportunities for process intensification such as combination of reaction and separation are 
investigated and proposed in this step as well. Process intensification for reaction-separation 
systems has been widely applied in industry in the form of reactive distillation, multiphase 
reaction systems with in situ product or by-product removal or controlled released reactants in 
the multiphase reactors, multiphase membrane reactors and multiphase prevaporation reactors.  
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Methods and Tools: Unit operation database, solvent analysis tools, reactor design methods, 
attainable region concepts. 
Required Data: Solvent screening, how separation affects the equilibrium, reaction conditions, 
and productivity. 
Information obtained:  Reactor design, opportunities for process intensification or hybrid 
operation 
Step B.6. Is separation required? 
Step objective: To define the objectives of the separation in case that separation is needed after 
a reaction. 
The last step of the section B is to perform an evaluation on whether a separation of the main 
reaction product of the specific step (when NR<total reaction steps) is required or not for each 
step. First, all the information from the Steps B.1-B.5 is collected for each step, then, the 
reaction mixtures are analyzed in terms of compounds (e.g. reactants, catalyst). Then process 
synthesis rules are applied, for example, if the conversion of the reactant of the reaction step 1 
is not complete and this reactant is inert for the next reaction step then separation of the reactant 
is not needed. Another concern in pharmaceutical processes, is that different solvents might be 
used for different reaction tasks. In the case of reaction in series where solvent 1 (S1) is required 
for the reaction step 1 and another solvent (solvent 2, S2) is required (because S1 is not 
performing well) for the second reaction step, solvent 1 needs to be removed and replaced with 
solvent 2, therefore, a solvent swap operation is needed to remove S1 and replace it with S2. 
Another consideration has to do with the possibility of recycling the unreacted raw materials, 
catalyst or solvent. In this case, it is required to make sure that product contamination is not 
possible and the quality of the product remains high.  
Required Data: Information obtained from the previous steps.  
Information obtained: Separation objectives 
The overall outcome of the reaction analysis section B is illustrated in Figure 3.3 where the 
reaction compound, the reaction operation, and the objectives of the separation are shown. 
 
Figure 3.3 Information obtained from the succesful implementation of Section B.  
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In Figure 3.4, the detailed work-flow, data-flow and methods and tools required for the 
implementation of the Section B are illustrated in detail.  
 
Figure 3.4 Work-flow, methods and tools and data flow corresponding to Section B for the reaction 
analysis. 
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3.3.3 Section C. Separation Synthesis  
Section objective: To determine the type, the sequence and design of the unit operations that 
are required to satisfy the separation objectives, defined in Step B.6 (see Figure 3.3).  
The complexity of the work-up and the final purification is related to the compounds present in 
the final reaction mixture, for example, when the amount of the side-product is low then the 
work-up might be less energy demanding or fewer unit operations might be required. The 
selection of proper separation tasks might improve the process in terms of total unit operations 
needed, minimization of solvent requirement, lower operational costs, and better sustainability 
performance. In addition, due to the complexity of the main product, operational limitations 
have to be taken into account in order to define the design space of the unit operations. 
Step C.1. Mixture analysis 
Step objective: Analysis of all the compounds present in the mixture to be separated. Separation 
tasks identification. 
The objective here is to collect all the required information for the identification of the feasible 
separation tasks that can be used in order to satisfy the separation objectives after the specific 
reaction task. First, the molecular structures of the organic compounds involved in reaction 
mixture are collected. Pure compound and mixture properties are collected using databases or 
property prediction methods (ICAS-ProPred). Finally, the feasible separation tasks are 
identified as it has been proposed by Jaksland et al. (1996) [163] and by Tula et al. [164].  
Required data: Compound, Separation objectives, pure compound and mixture properties. 
Information obtained: Binary ratio matrix, azeotropic information, separation tasks. 
Methods and tools: ICAS platform (CAPEC database, ProPred, AzeoPro), Process synthesis 
methods [163], [164]. 
Step C.2 Generate separation alternatives 
Step objective: Determine the sequence of the unit operations and generate process alternatives.   
After the analysis of the systems in step C.1, the sequence of the separation unit operations can 
be determined by combining the obtained information, with heuristics for process synthesis and 
driving force principles together with the objectives defined for the specific mixture to be 
separated. The result of this step is the generation of separation alternatives that can achieve 
the objectives, and they are represented as SFILES ,which is a text string representation of the 
process flowsheet or state task network [167]. 
Required data: Separation tasks, process information related to the specific case. 
Information obtained: Process alternatives for the achievement of the separation alternatives.  
Methods and tools: Driving force principles [168], Process synthesis methods [163], [164], 
literature. 
Step C.3. Separation process selection 
Step objective: Selection of the most promising alternatives. 
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After the generation of the process alternatives to achieve the separation objectives, the most 
promising alternatives are to be selected for further analysis. The main concern is the high yield 
and purity of the product and additional concerns might be required energy, number of unit 
operations, process safety and operation time. 
Required data: Process alternatives, criteria to rank alternatives. 
Information obtained: A feasible number of process alternatives that satisfy the constrains. 
Methods and tools: Process evaluation tools, indexes to rank the alternatives based on 
predefined criteria. 
Step C.4. Unit operation specification 
Step objective: To analyse the unit operations of a specific flowsheet. 
In this step, the separation factor and the conditions of the separation are to be identified. For 
separations which are based on phase creation (e.g. vapour-liquid), the corresponding phase 
diagram (VLE) should be analysed to obtain the recovery factors. Additionally, in this step 
solvent selection should be performed for the identified solvent-based separation tasks. If the 
solvent for separation is different from the solvent in the reaction, then a solvent swap operation 
is needed. The main aim of the solvent swap method is to identify the swap solvent that is 
suitable for the swap operation and the subsequent separation task and at the same time, key 
performance criteria such as operation time, solvent use, and generated waste are low. In the 
case that the reaction is solvent free, the solvent is selected using the well-established methods 
proposed by Gani et al. [17].  
Required data: Phase equilibrium, process flowsheet (or state-task network).  
Information obtained: Separation factors, Process conditions, solvents. 
Methods and tools: Solvent selection methods, Solvent swap method, Thermodynamic models.  
Step C.5. Batch or continuous ? 
Step objective: Gathering all the information from the previous steps and in corporation with 
the decisions taken during the reaction analysis steps (Section B), a decision on whether the 
unit operations of the separation process can be operated in batch or continuous mode is made. 
In general, most of the unit operation involved during the work-up in pharmaceutical processes 
such as distillation, liquid extraction and membranes are compatible in continuous or semi-
continuous mode [7]. The crystallization step, determines the final product quality and purity, 
it is usually followed by filtration, and drying and they are usually operated in batch or semi-
batch mode. However, different types of continuous crystallization operations have been 
recently published [49], [53], [58]. 
Required data: Information from previous steps. 
Information obtained: Batch or continuous operation. 
Methods and tools: Unit operation database. 
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Step C.6. Design of the unit operation 
Step objective: The last step is the design of the specific unit operation, in this step all the design 
parameters need to be specified/calculated such as the volume of the crystallizer and the amount 
of the solvent required to achieve the separation. 
Required data: Design parameters, operating parameters, solvent, phase diagrams. 
Information obtained: Design of unit operations. 
Methods and tools: Unit operation database, solvent analysis tools. 
The expected outcome of the section C is illustrated Figure 3.5 where is shown the reaction 
mixture to be separate, the separation task identification, the ranking of the process alternatives 
and the state task network. 
 
Figure 3.5 Expected outcome through the analysis in section C. 
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Figure 3.6 Work-flow, methods and tools and data flow corresponding to section C for the separation 
synthesis and analysis. 
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process integration, process control, and implementation of monitoring and control strategies 
and process operation.  
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Step D.1. Process simulation and evaluation  
Step objective: To simulate and evaluated the obtained process 
Using the obtained process flowsheet (or state-task network) and all the information obtained 
during the analysis such as operation conditions, reaction information and separation factors, 
process simulation can be performed by using model-based methods (e.g. simple mass & 
energy balances, or rigorous models) or experimental-based methods. Performance criteria 
such as process efficiency (e.g. in terms of yield or operation time), product purity, productivity, 
energy required and solvent consumption are calculated in order to evaluate the process. In 
addition, process analysis is performed to identify possible opportunities (e.g. high energy or 
mass use) for process improvement. For example, environmental metrics to calculate the impact 
of the produced waste such as the toxicity into the environment are calculated using the WAR 
algorithm. Based on the results and depending on the source of the impact, a target for 
optimization can be defined, for example, when the impact from the purge of the recycle to the 
reactor is high, it might be an indication that reaction optimization needs to be performed. 
Sustainability analysis can also be performed to identify parts of the process where the 
utilization of energy or mass is high and translate this into optimization targets. Finally, LCA 
analysis can also be performed to analyse and evaluate the environmental impact of the whole 
process, from the extraction of raw materials to its end-of-life. In this way, the environmental 
impacts, from the selection of the synthesis routes, to the selection of unit operation or to the 
selection of the product distribution to the market can be well understood and be subject of 
process optimization.  
Required data: Process flowsheet (or state-task network), operating parameters, design 
parameters and process conditions. 
Information obtained: Mass and energy balances, Performance criteria, Sustainability metrics 
(see Table 4.7), economics, environmental impact. 
Methods and tools: Rigorous model-based simulation tools (ASPEN, SuperPro, ICAS, 
Dynochem), dynamic plant-wide models, analysis tools (ECON, SustainPro, LCSoft). 
Step D.2. Process optimization/control/monitoring and validation  
Step objective: Perform optimization, establish control and monitoring strategy, and validate 
the process. 
Process optimization is defined and performed to satisfy the optimization targets identified 
from Step D.1 and to improve the overall performance of the developed process. One possibility 
for process optimization in pharmaceutical processes is solvent recycle and integration, where 
high purity solvents are required in order to avoid any possibility of product contamination. 
The solvent recovery system within pharmaceutical processes implies high operating costs 
which in most of the cases leads to solutions such as discharging as a waste the used solvents 
during the production of pharmaceutical products and incinerated them [169]. To deal with the 
synthesis of the solvent recovery system, Ahmad et al. [20] proposed a systematic approach for 
generation of batch processes with integration solvent recovery and recycling and  Linninger et 
al. [21] presented the optimization of structural process flowsheet design decisions while 
proposing the optimal sequence of a solvent recovery system. Other opportunities of process 
optimization is energy integration [14], which can reduce the operating costs of a multipurpose 
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production plant and introduction of process intensification (e.g. integration of reaction-
separation) in order to reduce plant footprint, energy and mass required [7]. 
Process analytical technology (known as PAT) and Quality-by-design (QbD) approaches have 
an important role in the analysis, development, design and control of pharmaceutical processes 
by enhancing the process understanding due to fast process knowledge acquisition and 
establishing the design space in order to ensure that the predefined product quality objectives 
are satisfied. A systematic method to assist the selection of PAT systems for different process 
has been proposed by Singh et al. [170] where the critical quality parameters are first identified 
and the selection is based on economic criteria, reliability criteria and possibilities of integration 
with a control system. Process control can be established at this point or simultaneously with 
the design phase using the driving force method proposed by Mansouri et al. [171]. For the 
evaluation and implementation of different control strategies, the dynamics of the systems need 
to be known, this can be a challenge for pharmaceutical processes, as the knowledge of the 
system dynamics are often not know. The final optimal design is then validated through detailed 
simulation and/or experimentation. 
Required data: Optimization targets, variables to be controlled, variables to be monitored. 
Information obtained: Process performance criteria, Optimized design, control, and 
monitoring techniques. 
Methods and tools: Plant-wide dynamic models, rigorous model-based simulation tools 
(ASPEN, SuperPro, ICAS, etc.), ICAS-PAT.  
Step D.3. Process operation 
Step objective: The pharmaceutical processes are taking place in multipurpose plants where 
different products are produced at different times. An optimal planning and scheduling should 
be performed to optimize the use of time, utilities and minimize the operation costs. In addition, 
process operation should be proposed for processes, which are characterized by their periodic 
operation. For example, in case of monoclonal antibodies purification using semi-continuous 
chromatographic columns, an efficient operation strategy needs to be established to maintain 
continuous operation. Another example, deals with the operation of enzyme-catalysed 
processes where the process efficiency drops because of the enzyme deactivation, therefore the 
process operation should be investigated in order to maintained steady state operation. 
Required data: Operation objectives. 
Information obtained: Operation strategy.  
Methods and tools: Plant-wide dynamic models, planning and scheduling methods and tools 
(SuperPro, Aspen). 
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Figure 3.7 Work-flow, methods and tools and data flow corresponding to Section D for the process 
simulation, evaluation, operation and optimization. 
3.4 Conclusions  
In this chapter, the overall systematic framework to assist the pharmaceutical process 
development and investigate opportunities for implementation of continuous manufacturing by 
enhancing the process understating has been presented. A detailed explanation of the sections 
and the steps of the systematic framework has been given in terms of objectives, data flow and 
required methods and tools to achieve the step objective. The developed integrated framework, 
tackles the pharmaceutical process development problem by providing a data rich environment 
where the important process variables are identified and their affect in the process can be 
understood. In this way, the overall process is decomposed in sub-problems: the reaction 
pathway, reaction analysis, and separation synthesis and process evaluation/optimization. For 
each sub-problem, a procedure that takes into account all the important aspects of the problem 
is followed to ensure that a good decision is made based on available data. The framework is 
suitable for problems related to process synthesis of a completely new process (batch or 
continuous) or to retrofit an existing process with known or unknown process flowsheet (or 
state task network). The main objectives of the framework are:  
a. The improvement of the reaction pathway (organic or biochemical) by identifying 
possibilities of improvement and evaluating sustainability metrics.  
b. Improvement in the individual reactions in terms of productivity, selectivity, condition 
selection, and solvent selection. 
c. Improvement in reactor design. 
D.1.Perform Process 
Simulation And Evaluation
D.3. Process Operation 
Process Simulation tools ( e.g. PRO II, ASPEN 
HYSYS, SuperPro etc.)
Dynamic plant wide models,
Cost estimation tools (e.g. ECON)
Sustanability Analysis (SustainPro) Process efficiency (for each unit operation), product (and impurities) flowrate, energy and solvent consumption, mass and energy balances, 
sustainability factors, identification of process drawbacks 
Desing parameters and operating parametes for each unit operation, 
flow rates, process conditions, information from previous steps   
Model based simulation based on different scenarios,
Planning and Scheduling 
Need to improve the operation 
Operation strategy 
 API optimized process
Design space 
PAT
Workflow objectives:
1. Process simulation  
2. Evaluation, Integration, Optimization
3. Operation
4. Monitoring and Control
5. Validation 
Obtained process flowsheet 
or state task network
D.2. Process optimization, 
control, monitoring and 
validation
Experimentation, simulations,
Mathematical models for optimization (ICAS-MoT, 
MATLAB)
Dynamic plant wide models 
ICAS-PAT
Optimization targets, Variables to be controlled and monitored 
Process performance criteria, optimized design, monitoring and 
control strategy 
Methods and Tools Information (in/out) 
Section D. Process Simulation, Evaluation, 
Operation and Optimization 
Workflow
Methods and Tools
Information flow
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d. Evaluation of implementation of continuous manufacturing during the reaction or the 
wok-up and batch to continuous. 
e. Improvement in the synthesis of separation process and determining the type and the 
sequence of the unit operations. 
f. Investigation of process intensification opportunities.  
g. Solvent selection for reactions, crystallization, solvent swap, liquid-liquid extraction 
and distillation. 
h. Process evaluation based on mass and energy balances, sustainability metrics, process 
performance criteria. 
i. Process control and monitoring. 
j. Process optimization/integration and operation. 
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4 FRAMEWORK FOR PHARMACEUTICAL 
PROCESS DEVELOPMENT: SUPPORTING 
METHODS AND TOOLS 
In this chapter, the different methods and tools used within the framework are presented. First, 
the methods required for the successful implementation of the framework are presented. 
Second, the computer-aided tools are presented where the methods and tools developed prior 
to this work or developed by other researchers are briefly explained and the ones developed 
during this project are explained in detail. 
4.1 Methods 
4.1.1 Process modelling 
For the development of different type of models the systematic modelling methodology 
proposed by Heitzig et al. [172] is used. The modelling work is divided into four phases and 
within each phase a sequence of steps is proposed. 
 Phase I. Modelling objective and system information 
Details for the reasons why the model needs to be developed, variables to be calculated from 
the model, model accuracy, model application, assumptions, phenomena taking place in the 
system and available experimental data are defined in Phase I. 
 Phase II. Model construction 
The mathematical model is constructed, model analysis is performed and solution sequence is 
defined. 
 Phase III. Model identification/discrimination 
Parameter estimation, sensitivity analysis and statistical analysis are performed in phase III. 
 Phase IV. Model evaluation/validation 
Modeling and synthesis of pharmaceutical process: moving from batch to continuous 
 
56 
 
Model validation is performed in this step using experimental data that was not used in the 
parameter estimation.  
Once the four phases are completed, the model is ready to be used for simulation and 
optimization studies. The developed model is then stored in the model library where it can be 
retrieved and reused. 
4.1.2 Multiphase reactive systems modelling  
For the model development of multi-phase reactive systems a methodology developed by 
Anantpinijwtna et al. [173] has been considered. This method consists of modules to describe 
the physical equilibrium of the compounds between the reaction phases; kinetics and mass 
transfer based models, and an overall reactor model consisting of the balance equations, the 
constitutive models (physical equilibrium and kinetic model) and the conditional equations. 
4.1.3 Reaction classification 
The reaction is then classified according to Roberge et al. [166] classification, which is based 
on the reaction time: type A (very fast reaction, reaction time < 1 sec, mass transfer controlled), 
type B (fast reaction, reaction time between 1 sec and 10 min) and type C (slow reaction, 
reaction time > 10 min).  
4.1.4 Mass and energy transfer limitations  
Mass and heat transfer limitations can be identified according to Hartman et al. [9] roadmap 
where the reaction mass limitations are evaluated using the Damköhler number (Da, ratio of 
the reaction rate over the mass transport). If the Da number value is greater than 1, the reaction 
rate is higher than the mixing rate. Similarly, the heat transfer limitation are evaluated through 
the β number (produced heat from reaction over rate of heat being removed/added).  
4.1.5 Process synthesis 
To identify the separation technique and the sequence of the separation tasks, the method 
proposed by Jaksland et al. [163] and extended by Tula et al. [164] has been considered. The 
method is based on the thermodynamic insights where the analysis of the compound in terms 
of thermodynamic properties is essential and based on the relationship between compound 
properties the separation techniques are identified. Initially, compound are searched in 
databases such as the CAPEC database [174] and their pure properties are retrieved. In case 
that the pure compound properties are not available in the databases, then property prediction 
tools (ICAS-ProPred, part of the ICAS platform [174]) are used in order to estimate the missing 
properties. Mixture analysis to identify difficult separations such as azeotropic mixtures is 
performed through databases such as ICAS-AzeoPro (an information based toolbox from 
ICAS), which identifies the azeotropes and provides a solution for the specific azeotrope. Once 
the mixture analysis has been performed, the so-called binary ratio matrix, which is the ratio of 
the each pure component property of all the binary pairs, is created. According to the method 
developed by Jaksland [163], every operation task can be associated to one or more pure 
component property. Based on the calculated ratio of the pure properties of the two compound, 
the process synthesis method, and some additional constrains, the feasible separation tasks for 
the specific binary pair are identified. Then, the identified separation tasks are combined based 
on processing rules and the separation objectives. All the combination of the feasible alternative 
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process flowsheets are generated and represented using as SFILES, which is a text 
representation of a flowsheet [167]. Figure 4.1 illustrates a process flowsheet, the process 
groups and the SFILES representation. 
 
 
SFILES: (iA)(iB)(rAB/pABCD)<1[<(iA)]<2[<(iB)](fA/BCD)1 (dsCD/B)2 (lm(C/D) 
(oC)(oD) 
Figure 4.1 SFILES representation of a process flowsheet [167].  
4.1.6 Solvent Selection 
For solvent selection problems, the established solvent selection four-step general procedure 
proposed by Gani et al. [17] has been considered. The solvent selection can be applied to any 
task that required a solvent to improve the performance of the task. The first step of the 
procedure is the “Problem identification” where the actual problem and the direction required 
to solve the problem are identified. In the first step, the need for solvent use is questioned, by 
investigating whether the operation task can be performed in another way. For example, “is it 
possible a reaction to be performed in a solvent-free environment?” or “is it possible a solvent-
based separation to be performed in other physical separation ways?”. In the second step, the 
criteria that the solvent needs to satisfy must be defined. For example, when solvent is required 
as a reaction medium it should be a liquid at the operating conditions, therefore, the boiling 
point at the reaction pressure should be higher than the operating temperature. There are also 
cases where the solvent has a specific function, for example, it should create a second phase 
where the product is selectively extracted, therefore, and the reaction product should be more 
soluble in the extraction solvent than in reaction solvent and the rest of the compound must not 
be soluble in the extraction solvent. Once the search criteria have been defined, the third step 
of the procedure is to perform the search. Different approaches might be used to perform the 
search such as database search, expertise and experience and/or computational (molecular 
design and/or screening of a predefined list) approaches. The final step of this procedure is the 
final verification of the selection that can be performed either by using rigorous model-based 
methods or experimental procedures [17]. The methodology is illustrated in Figure 4.2. 
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Figure 4.2 General solvent selection methodology proposed by Gani et al. [17]. 
 
4.1.6.1 Methodology application 
The proposed general methodology for solvent selection has been used in many different 
problems taking into account the specific needs of the application, such as multi-step organic 
reaction systems [124], [125], crystallization processes [128], [130] and separation design 
[175]. 
4.1.6.2 Solvent swap in pharmaceutical processes 
This general procedure (see Figure 4.2) has been applied is the selection of swap solvents for 
the pharmaceutical processes. It has been extended in this project by adding the specific needs 
of solvent swap problems in pharmaceutical process.  
In pharmaceutical processes, as it has been mentioned, solvents have a multipurpose role since 
different solvents can be used in different processing steps, such as chemical reaction, 
separation, and purification of the active pharmaceutical ingredient (API). In these processes, 
very often, a reaction may take place in solvent-1 (S1) and the next processing step (e.g. 
reaction, crystallization, extraction, or washing) may require a different solvent-2 (S2), because 
the process performance is better in S2 than in S1. Therefore, solvent swap (or solvent 
exchange) is a common and important task in API production line within pharmaceutical 
industry. In this project, batch distillation is considered as the operation to perform the solvent 
swap task (see Figure 4.3). In this case, the swap solvent is mixed with the original solvent and 
the API and enters at the bottom of the batch distillation column. The original solvent is distilled 
off and collected as the top product while the swap solvent together with the API are collected 
as the bottom product.  
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Figure 4.3 General representation of the solvent swap task as a batch distillation operation. 
 
To successfully perform the solvent swap task by batch distillation the solvents (original and 
swap) must satisfy certain criteria (see Table 4.1), such as boiling point difference between the 
original solvent and the swap solvent, high average relative volatility between the original and 
the swap solvent and preferably no azeotrope formation, in addition to the solubility of the 
solute (API).  
Table 4.1 Criteria for good solvent swap. 
Criteria Value Tool 
Boiling point difference Tb, Original solvent << Tb, Swap solvent 
Pure compound databases/ 
Property prediction tools 
Average relative 
volatility αoriginal solvent/swap solvent >> 3 
Pure compound databases/ 
Property prediction tools 
Azeotropes Preferably no 
Databases/ predictive models 
(i.e. UNIFAC in case of no 
available experimental data) 
 
The methodology for solvent swap performed by batch distillation is illustrated through a 
workflow diagram in Figure 4.4. It consists of four main steps, each of which requires specific 
methods-tools (shown on the left hand side of Figure 4.4) and data-flow (shown on the right 
hand side of Figure 4.4) for their implementation. The developed methodology has been 
implemented in the overall integrated framework in Steps B.6 and C.4. It can be applied when 
it has been identified through the overall framework that the solvent used in a certain processing 
task cannot be used in the next processing task (see Figure 4.5).  
 
Modeling and synthesis of pharmaceutical process: moving from batch to continuous 
 
60 
 
 
Figure 4.4 Systematic methodology for solvent swap tasks performed by batch distillation. 
 
Step 1. Problem definition 
In this step, the swap problem and the objectives of the specific solvent swap task are defined. 
Details of the original solvent, the process where it is used and the need for replacing it with 
another are specified (see Figure 4.5). Note however, as shown in Figure 4.5, a number of other 
tasks also need to be performed after the swap operation. For example, for the synthesis of an 
API, a reaction task first needs to be performed, followed by different separation tasks. The 
reaction task requires a solvent (S1, original solvent). However, S1 may not be efficient for the 
crystallization task following the reactor. Therefore, another solvent (S2, swap solvent) is 
required. Therefore, the objective of the swap problem is to select a swap solvent that can 
replace the original solvent through batch distillation and that can perform the separation task 
efficiently. Alternatively, details for the swap solvent to be used in the separation task can be 
specified in order to identify a suitable solvent for the reaction task (this is the reverse design 
solution approach). That is, if a solvent (swap solvent) is the best option for a crystallization 
task (the downstream processing step) but not very good for the upstream processing step (e.g.  
Start 
Step 1. Problem 
definition Original solvent, Process details
Step 2. Generate feasible 
solvent candidates
Databases 
Property Prediction tools
Phase analysis tools (VLE)
Pure compound properties, Azeotropic 
information, VLE data
List of feasible solvent candidates,
Solvent swap process classification
Step 3. Candidate 
Analysis
Solvent candidates from step 2
Process considerations for the following 
task
Preselected solvents,
Solubility limits
Mixture Analysis Tools
Phase analysis tools (SLE, LLE)
Step 4. Validation
Preselected solvents,
Process Specification
Performance criteria calculation 
(operation time, solvent charges) solvent 
use, product losses)
Dynamic batch distillation tools:
(i.e. ASPEN batch, ICAS still, 
Dynochem)
EndMethods and Tools
Workflow 
Information flow
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reaction task), which solvent to use for the reaction task so that both processing steps can be 
performed at high efficiency? 
A simple task network of a pharmaceutical process involving a reaction task, a solvent swap 
task and a downstream processing task that can be performed by reaction, crystallization, 
liquid-liquid extraction or washing operations, is illustrated in Figure 4.5. In the text below, 
each of the downstream processing tasks are briefly described. 
Solvent swap task 
The solvent swap task is employed in order to replace the original solvent with a swap solvent. 
In this project, only batch distillation is considered for the swap operation, Figure 4.3. 
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Figure 4.5. Downstream processing options after swap operation. 
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Step 2. Feasible solvents candidates 
The objective of this step is to generate a list of all the feasible swap solvent candidates that 
can be used to swap the original solvent by batch distillation. The detailed work-flow and data-
flow diagram for Step 2 of the methodology is illustrated in Figure 4.3. 
 
Figure 4.6 Work-flow diagram to identify the list of feasible solvent candidates in Step 2. 
 
Solvent swap task: Batch distillation 
Given the original solvent and considering the criteria presented in Table 4.1, the feasible swap 
solvents for the original solvent are identified through a database search of their target 
properties and/or by applying computer aided molecular design techniques [17]. Each candidate 
swap solvent is evaluated in terms of separability from the original solvent through analysis of 
predicted phase behavior and the separation classified in terms of average relative volatility 
(αaver): “very easy” when αaver>>4; “easy” when 2.5<αaver<4; “difficult” when 2<αaver<2.5; “very 
difficult” when 1.5<αaver<2; “impossible” when αaver<1.5 and “conditional” when an azeotrope 
is formed. In Figure 4.7, an easy operation and a conditional swap operation are highlighted. 
The marked areas in Figure 4.7 illustrates the areas of interest for analysis of the VLE (vapor-
liquid equilibrium) phase diagrams in batch distillation operations. In the region marked “easy 
swap”, the high temperature pure component point represents the swap solvent and through 
batch distillation, the original solvent is replaced in the bottom (residue) by the swap solvent. 
Because of the larger differences between the phase compositions of the involved compound, 
the batch distillation operation is easier in this region than in any other.  
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Exceptions to the above criteria do exist, namely, the formation in azeotropes and low average 
relative volatility where detailed analysis of VLE phase diagrams (see for example, Privat and 
Jaubert, ) are required to investigate the feasibility of the solvent swap task. In the case of 
minimum boiling point azeotropes, the VLE phase diagrams are used to determine the amount 
of the fresh swap solvent that must be added to remain in the desired side of the azeotrope, that 
is, the “conditional swap” region in Figure 4.7. In this case, the bottom (residue) again contains 
the swap solvent while the top product contains mainly the azeotrope. Note that by operating 
the batch distillation in the “conditional swap” region, it is also possible to swap a higher boiling 
point solvent with a lower boiling point swap solvent in the case of minimum boiling 
azeotropes. Their selection, however, depends on the amount of solvent swap required, 
operational costs, and the next operational task in the process. 
 
Figure 4.7 Analysis of VLE phase diagrams.  
Some azeotropes are known to be pressure sensitive. In the case of pharmaceutical processes, 
since the compounds involved may be sensitive to high temperatures, the effect of pressure, 
lower than atmospheric on the azeotrope condition also needs to be considered. In some cases, 
lowering the pressure, the separation problem becomes easier because of the movement of the 
azeotrope – see the positive vacuum effect in Figure 4.8. Therefore, a lower pressure operation 
of the solvent swap task is desirable.  
 
Figure 4.8 The vacuum effect in the binary VLE phase diagram. 
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Step 3. Candidate analysis 
Swap solvents are selected not only for their ability to replace the original solvent by batch 
distillation but also for their performance in the downstream processing tasks. Depending on 
the processing task different solvent properties (for example, boiling and melting point 
temperatures confirm that the swap solvent would remain as a liquid during a specific 
operation) and phase behaviour (for example, solid solubility is important for crystallization 
while liquid miscibility is important for extraction) are selected as target properties. The 
candidate analysis considers all these properties. The properties and the type of phase behaviour 
important for each downstream processing task are briefly described below.  
 Solvent properties and phase behaviour 
Reaction task 
To identify the desired properties of a solvent for the reaction task, the reaction should be 
analysed in terms of products, reactants, reaction phase, reaction conditions, and solvent role. 
If, for example, a reactant is in solid state at ambient temperature a solvent that can dissolve 
this compound is needed, for example, one of the desired properties of the solvent in this case 
is the solubility parameter of the solvent, which has to be similar to the reactant’s solubility 
parameter. Therefore, the two compounds will be most likely soluble in each other. Also, as 
these reactions are usually in the liquid phase, the solvent needs to be in the liquid state during 
the reaction, which means that the boiling point of the solvent needs to be higher than the 
reaction temperature and the melting point needs to be lower. Another example is, when the 
solvent needs to have a specific role, such as to create a second phase with the reaction mixture 
so that the reaction takes place in one phase and the product moves to another phase, which can 
be evaluated through liquid-liquid equilibrium (LLE) studies. An extensive discussion for 
solvent selection in organic reactions is found in the literature [124]–[126]. 
Crystallization task 
For solid solubility (or precipitation) calculations, pure compound properties such as melting 
point (Tm), and the solute enthalpy of fusion (ΔΗfus) are required as well as liquid phase activity 
coefficient (γs) of the solute in the solvent calculations. Since experimental data for these 
properties for APIs may not be available, predictive models (such as UNIFAC[61] and NRTL-
SAC [62], [176]) to predict the solid-liquid equilibrium are employed [127]. In addition, in the 
presence of few experimental data points, the model parameters of the predictive models are 
regressed or fine-tuned to make the necessary predictions. In this way, the solid solubility 
calculations using predictive models leads to satisfactory results [127].  
Extraction task 
For extraction tasks, operations involving solid-liquid equilibria as well as liquid-liquid 
equilibria are employed to screen the swap solvent candidates. The LLE calculations are 
required to guarantee the liquid phase split and the SLE calculations are required to determine 
the operating condition solute recovery with the swap solvent.  
Washing task 
During the washing step, water is used to remove impurities (such as salt impurities), therefore 
the swap solvent needs to have a higher capacity to dissolve the API than the original solvent, 
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and must be immiscible with water. LLE calculation to guarantee the miscibility gap with water, 
while and SLE calculation verifies the solubility of the solute.  
The detailed analysis in Step 3 leads to the preselection of the swap solvents that can be used 
in the swap process and have the desired process performance for the subsequent processing 
task.  
Step 4. Validation 
The objective of this step is to validate the selection of the swap solvent candidates from step 
3 through rigorous dynamic batch distillation simulations of the solvent swap operation. Given 
the initial conditions (composition and temperature), the process specification (operating 
pressure, boil-up flowrate and the still volume) and having calculated the solubility limits (the 
minimum volume can be identified for different solvents) the simulation is performed to 
calculate important process criteria such as operation time, swap solvent charges (in the case 
of “put and take” swap process), total solvent use, total solvent losses and product loses. The 
results are used to compare the performance of different solvents in order to identify the best 
performing solvent with respect to operation criteria and also different solvent swap operation 
can be compared (“put and take” and “constant volume” operational procedures).  
4.2  Knowledge databases 
Knowledge database have been created by systematically collecting measured data or 
calculating data. The data from database can be retrieved and used in different cases. 
4.2.1 Reaction database 
In this project, a reaction database has been developed with specific focus on reactions taking 
place in pharmaceutical processes and multiphase reactions within pharmaceutical industry. 
The reactions in this database have been categorized according to the reaction type, the target 
product to be produced (when single-step or multistep reactions are considered), the reaction 
product, and the effect of the solvent use on the reacting system. Reaction conditions 
(temperature, pressure etc.), reaction compound (reagents, catalysts etc.), reaction data 
(conversion, selectivity, etc.), scaling information and finally batch or continuous processing. 
For each reaction entry, a description of the process exists and the references are provided. A 
more detailed description of the database development and structure follows later. The 
developed database fulfils criteria that have been defined as necessary for this type of reaction 
databases [97].  
This reaction type database, more specifically aims to: 
1. Identify reactions, which are used to produce different types of products (API, 
Intermediates). 
2. Identify reactions to be utilized, for a given compound availability. 
3. Investigate the function of different type of solvents in single/multiphase reactive 
systems. 
4. Facilitate the choice of the reaction conditions. 
5. Evaluate reaction pathway in terms of yield, cost, sustainability metrics  
6. Facilitate the reactor design from available experimental data and kinetic models. 
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The data required to develop a reaction type database to satisfy the abovementioned objectives 
has been acquired from numerous published articles and patents. The obtained knowledge from 
these sources has been structured in a database and stored for easy information retrieval and re-
use in different possible applications. The database consists of classes, sub-classes, instances, 
and objects. A class is a representation for a conceptual grouping of similar terms. Classes are 
the focus of most ontologies. A class describes concepts in the domain. A class can have 
subclasses that represent concepts that are more specific than the super class [177]. 
Knowledge database development 
For the development of the reaction type database, the main knowledge categories known as 
classes are the reaction type, the reaction, phases involved, how the phases are created, solvent 
use, solvent function, type of solvent, reaction conditions, available data and finally operation 
mode (listed in Table 2.1). The first knowledge class consists of different reaction types that 
are commonly found in pharmaceutical processes (e.g. hydrogenation). The set of these reaction 
types are called the instances of the class. The second class of the knowledge database is the 
reaction, which is divided in four sub-classes, the reactants, reaction products, and target 
product and reaction information (see Figure 2.2). The instances of the three first sub-classes 
of the second class are classified in terms of name of the compound, type of the compound and 
molecular structure while the forth class summarizes information for the specific reaction. This 
type of information is crucial to identify the structural changes of the compounds during the 
reaction. The fourth class of the database consists of instances describing the phases involved 
in the specific reaction. It is important to note that this class connects the reaction information 
with the reaction performance class, which will be described later, and it has an important role 
in the database since in this way, the advantages of using a multiphase or a single-phase system 
are identified. The next two classes of the database consist of instances describing the solvent 
function, in case a solvent has been used in the reactive system, for example the solvent function 
is “creates a second phase and removes the reaction product”, and the type and name of the 
used solvent. The last three classes of the reaction knowledge database consist of instances 
describing the reaction performance under certain conditions. The reaction conditions class 
consists of instances, which have to do with the reaction variables such as reaction temperature, 
amount of reactants, catalyst (type and amount), pH, pressure, and the need to use acid or base. 
The data class consists of four sub-classes, reaction data, dynamic data, kinetic model, and 
scale. The instances of the reaction data sub-classes are information related to reaction time (or 
residence time), conversion, selectivity, reaction yield and overall process yield (usually after 
isolation and purification). The instances of the dynamic data are sets of experimental data that 
can be used to fit or to develop a kinetic model. The next sub-class describes the availability of 
kinetic model that can be used either directly, or after fitting to the experimental data for 
reaction optimization studies. The last sub-class of the data class provides important 
information on the scale the reaction has been performed. Finally, the last class of the database 
is the operation mode, the instances of this class can be different operational modes such as 
batch reaction or flow reaction. 
Database structure 
Table 2.1 lists the classes of the databases in the first column, the second column relates the 
classes with the instances that the classes contain and the third column the list of instances is 
given for different classes. The structure of the database is visually shown in Figure 2.1.  
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Table 4.2 Main classes of the reaction type database with the description of the corresponding 
instances.  
Main Classes Relation with instances  Instance description  
Reaction Type, T T=[T1, T2, ..., Ti, …, Tn] 
Ti: reaction type in the 
knowledge base (e.g.  acylation 
etc.) 
Reaction, R R=[R1, R2, ..., Ri, …, Rn] 
Ri: reaction of the ith reaction 
type; for each reaction 
information about the reactants 
and reaction products are 
provided as well as information 
for the target product and process 
( for example: 1st step for 
production of an API) 
Phases involved, P  P=[P1, P2, ..., Pi, …, Pn] 
Pi: phases of the ith reaction (e.g.  
organic-aqueous, organic-gas 
etc.) 
How phases are created, C C=[C1, C2, ..., Ci, …, Cn] Ci: (e.g. solvent etc.) 
Solvent function, F F=[F1, F2, ..., Fi, …, Fn] Fi: (e.g. phase creation, carrier etc.) 
Solvent type, ST ST=[ST1, ST2, ..., STi, …, STn] STi: (e.g. ether, alcohol etc.) 
Solvent, S S=[S1, S2, ..., Si, …, Sn] Si: Solvents in ith reaction 
Reaction condition, RC RC=[RC1, RC2, ..., RCi, …, RCn] 
RCi (e.g. Temperature, 
composition, cat, pH etc.) 
Data, D D=[D1, D2, ..., Di, …, Dn] 
Di (reaction data: conversion, 
selectivity, reaction time, and 
dynamic data: concentration vs. 
time, scale information and 
kinetic models etc.) 
Operation Mode, OP OP=[OP1, OP2, ..., OPi, …, OPn] OPi: batch, continuous, fed batch 
 
In Figure 4.6 the graphical representation of the reaction type database is illustrated.  
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Figure 4.9 Graphical representation of the structure of the reaction type database. 
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In Figure 4.7 the subclasses and the values of each instance in the “Reaction” class are 
described. For example each reaction has reactants, reaction products and it can be used to 
eventually produce a target product (in case of multi-step reactions), each of the sub-classes 
take values such as the name of the compound (N), the type of the compound (T, for example, 
alcohol) and the structure of the compound. The reaction info subclasses takes text values that 
can be used to give useful insights for the reaction.  
 
Figure 4.10 Representation of the sub-classes of the “Reaction, R” class, together with the 
corresponding instances. 
 
4.2.2 Unit operation database 
A database which provides information for different unit operations (batch, continuous or batch 
to continuous) has been developed. This database is based on published examples from 
literature where the reaction system converted from batch to continuous or the unit operation is 
operated in continuous mode. It provides an information-based selection procedure which takes 
into consideration the main design parameters (such as residence/reaction time, heat transfer 
and mass transfer limitation) and phases presence in the reaction. The selection has to be further 
evaluated either by performing experiments or developing detailed reaction models. Table 4.3 
lists the criteria to choose between continuous reactors.  
Table 4.3 Chossing between continuous reactor [178].  
Reactor Mode CSTRs PFR Microreactor 
Handling of solids ++ - -- 
Gas evolution ++ - -- 
Slow reaction kinetics ++ - -- 
High conversion per volume - ++ ++ 
Narrow residence time distribution - ++ ++ 
Initial heat sink + - - 
Low operational complexity - ++ -- 
Low level of equipment intensity + ++ -- 
Enhanced heat transfer - + ++ 
Enhanced mass transfer  - + ++ 
Low cost  + + -- 
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Unit operation database structure 
Figure 4.11 illustrates the graphical structure of the unit operation database.  
 
Figure 4.11 Graphical representation of the unit operation database.  
 
Table 4.4 lists the classes of the databases in the first column, the second column relates the 
classes with the instances that the classes contain and the third column the list of instances is 
given for different classes. 
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Table 4.4 Main classes of the unit operation database and description of the corresponding instances. 
Main Classes Relation with instances  Instance description  
Type of operation, T T=[T1, T2, …, Ti, …, Tn] 
Ti: operation type in the 
process(e.g. synthesis, 
purification) 
Operation mode, OM OM=[OM1, OM2, …, Omi, …, Omn] 
Omi: operation mode of the unit 
operation Ti (e.g. batch 
purification) 
Unit operation, UO UO=[UO1, UO2, …, Uoi, …, Uon] 
Uoi: unit operation of the ith 
operation type and operation 
mode (e.g. continuous synthesis, 
CSTR) 
Essential properties, EP EP=[EP1, EP2, …, Epi, …, Epn] 
Epi: important primary (relative 
volatility) and mixture properties 
(LLE) 
Operation and design 
parameters, OP OP=[OP1, OP2, …, Opi, …, Opn] 
Opi: operation parametes (e.g. 
temperature, pressure), design 
variables (e.g. residence time) 
 
 
4.2.3 Solvent Swap database 
This database consists of solvents that are commonly used in pharmaceutical processes and 
provides information on the feasibility of the solvent swap task. The objective of this database 
is to provide the data required for the calculations in Steps 2-4 of the solvent swap methodology. 
The solvents that are included in the database are listed in Table 4.5 with values for a selected 
set of pure compound properties, such as boiling point temperature (Tb), melting pointing 
temperature (Tm) and solubility parameter (SolPar). The solvents listed in Table 4.5 can also be 
considered a special set because another from the list can swap them. 
Table 4.5 Solvents commonly used in pharmaceutical processes. Bold numbers: predicted using ICAS-
ProPred. 
Solvent Formula CAS MW (gr/mol) Tb (°C) 
Tm 
(°C) 
SolPar 
(MPa½) 
Dichloromethane (DCM) CH2Cl2 75-09-2 84.93 39.8 -95.1 20.4 
Methyl tetr-butyl ether 
(MTBE)  C5H12O 1634-04-4 88.15 55.2 -108.6 15.1 
Acetone C3H6O 67-64-1 58.08 56.0 -94.8 19.7 
i-hexane (or 2-methly 
pentane) C6H14 107-83-5 86.18 60.2 -153.7 14.4 
Methanol (MeOH) CH4O 67-56-1 32.04 64.8 -97.6 29.6 
Tetrahydrofuran (THF) C4H8O2 109-99-9 72.11 65.0 -108.3 19.0 
Ethyl acetate (EtAc) C4H8O2 141-78-6 88.11 77.1 -83.6 18.3 
2-methyltetrahydrofuran 
(MeTHF) C5H10O2 96-47-9 86.30 78.0 -80.7 18.3 
Methylethyl ketone 
(MEK) C4H8O2 78-93-3 72.11 79.5 -86.6 18.9 
Acetonitrile (MeCN) C2H3N 75-05-8 41.05 81.6 -43.8 24.1 
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2-propanol (IPA) C3H8O 67-63-0 60.10 82.3 -89.5 23.4 
Isopropyl acetate (IPAc) C5H10O2 108-21-4 102.13 88.6 -73.4 17.2 
Water H2O 7732-18-5 18.01 100.0 0.0 47.8 
Toluene C7H8 108-88-3 92.14 110.6 -94.9 18.3 
Methyl-isobutyl-ketone 
(MIBK) C6H12O 108-10-1 100.16 116.5 -84.0 17.4 
Acetic acid C2H4O2 64-19-7 60.05 117.9 16.6 19.0 
N,N-Dimethylformamide 
(DMF)  C2H7NO 68-12-2 73.10 152.0 -60.4 23.9 
Anisole (or 
methoxybenzene) C7H8O 100-66-3 108.14 153.7 -37.5 20.1 
N-Methyl pyrrolidone 
(NMP) C5H9NO 872-50-4 99.13 202.0 -24.0 23.2 
Ethanol (EtOH) C2H6O 64-17-5 46.07 78.2 -114.1 26.1 
1-Butanol (n-BuOH) C4H10O 71-36-3 74.12 117.7 -89.8 23.3 
2-methyl-1-propanol (iso-
BuOH) C4H10O 78-83-1 74.12 107.8 -108.0 22.9 
 
The feasibility of the swap operation for each pair of solvents in this database has been check 
through rigorous dynamic simulations of the corresponding batch distillation operations. 
Taking also into account the criteria for good solvent swap (Table 4.1), the azeotropic 
information collected for each pair, the VLE phase diagrams and the vacuum effect on VLE, a 
selection guide for swap solvents (and the reverse problem) has been developed. Figure 4.12 
and Figure 4.14 illustrate these selection guides while Table 4.6 lists some of the conditional 
swap information.  
Figure 4.12, Figure 4.13 and Figure 4.14 show for each pair of solvents, the feasibility of the 
swap operation. Based on the simulated data, the swap operation is classified in terms of very 
easy (I), easy (II), difficult (III), very difficult (IV), impossible (X) and conditional (CXX). In 
Figure 4.12, the original solvents are placed on the diagonal axis and the swap solvents are 
placed on the vertical axis. Therefore, for any given original solvent, the feasibility of its 
replacement by a swap solvent can be determined by simply checking the entire swap solvents 
listed in the corresponding column, while for a swap solvent, the feasibility of all the original 
solvents it could replace can be found by checking the original solvents listed in the 
corresponding row. Figure 4.13 shows similar information but with the swap solvents in the 
diagonal axis and the original solvents in the vertical axis. 
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Figure 4.12 Feasibility of swap operation for different solvent pairs(swap solvent versus original 
solvent). Classification of swap operation in terms of very easy (I), easy (II), difficult (III), very 
difficult (IV), impossible (V) and conditional (CXX). 
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Figure 4.13 Feasibility of swap operation for different solvent pairs (original solvent versus swap 
solvent). Classification of swap operation in terms of very easy (I), easy (II), difficult (III), very 
difficult (IV), impossible (V) and conditional (CXX). 
Figure 4.14 shows the effect of vacuum application on the solvent swap task. This guide is used 
to identify for conditional swap operation, whether or not vacuum is beneficial.  
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Figure 4.14 The effect of the vacuum on the swap operation (VLE phase diagram). Positive effect 
means the vacuum makes the separation easier. Negative effect means that the vacuum makes the 
separation more difficult. No effect means that vacuum make the separation neither more difficult nor 
easier. 
 
The solvent pairs that form a minimum boiling azeotrope have been classified as conditional in 
terms of the solvent swap task that will need to be performed if they are involved. Therefore, 
when such a pair is encountered, the amount of the swap solvent to be charged for batch 
distillation should be such that the solvent-swap solvent mixture will lie in the conditional swap 
region (see Figure 4.7). This would then guarantee a batch residue containing the swap solvent 
plus the reaction product while the original solvent plus low boiling impurities will be removed 
as the distillate product. For the conditional swap pairs found and stored in the database (Figure 
4.12 and Figure 4.14), the corresponding azeotrope composition of the solvent is listed in Table 
4.6 in terms of mass and mole percent. In addition, through simulations of batch distillation 
involving each pair, the swap operation is classified. 
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Table 4.6 List of the conditional solvent pairs together with their azeotropic composition and swap 
operation classification. Solvent pairs classified as “Conditional” swap operation, together with the 
maximum mixture composition in terms of original solvent (*) and classification are listed. 
 Conditional solvent pair Azeotrope Composition (original solvent)  
  Original Swap mol% mass%  Classification 
C01 Methanol i-hexane 65 85 EA 
C02 IPA Toluene 25 35 VE 
C03 Methanol Toluene 25 45 VE 
C04 IPA IPAC 45 60 VD 
C05 methanol ETAC 40 65 VD 
C06 methanol MTHF 35 20 DF 
C07 methanol MEK 35 55 DF 
C08 IPA MeCN 60 5 DF 
C09 Methanol MeCN 35 40 EA 
C10 THF MeCN 25 20 VE 
C11 IPA water 45 20 VE 
C12 i-hexane water 20 10 VE 
C13 Toluene water 60 25 DF 
C14 IPAC water 50 20 VE 
C15 ETAC water 40 20 VE 
C16 THF water 30 10 VE 
C17 MTHF water 40 15 EA 
C18 MTBE water 20 10 VE 
C19 MIBK water 70 35 EA 
C20 MEK water 40 15 VE 
C21 ACNT water 40 25 VE 
C22 i-hexane Methanol 50 30 VE 
C23 ETAC IPA 40 35 VD 
C24 MTHF IPA 40 35 VD 
C25 MTBE Methanol 45 25 DF 
C26 MEK IPA 45 40 VD 
C27 acetone Methanol 40 25 VD 
C28 MeCN IPA 55 65 DF 
C29 MeCN Toluene 25 45 VE 
C30 water Toluene 50 85 EA 
C31 water IPAC 65 95 DF 
C32 water MIBK 40 80 EA 
C33 THF Ethanol 9 6 EA 
Note: EA= Easy; DF= Difficult; VD= Very difficult; VE=Very easy 
All the necessary calculations for Step 2 of the methodology have been performed during the 
creation of the swap solvent database (represented by Figure 4.10 -Figure 4.14 and Table 4.6). 
Therefore, unless a solvent not listed in the database is used, no calculations are required for 
step 2. Figure 4.12-Figure 4.14 and Table 4.6 are used as a guide for the quick identification of 
the swap solvents, when the original solvent is known or vice versa.  
4.2.4 Pure compound database 
The CAPEC database contains information of pure compound properties and it is used to extract 
the pure compound properties of the compound. In addition, VLE experimental data, interaction 
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parameters for VLE analysis (e.g. UNIFAC parameters), and miscibility calculations/ 
information are available [174]. 
4.2.5 Monitoring and control database 
The PAT knowledge database has been developed prior to this project by Singh et al. (2010) 
and it aims to support the selection of suitable process monitoring and analysis tools for a 
specific application or process and to support the search for the range of potential applications 
of a specific monitoring tool [177]. The ICAS-PAT database includes information for 
monitoring and control for fermentation processes (tasks: fermenter, mixing task and steriliser), 
tablet manufacturing process (tasks mixing, milling, granulation, tablet storage, tablet press and 
tablet coater) and for cheese manufacturing processes (tasks: milk storage tank, pasteurizer and 
cooling system). The monitoring and control database also needs to be expanded including the 
advances of PAT and control technologies for different types of equipment involved in 
pharmaceutical processes, for example, crystallization (different types of batch and continuous 
crystallizers) and reactors (including the new technologies, e.g. microwaves). 
4.2.6 Model libraries 
Model libraries are essential for the application of the framework as generic developed models 
can be stored, retrieved, and used for the analysis and simulation of the defined system.  
4.2.6.1 Process models 
Generic process models are needed for the simulation and analysis of different unit operations. 
For most of the common unit operations, process models have already been developed and 
implemented in templates, which can be easily retrieved and reused in many different 
applications. In this field, a development for the pharmaceutical processes is required because 
of the introduction of new technologies (e.g. micro-fluid). Therefore, new models based on first 
principles have to be developed in order to simulate new technologies.  
4.2.6.2 Property prediction models 
Pure compound properties for APIs and solvents that are not available in the CAPEC database 
are predicted by the methods available in ICAS-ProPred. The only information needed is the 
molecular structural information of the compounds.  
4.2.6.3 Kinetic models 
A library of kinetic models is essential for the kinetic modelling of the reactions because the 
use of the library can be of great assistance when a new kinetic model needs to be developed. 
4.3 Computational Tools 
The computational tools are necessary for the generation of required data, which is needed, for 
the application of the presented framework and the methodologies. A general description of the 
computational tools is provided, shifting the emphasis on the developed tools during this 
project. The computational tools are classified as, mathematical solvers, solvent design/analysis 
and selection tools, process synthesis, simulation and evaluation tools.  
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4.3.1 Mathematical solvers 
To solve the developed models, mathematical solvers such as ICAS-MoT and MATLAB ® can 
be used. 
4.3.2 Solvent design, analysis and selection 
Computer aided tools have been developed by Gani et al. for solvent selection, design and 
analysis and implemented in ICAS platform. ICAS-ProCAMD is a tool developed for solvent 
selection and design, this tool is based on predictive thermodynamic models based on group-
contribution models. In combination with atom connectivity rules it generates molecules that 
have predefined desired pure component and mixture properties. The search can be limited to 
compounds that are known in the database but it is also able to design new molecules [179]. 
Another tool that has been developed by the same group, ICAS-SolventPro, which is used for 
the solvent analysis. ICAS-SolventPro assists in the selection and analysis for solvents for 
different unit operation where a solvent is required, solvent selection for organic reactions, 
solvent screening and mixture design and a new option is swap solvent selection [180]. 
Solubility calculation and solid-liquid equilibria can be performed using predictive models such 
as UNIFAC [61], PC-SAFT [63], and NRTL-SAC [62], when experimental data is available, 
it can be used to estimate the model parameters so the prediction becomes more reliable. For 
the swap solvent selection, the tool is able to identify all the solvents that are suitable for the 
swap process (when batch distillation is considered as the swap task), the data for solvent swap 
behind the tool is based on the developed database for swap solvent selected which has been 
explained in Section 4.2.1.3. A screenshot of the tool for swap solvent selection is illustrated in 
Figure 4.15. 
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Figure 4.15 Screen-shot from the main page of ICAS-SolventPro. The solvent swap computer aided 
tool is integrated with the ICAS-SolventPro which is part of ICAS platform [174]. 
 
4.3.3 Process synthesis 
Pro-CAFD is a computer aided-tools that has been developed by Tula et al. and it is based on 
the process synthesis methodology published in [164]. 
4.3.4 Process simulation tools  
The role of process simulation in pharmaceutical process is to validate the decisions taken 
during the process development and to perform the energy and mass balances calculations for 
the developed processes. The simulation results can be used to: 
a. Calculate process performance criteria such as product quality, production time, 
resources required (e.g. solvent), energy required and generated waste.  
b. Perform process analysis in terms of economics and sustainability by using process 
evaluation tools (discussed in section 4.3.5). 
c. Validate new design proposed based on the process evaluation analysis. 
d. Perform process optimization. 
e. Planning and scheduling. 
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Tools such as AspenTech/Aspen-batch, Scale-up Systems/Dynochem, Intelligent 
Inc./SuperPro and ICAS platform [174] can be used.  
4.3.5 Process evaluation  
Process evaluation tools such as cost analysis, LCA, sustainability analysis (ICAS SustainPro), 
“green” metrics (see Table 4.7) are important for the analysis of the developed process. The 
process analysis is used to identify possible process hotspots that can be translated to 
optimization targets. The reviewed  by Constable et al. [133] “green” metrics are listed in Table 
4.7, where for each metric, an explanation and the equation to quantify a specific metric are 
given.  
Table 4.7 Metrics for “green” chemistry as they have been proposed to literature. Reviewed by 
Constable et al. [133]. 
Metric Explanation  Equation 
Effective 
Mass yield 
(EM)  
the percentage of the mass of 
product over the overall mass 
of non-begin compounds 
used during the synthesis 
ܧܯሺ%ሻ
ൌ ܯܽݏݏ ݋݂ ݌ݎ݋݀ݑܿݐݏ ሺ݇݃ሻܯܽݏݏ ݋݂ ݊݋݊ െ ܾ݁݊݅݃݊ ݎ݁ܽ݃݁݊ݐݏ ሺ݇݃ሻ ݔ100% 
E-factor The mass of total waste 
produced for a given amount 
of produced product 
ܧ െ ݂ܽܿݐ݋ݎ ൌ ܶ݋ݐ݈ܽ ݓܽݏݐ݁ ሺ݇݃ሻ݇݃ ݌ݎ݋݀ݑܿݐ  
Atom 
Economy 
How much of the reactants 
remain in the product 
ܣݐ݋݉ ܧܿ݋݊݋݉ݕሺ%ሻ ൌ ܯܹ ܲ ∑ሺܯܹ ܣ, ܤ, ܦ, ܨ, ܩ, ܫሻ ݔ100 
Where A, B, D, F, G, I: reactants; P: product 
Mass 
Intensity 
(MI) 
Total mass used to produce 
the product  
ܯܫ
ൌ ܶ݋ݐ݈ܽ ݉ܽݏݏ ݑݏ݁݀ ݅݊ ܽ ݌ݎ݋ܿ݁ݏݏ ݋ݎ ݌ݎ݋ܿ݁ݏݏ ݏݐ݁݌ ሺ݇݃ሻܯܽݏݏ ݋݂ ݌ݎ݋݀ݑܿݐ ሺ݇݃ሻ  
Carbon 
efficiency   
Percentage of carbon of the 
reactants that remain in the 
final product 
ܥܽݎܾ݋݊ ݂݂݁݅ܿ݅݁݊ܿݕ ሺ%ሻ
ൌ ܽ݉݋ݑ݊ݐ ݋݂ ܿܽݎܾ݋݊ ݅݊ ݌ݎ݋݀ݑܿݐܶ݋ݐ݈ܽ ܿܽݎܾ݋݊ ݌ݎ݁ݏ݁݊ݐ ݅݊ ݎ݁ܽܿݐܽ݊ݐݏ ݔ100 
Reaction 
mass 
efficiency 
(RME) 
Mass of reactants remaining 
in the product 
ܴܯܧ ሺ%ሻ ൌ ݉ܽݏݏ ݋݂ ݌ݎ݋݀ݑܿݐሺ݇݃ሻ݉ܽݏݏ ݋݂ ݎ݁ܽܿݐܽ݊ݐݏ ሺ݇݃ሻ ݔ10 
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5 CASE STUDIES 
In this chapter, four case studies are presented, highlighting in each one of them the 
applicability of the framework. The first case study deals with process analysis and 
development of the process for the production of ibuprofen. The second case study deals with 
the swap solvent selection problems where the developed solvent swap methodology is applied 
in four different examples. The third case study deals with process intensification of a 
multiphase reactive system. The final case study deals with process operation problem for 
productivity improvement of a reactor plant. 
5.1 Case study 1: Ibuprofen synthesis 
Ibuprofen (2-(4’-isobutylphenyl) propionic acid) has been selected as the target compound for 
the application of the integrated framewok. Ibuprofen is a well-known nonsteroidal anti-
inflammatory drug (NSAID) used for relieving pain, alleviating fever, and reducing 
inflammation. Ibuprofen was derived from propanoic acid by the research of Boots Company 
during the 1960s and patented in 1961. The original Boots synthesis of ibuprofen consisted of 
six steps, started with the Friedel-Crafts acetylation of isobutylbenzene. Reaction with ethyl 
chloroacetate (Darzens reaction) gave the α,β-epoxy ester, which was hydrolysed and 
decarboxylated to the aldehyde. Reaction with hydroxylamine gave the oxime, which was 
converted to the nitrile, then hydrolysed to the desired acid [181]. 
5.1.1 Problem definition  
The objective of this case study is to: 
 Investigate the reaction pathways to produce ibuprofen. 
 Perform reaction analysis. 
 Generate the state-task network (or the flowsheet) to produce high purity ibuprofen 
crystals.  
 Generate process alternatives. 
 Perform process analysis/simulation and evaluation. 
 Target production: 75 kg per batch.  
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5.1.2 Section A. Reaction pathway identification  
Step A.1. Select API or intermediate: Ibuprofen 
Step A.2. Reaction pathway identification: Using the reaction type database and searching for 
“Ibuprofen” as the target product (the search and the results are illustrated in Figure 7.1 in 
chapter 7, Appendix A) three reaction pathways have been found. The currently used process 
which has been published by Elango et al. [182] and it consists of three reaction steps, a Friedel 
craft acylation, a hydrogenation and finally, a carbonylation step. The individual reaction steps 
of the selected pathway have been the focus of reaction optimization studies by many research 
groups. The other two reaction pathways have been recently discovered independently by 
McQuades’s group [147] and Jamison’s group [148], both pathways consist of a Friedel crafts 
acylation, an aryl migration step and a saponification step. The BHC pathway [182] is 
illustrated in Figure 5.1, the details for the other two reaction pathways are illustrated in Figure 
7.2 in Appendix A.  
 
 
Figure 5.1 BHC reaction pathway, obtained from Elango et al. [182]. 
 
A simple evaluation based on “green” metrics (Table 4.7) has been performed and illustrated 
in Figure 5.2. For the analysis the BHC pathway without and with recycle of HF and IBB, the 
pathways proposed by Bogdan et al. [147], and by Snead et al. [148] have been considered. The 
effective mass yield (EM), which is a ratio of the produced product (in mass, kg) over the total 
amount of non-benign reactant, has been first evaluated. As it is illustrated in Figure 5.2, the 
step 1 of the BHC synthesis requires larger amounts of non-benign reactants compared to 
pathway 2 and 3, whereas the reaction step 2 and 3 require much less non-benign reactants. 
Another metric that has been evaluated is the mass intensity (MI), which shows the total 
required mass for the reaction per kg of product. In Figure 5.2, it can be seen that the first 
reaction steps of the pathway 2 and 3 require less amount of reactants than the amount required 
for BHC without considering the recycle. However, when recycle is considered, the MI metric 
has lower values for BHC pathway than the other two pathways where recycle is not possible. 
In addition, the pathway proposed by Snead et al. [148] requires much less amount of reactants 
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than what is required in pathway 3. The E-factor metric shows the generated waste per kg of 
product. The first step of BHC pathway has been found to be the main contributor in the E-
factor metric, even if the step 1 produces a small amount of waste during the reaction, the large 
value of E-factor comes because large stoichiometric amounts of solvent and reactant are 
needed. When the solvent and the reactant are recycled back in the reactor, the E-factor reduces 
dramatically while the small value of e-factor is because the small amount of non-recovered 
solvent and reactant (~1%).  The other two pathways have relatively higher values of E-factor, 
which means that larger amounts of waste are generate through the synthesis. The generated 
waste for the proposed pathway by Snead et al. has been found slightly less compared to the 
reaction pathway proposed by Bogdan et al. 
 
(a)  (b)  
(c)  (d)  
Figure 5.2 Green metrics evaluation for the reaction pathways found in reactiontype database.  
 
Finally, the atom efficiency has been evaluated for the all the reaction pathways and is 
illustrated in Figure 5.2 (d). It can be seen that the atom efficiency for the BHC reaction pathway 
is higher than the other two pathway as most of the atoms in the reactants remain in the final 
product. Whereas, the atom efficiency is much lower for the two recently developed flow 
pathways, which means that these pathways generate more waste than the BHC pathway. 
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5.1.3 Section B. Reaction analysis 
Step B.1 Data collection. 
Reaction Step 1. Friedel-Craft acylation 
The ibuprofen synthesis starts with an acylation through Friedel-Craft reaction, where 
isobutylbenzene (IBB) reacts with an acetylating agent (acetic anhydride) to produce 4-
isobutylacetophenone (4-IBAP). The reaction phase consist of two phases a hydrogen fluoride 
rich phase which consists of acetylating agent, the reaction product and small amount IBB that 
is slightly soluble in HF, and the IBB rich phase. The catalyst for this reaction is hydrogen 
fluoride as it acts as a strong Lewis acid, which is required for the Friedel-Crafts acetylation. 
The reaction data has been retrieved from the reaction database and it is given in Table 5.1. 
 
Table 5.1. Prelimenary data collected for Friedel-Craft acylation step. 
Reaction Step:   
Friedel-Craft acylation Reactant A: Isobutylbenzene (IBB) 
 Reactant B Acetic anhydride 
 Main Product 4-Isobutylacetophenone 
 Side Products 2-isobutylacetophenone; acetic acid; acetyl fluoride  
 Phases IBB rich phase-HF rich phase 
 Solvent  HF 
 Solvent Role Product extraction  
 Catalyst HF (Acid source) 
 Reaction conditions  T = 80oC; P =0.7 MPa; t = 3 hr  
 Reaction data  XIBB = 85%; SIBAP =81% 
 Experimental data  Starting and end points 
 Scale Lab scale 
 Models  Not available 
   
 
Reaction Step 2. Hydrogenation 
The second reaction step is a hydrogenation step where the produced 4-IBAP from the first 
reaction step reacts with hydrogen (H2) in the presence of hydrogen catalyst to form 1-(4´-
isobutylphenyl) ethanol. The hydrogenation reaction is a heterogeneous multiphase catalytic 
reaction which involves three phases (gas-liquid-solid). The hydrogenation catalyst might be 
Pd/C or Raney Nickel which is insoluble in reaction phase and it can be easily recovered and 
re-activated [38], [183]. The reaction is a solvent-free reaction, but solvent can also be used to 
bring the reactants together and decrease the overall reaction time. For the analysis and reaction 
optimization, available data and kinetic models are available. The reaction data has been 
retrieved using the reaction type database is given in Table 5.2. 
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Table 5.2 Prelimenary data collected for the hydrogenation step. 
Reaction Step:   
Hydrogenation Reactant A: 4-isobutylacetophenone 
 Reactant B Hydrogen 
 Main Product isobutyl phenyl ethanol 
 Side Products p-isobutyl styrene, p-isobutyl ethyl benzene 
 Phases G-L-S 
 Solvent  Solvent free or Methanol 
 Solvent Role Dissolve reactants 
 Catalyst See Table 5.3 
 Reaction conditions See Table 5.3 
 Reaction data  See Table 5.3 
 Experimental data  
Dynamic data (concentration 
with respect time) for different 
reaction conditions 
 Scale Lab scale 
 Models  Available 
 
Table 5.3 lists different catalysts and the corresponding reaction conditions for the 
hydrogenation step as they have been reported in literature by different researchers and stored 
in reaction database.  
 
Table 5.3 Hydrogenation Step: Review of different catalysts and solvents. 
Catalyst  Promoter  Solvent  T (K) PH2 
(MPa) 
Conversio
n 4-IBAP 
(%) 
Selectivity 
IBPE (%) 
Yield 
IBPE 
(%) 
Ref 
Pd/C - MeOH 303 0.68 99.5 96.6 - [182] 
Raney Ni - - 353 0.68 >99 98 - [182] 
Pd/C aq. NaOH - 298 0.86 99.5 - 92 [182] 
10% Ni/HY NaOH MeOH 393-413 5.7-5.9 75 75 - [184] 
Ru/Al2O3 - MeOH 373-398 3.4-6.2 76 60 45 [32] 
Pd black - Cyclohexane 373 2 90 58 52 [33] 
Pd/SiO2 - n-Decane 373 2 90 69 62 [34] 
Pd/SiO2 - n-Decane 373 1 90 80 72 [185] 
Pd/C NaOH EtOH 343 2 100 96.4 96.4 [186] 
 
Reaction Step 2. Carbonylation 
To convert the produced 1-(4´-isobutylphenyl) ethanol to the final product, ibuprofen, and a 
carbonylation reaction step is used. The reaction is a three phase reaction (G-L-L) where the 
reactants and products form the organic phase, the catalyst and the acidic promoters are in the 
aqueous phase and finally carbon monoxide is in gas phase. The reaction is a solvent-free 
reaction and it is taking place above the melting point of the organic compounds, solvent can 
also be used in order to bring the reactants together and to finally increase the reaction rate. The 
collected data has been retrieved from the reaction type database is given in Table 5.3. 
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Table 5.4 Prelimenary data collected for the carbonylation step. 
Reaction Step:   
Carbonylation  Reactant A: isobutyl phenyl ethanol (IBPE) 
 Reactant B CO 
 Main Product Ibuprofen 
 Side Products 
Isobutyl styrene (IBS), 1-(4-
isobutylphenyl)-ethyl chloride 
(IBPCl), 3-(4'-isobutyl phenyl) 
propionic 
acid 
 Phases G-L-L 
 Solvent  Solvent free or MEK 
 Solvent Role Dissolve reactants 
 Catalyst PdCl2/PPh3 
 Reaction conditions  T = 110-140
oC; P =5-16.5 MPa; 
t = 2-4 hr  
 Reaction data  
XIBPE > 99%; SIBU =96-98%, 
SIPPA =1.00%, SIBPCl=1.00%, 
SIBS=0.2% 
 Experimental data  
Dynamic data (concentration 
with respect time) for different 
reaction conditions 
 Scale Lab scale 
 Models  Available 
 
Step B.2. Perform kinetic study 
The Friedel-Craft acylation is classified as a reaction class type C as the reaction time is above 
10 min. Mass transfer limitations do exists because of the low solubility of IBB in HF [187], 
therefore rigorous mixing is required to bring the reactants in contact. Dynamic data is not 
available and kinetic model has not been developed, therefore, the analysis of the reaction is 
based on published experimental results, which have been stored in reaction type database.  
The Hydrogenation reaction is classified as a reaction class type C, the mass transfer of 
hydrogen to the organic phase is the main limitation, which also controls the mechanism of the 
reaction. Therefore, a rigorous mixing is required to overcome this limitation. Dynamic data 
sets for different cases of 4-IBAP hydrogenation to IPBE at different conditions is available in 
literature. Kinetic models have also been developed and published and they can be used to fit 
and validate the experimental data. 
The Carbonylation reaction is classified as a reaction class type C. In this reaction, the mass 
transfer of carbon monoxide in the organic liquid phase and then reaction at the interface of 
organic-aqueous phase are the main limitations. Rigorous mixing and high partial pressure of 
carbon monoxide are required to overcome these limitations. Dynamic data for the 
carbonylation step is available and kinetic models published in literature have been used to fit 
and validate the experimental data. 
The main results from the kinetic study are given in Table 5.5, 
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Table 5.5 Kinetic study for the three reaction steps. 
Reaction Step: Reaction S.1  Reaction S.2  Reaction S.3  
Reaction Class [166] Slow C  Slow C  Slow C  
Mass Transfer  Mass Transfer Limitation  
Mass Transfer 
Limitation  
Mass Transfer 
Limitation  
Heat Transfer  no  Highly exothermic  no  
Equilibrium  No information  No information  No information  
Control Mechanism  Mass Transfer  Mass transfer and kinetics  
Mass transfer and 
kinetics 
Kinetic model Not available Fitted and validated  Fitted and validated 
 
In Figure 5.3 the kinetic model fitting in experimental data is illustrated. The kinetic model 
development is based on published kinetic models, hydrogenation step [34] and carbonylation 
step [37]. Model analysis and parameter estimation based on published data from different 
research groups has been performed in both models. In Figure 5.3, the fitted hydrogenation and 
carbonylation kinetic model for different sets of experimental data is illustrated.  
 
Hydrogenation: catalyst: Pd/C, aq. NaOH Hydrogenation: catalyst: Pd/C,  
  
Hydrogenation: catalyst: RuAl2O3, aq. NaOH Carbonylation: catalyst: PdCl2/PPh3 
  
Figure 5.3 Fitted kinetic model for the hydrogenation and carbonylation steps. 
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Step B.3 Evaluate Process Variables 
Reaction Step 1. Temperature is an important parameter for the Friedel-Craft reaction as a low 
boiling point solvent is used (HF). The reaction takes place in temperature between 45-80oC 
and high pressure is used to prevent hydrogen fluoride to vaporize. Rigorous mixing is required 
as IBB is slightly soluble with HF and it needs to be in contact with the acetylating agent, which 
is soluble in HF [187], [188]. Because of the lack of detailed reaction information such as 
experimental data and/or a validated kinetic model, the process variables evaluation is restricted 
to observations during the experimental analysis and process concerns.  
Reaction Step 2. To evaluate the reaction process variables for the hydrogenation reaction step 
the reaction kinetic model is used for simulation under different reactions conditions. Using 
simulations, the reaction variables such as temperature, concentration, pressure are evaluated 
using sensitivity analysis, as shown in Figure 5.4 and Figure 5.6. The amount of catalyst is 
crucial for the process as for higher amount (see Figure 5.4b) the reaction rate is high. However, 
the operation process space that the selectivity to the desired product is at the maximum value 
is very narrow (see Figure 5.4b) compare to the wider operational window obtained when lower 
amount of catalyst is used (see Figure 5.4a).  
(a)  (b)  
Figure 5.4 Simulation of the reaction performance for different amount of catalyst. 
The initial concentration of IBAP also affects the reaction rate; the reaction becomes slower for 
higher concentrations of IBAP (see Figure 5.5a). It has been also shown that the absence of 
water is important for the reaction as increase concentration of water increase the production 
of oligomers (see Figure 5.5b). 
(a)  
(b)  
Figure 5.5 Reaction simulation for higher initial concentration of IBAP (a) and presence of water in 
the initial mixture (b). 
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High operation temperature results higher production of by-products and lower temperature 
results in very low reaction rate where the conversion of the reactant is not sufficient high (see 
Figure 5.6b). As shown in Figure 5.6c the partial pressure of hydrogenation affects the reaction 
rate, for low pressure the reaction rate is very slow resulting in very low conversion and 
selectivity, at higher pressures the conversion and the by-products production are increasing.  
 
(a)  (b)  
(c)  
Figure 5.6 Sensitivity analysis of the reaction variables (amount of catalyst (a), temperature (b), partial 
hydrogen pressure (c) ) for the hydrogenation step. 
 
After the analysis of the reaction variables for the hydrogenation step it can be seen that using 
the system with RuAl2O3 the high selectivity of the desired product cannot be achieved. 
However, using the system with Pd/C catalyst and NaOH as it can be seen the high selectivity 
and high conversion can be achieved and the same reaction model can be used for the evaluation 
of the reaction variables. Using Raney nickel catalyst the performance of the reaction is similar 
or better that using Pd/C and aq. NaOH and less harsh conditions are used (lower pressures and 
lower temperatures). Unfortunately, dynamic data is not available when Raney nickel catalyst 
is used. Raney nickel catalyst is selected for further evaluation because the better reaction 
performance compare to the other catalyst systems used in different research articles. In case 
that, dynamic data becomes available, the kinetic model, used for the hydrogenation step can 
be used to fit the experimental data and used for optimization studies. 
Reaction Step 3.  The final carbonylation step has been evaluated similarly to the hydrogenation 
step. High reaction temperatures increase the reaction rate and the yield to the desired product 
Figure 5.7a while lower temperature results to lower reaction rate and longer reaction times 
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(see Figure 5.7b). Low partial pressures of CO decreases the reaction rate and the yield to the 
desired product whereas higher pressures increase the reaction rate and the yield (see Figure 
5.7c). The concentration of catalyst (see Figure 5.7e), promoters (see Figure 5.7d) and the 
concentration of water (see Figure 5.7f) affects the reaction rate and the yield to final product.   
The results are illustrated in detail in Figure 5.7. 
 
(a)  (b)  (c)  
(d)  (e)  (f)  
Figure 5.7 Reaction simulation for the carbonylation reaction under different process conditions. Plot 
(a) Reaction conditions used by [182] given in Table 7.5, the changes corresponding to each case are: 
plot (b) T = 80 oC, plot (c) PCO = 1 bar, plot (d) promoters concenrtation 0.121 mol/lt, plot (e) 1.124 x 
10-3 mol/lt and plot (f) cH2O =0.1 mol/lt. 
 
Table 5.6 gives the summary of the evaluation of the process variables, which affect the each 
reaction step and the decision in the process conditions.  
Table 5.6 Evaluation of process variable for all the reaction step to produce ibuprofen. 
Variable Reaction S.1  Reaction S.2  Reaction S.3  
Temperature  45-80oC  
High Temperature by-
products yield is higher, 
low temperature the 
reaction rate is low  
High Temperature 
increases the yield  
Mixing  Rigorous  Rigorous  Rigorous  
Concentration  no information Concentration of water increases the oligomers  
High Concentration 
of catalyst, substrate 
and promoter, yields 
to higher reaction 
rates  
Stoichiometry  
Excess of HF 
and Reactant 
(Ac2O)  
no information no information 
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Pressure  
High pressure to 
prevent mixture 
from boiling  
High pressure of H2 
increases the selectivity  High pressure PCO  
pH  Acidic environment  no information Acidic environment  
Decision on reaction conditions: 
Reaction 
Conditions  
T = 80oC  
P = 0.7 MPa 
t= 3 hr  
T = 30oC  
PH2 = 0.7 MPa  
t = 2 hr  
T = 120oC  
PCO = 5.4 MPa  
t = 2 hr  
Reaction Performance: 
 C: 85%  S: 81%  
C: 99.5%  
S: 98 %  
C: 100%  
S: 98%  
 
Step B.4 Batch or continuous?  
Reaction step 1: The Friedel-Crafts reaction is a reaction that can be benefit from in continuous 
mode, the mixing is going to be improved, and the recycle of unreacted IBB and HF can be 
facilitated. The reaction system consist of two phases, the IBB rich phase, and the HF rich 
phase. The HF-rich phase contains the acetylating agent and the produced product that is 
selectively dissolved in HF phase. By searching in the unit operation database, reactions of this 
type can be operated in a counter-current plug flow reactor with or without packing material. 
In this way, the reaction will take place and at the same time, the phases are separated. Then, 
the unreacted IBB can be recycled back while the HF-rich phase, which contains the main 
product and the acetylating agent, is a subject of further separation to separate the product from 
HF and acetylating agent. In this way, the solvent can be fully recovered and recycled back in 
the reactor.  
Reaction step 2: Continuous operation can be beneficial for the hydrogenation reaction as the 
mass transfer of the gas phase to the organic phase can be enhanced. Moreover, the selectivity 
towards the product reaches a maximum after some time and the decreases rapidly. The use of 
continuous mode can also ensure constant product quality. Using the unit operation database, a 
reaction like this can be operated in reactors such as fixed bed reactor or trickle-bed reactor 
where the catalysts resides in the reactor. 
Reaction step 3: For the carbonylation step, continuous mode can also be beneficial for the 
process as it will improve the mass transfer and it will allow higher carbon monoxide partial 
pressures. Using the unit operation database, a reaction like this can be operated in reactors 
such as plug flow reactor, or microreactors. 
For this case study, the following decisions are made: 
a. Continuous plug flow reactor, Lindley et al. [187] 
b. Fed batch reactor 
c. Fed batch reactor 
 
Table 5.7 lists the potential benefits of continuous operation for the reactions required for 
ibuprofen synthesis. Table 5.7 also lists the possibilities of continuous reactors that might be 
applied for the specific reaction type and the final decision. 
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Table 5.7 Batch to continuous reaction for ibuprofen production process.  
Step B.4. Batch or 
Continuous?  Reaction S.1  Reaction S.2  Reaction S.3  
 
Beneficial:  
a. Improved mass 
transfer,  
b. Recycle of HF, 
acetylating agent  
c. Recycle of IBB  
 
Beneficial:  
a. Improved mass and 
heat transfer,  
b. Higher hydrogen 
pressure  
c. Recycle of solvent (if 
used)  
 
Beneficial:  
a. Improved mass and 
heat transfer,  
b. Higher CO pressure  
c. Recycle of solvent (if 
used)  
 
Unit Operation 
database 
Two-phase plug flow 
reactor 
Trickle-bed reactor or 
plug flow reactor  
Continuous plug flow 
reactor or microreactor 
Decision  Continuous  Fed-batch Fed-batch  
 
Step B.5. Reactor Design 
The design of the reactors is based on simple design equations that are based on the residence 
time (or reaction time for batch reactions) and the flowrate (or the maximum amount). Table 
5.8 gives the calculated volume of the reactor involved in ibuprofen synthesis.  
 
Table 5.8. Reactor design for Ibuprofen synthesis. 
 Friedel Crafts Hydrogenation Carbonylation 
Operation  Continuous  Fed-Batch  Fed-Batch  
Mixture density 
(kmol/m3) 345 0.49 19.8 
Reaction time (hr) 2  3  2.6  
Total number of 
moles (mol) 82 588 756 
Volume (m3) 0.005 1.2 0.04 
Safety factor 30% 30% 30% 
Reactor Volume 
(m3) 0.0065 1.56 0.52 
Number of 
reactors 1; PFR 1; Batch 1; Batch 
Total operation 
time*,** 1 day 5hr 5.6hr 
*For the flow reactor, it was assumed 1 day operation in order to produce sufficient amount of 4IBAP to eventually produce 75kg 
of Ibuprofen. ** The total batch time includes 1 hr filling time; 0.5 hr heating time; the reaction time; 0.5 hr cooling time and 1 
hr emptying and washing time. 
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Step B.6. Is separation required?  
Reaction step 1: Separation is required after the first reaction step; the product stream consists 
of HF, product, and acetylating agent. HF needs to be separated and recycled back in the reactor 
in order to avoid any disposal to the environment of this not environmentally benign solvent. 
The acetylating agent needs to be separated and returned to the reaction and finally the product 
has to recover in a good purity for the next reaction step.  
Reaction step 2: Separation is required to remove the hydrogen and the catalyst, the later needs 
to be recovered, regenerated, and reused. The by-products from the reaction need to be removed 
as well.  
Reaction step 3: Separation is required for the last reaction step to remove carbon monoxide, 
the aqueous phase with the catalyst and the promoters and finally to purify ibuprofen from the 
impurities. 
Table 5.9 lists the objectives of the separation for each reactive step. 
 
Table 5.9. The separation objective for each reactive step of Ibuprofen’s synthesis.  
Reaction step  Separation? Objectives 
Friedel crafts  Yes 
Hydrogen fluoride recovery and recycle 
Acetylating agent needs to recovered and 
recycled 
Product must be purified 
Hydrogenation  Yes 
Hydrogen 
Catalyst 
By-products separation 
Carbonylation Yes 
CO 
Water phase  
Catalyst 
Product purification 
 
After the reaction analysis in section B, the proposed production process for ibuprofen is 
illustrated in Figure 5.8.  
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Figure 5.8 Production process of Ibuprofen based on the information obtained using Section B. 
5.1.4 Section C. Separation synthesis 
In this section, the objective is to generate separation processes to achieve the objectives 
defined in Step B.6. To determine the separation process a detailed analysis is required, 
therefore, the analysis and the results for Steps C.1-C.2 are illustrated in detail using one 
reaction step. For the rest of the reactive steps, the main output is going to be illustrated while 
the detailed analysis is given in Appendix A (Table 7.1-Table 7.5).  
Step C.1. Mixture Analysis 
The mixture analysis for the Friedel-Crafts acylation and the Hydrogenation reactive step is 
illustrated in Appendix A. The application of the steps C.1-C.2 is highlighted in detail through 
the carbonylation reaction step of ibuprofen synthesis. Table 5.10 lists the compounds after the 
carbonylation reaction has been completed, the role of the compound during the reaction and 
in which phase they are after the end of the reaction. Note, that in the analysis the catalyst and 
the promoters are not directly considered as they are soluble in water and it is considered that 
they are going to be separated together with the aqueous phase.  
Table 5.10 Description of the compound involved in the carbonylation reaction 
Component   Formula Role Phase 
Carbon 
monoxide (A) CO Reactant Gas 
Water (B) H2O Solvent 
Aqueous (with aqueous 
soluble compound) 
IPBE (C) C12H18O Reactant Organic 
IBU (D) C13H18O2 Main Product Organic 
IPPA (E) C13H18O2 By-product Organic 
IBS (F) C12H16 By-product Organic 
 
Reaction 
S.1
Separation 
1
Separation 
3
Reaction 
S.3
Reaction 
S.2
Separation 
2
Isobutyl benzene 
Acetic anhydride  
Acetic acid
Hydrogen
By-product
Ibuprofen (99.9%) Carbon monoxide
4 isobutyl 
acetophenone 
1-(4'-
isobutylphenyl)ethanol 
75kg
Hydrogen Fluoride (liq.)
Acetic anhydride
HF
Isobutylbenzene
H2
Cat (Pd/C or Raney Ni)
PdCl2/PPh3
H3O+/X-
API 
purification
Polar Solvent
Mother liquor
CO
Without the use of 
solvents
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The pure compound properties are listed in Table 5.11, where the properties of the compound 
in bold have been retrieved from CAPEC database. The pure compound properties of the rest 
have been estimated using ICAS-ProPred and have been stored in CAPEC database.  
Table 5.11 Pure compound properties for the compounds involved in the carbonylation step. 
 MW (gr/mol) Tb (K) Tm (K) 
SolPar 
(Mpa½) 
Hfus 
(kJ/kmol) 
Pvap 
(kPa) RG (Å) 
Mv 
(m3/mol) 
CO 28.01 81.65 68.15 6.04 740.98 4000* 0.558 0.03 
Water  18.00 373.15 273.15 47.81 6001.70 3.54 0.62 0.02 
IPBE 178.28 538.74 295.26 19.51 16800.00 0.00 0.00 0.19 
IBU 206.28 588.00 348.40 20.20 21900.00 0.00 5.76 0.20 
IPPA 206.28 591.37 347.25 21.48 21320.00 0.00 0.00 0.21 
IBS 160.25 524.00 231.17 18.05 13370.00 0.01 5.10 0.18 
*at T= 130Κ 
The binary ratio matrix is given in Table 5.12. According to Jaksland et al. [163] and Tula et 
al. [164], based on the created binary ratio matrix the feasible separation tasks can be identified.  
Table 5.12 Binary ratio matric for a select set of properties. 
Binary  MW Tb  Tm  SolPar Hfus Pvap RG  Mv 
IPBE/IBU 1.16 1.09 1.18 1.04 1.30 9.33 1.03 1.04 
IPBE/IPPA 1.16 1.10 1.18 1.10 1.27 ∞ 1.43 1.10 
IPBE/Water 9.90 1.44 1.08 2.45 2.80 12633.74 1.13 10.46 
IBU/IPPA 1.00 1.01 1.00 1.06 1.03 ∞ 1.47 1.05 
IBU/Water 11.46 1.58 1.28 2.37 3.65 117914.94 1.16 10.88 
IPPA/Water 11.46 1.58 1.27 2.23 3.55 ∞ 1.27 11.47 
IBS/IPBE 1.11 1.03 1.28 1.08 1.26 18.67 1.09 1.04 
IBS/IBU 1.29 1.12 1.51 1.12 1.64 174.22 1.07 1.08 
IBS/IPPA 1.29 1.13 1.50 1.19 1.59 ∞ 1.57 1.14 
IBS/Water 8.90 1.40 1.18 2.65 2.23 676.81 1.24 10.10 
 
Based on the binary ratio matrix, the identified separation tasks for each binary pair are listed 
in Table 5.13.  
Table 5.13 Identified separation tasks for the separation of the reaction mixture after the carbonylation 
step.  
Binary pair Separation tasks 
IPBE/IBU Crystallization, distillation, prevaporation,  
IPBE/IPPA Crystallization, distillation, prevaporation 
IPBE/Water Liquid-liquid phase separation 
IBU/IPPA solvent crystallization,  
IBU/Water Liquid-liquid phase separation 
IPPA/Water Liquid-liquid phase separation 
IBS/IPBE Crystallization, distillation,  
Modeling and synthesis of pharmaceutical process: moving from batch to continuous 
 
98 
 
IBS/IBU Liquid membrane, prevaporation, crystallization,  
IBS/IPPA Liquid membrane, prevaporation,  
IBS/Water Liquid-liquid phase separation 
 
Based on the identified separation tasks, the selected process groups are listed in Table 5.14.  
 
Table 5.14 Generated process groups for the separation of the carbonylation raction mixture. The 
chemical species CO, water, IPBE, IBU, 3-IPPA and IBS are represnted with A-F respectively.  
Process groups 
crDE/CF crDEC/F crC/F crD/CF fA/BCDEF 
dsDE/CF dsDEC/F dsC/F dsD/CF rABCDEF 
lmDE/F lmD/F lmE/F dsDE/C  
pvDE/F pvD/F pvE/F pvC/E  
scD/SE scD/SCEF scD/SEF crE/CF  
dsS/E dsS/CEF dsS/EF dsE/CF  
lmS/E lmS/CEF lmS/EF crDE/C  
Note: distillation (ds), crystallization (cr), flash (f), reaction (r), prevaporation (pv), solvent 
crystallization (sc), liquid membrane (lm) 
 
Step C.2. Separation alternatives generation 
The structurally feasible process alternatives for the carbonylation step are listed in Table 5.15 
in the form of SFILES. The generated process alternatives marked with bold (number 2, 7, 8 in 
Table 5.15) have been described in literature by Elango et al. [182] and Zey et al.[189]. The 
later patent describes different methods to purify mixtures compromising ibuprofen after the 
carbonylation step. 
 
Table 5.15 Structurally feasible process alternatives for the carbonylation step. The chemical species 
CO, water, IPBE, IBU, 3-IPPA and IBS are represnted with A-F respectively. 
Rank Process Alternatives [SFILES] 
1 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(scD/SCEF)[(oD)](lmS/CEF)[1(oS)](oCEF) 
2 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(scD/SCEF)[(oD)](dsS/CEF)[1(oS)](oCEF) 
3 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(crDE/CF)[(oCF)](scD/SE)(lmS/E)[1(oS)][(oE)](oD) 
4 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(crDE/CF)[(oCF)](scD/SE)(dsS/E)[1(oS)][(oE)](oD) 
5 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(crDEC/F)[(oF)](crDE/C)[(oC)](scD/SE)(lmS/E)[1(oS)][(oE)](oD) 
6 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(dsDE/CF)[(oCF)](scD/SE)(lmS/E)[1(oS)][(oE)](oD) 
7 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(dsDE/CF)[(oCF)](scD/SE)(dsS/E)[1(oS)][(oE)](oD) 
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8 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(crDEC/F)[(oF)](crDE/C)[(oC)](scD/SE)(dsS/E)[1(oS)][(oE)](oD) 
9 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(crDEC/F)[(oF)](dsDE/C)[(oC)](scD/SE)(dsS/E)[1(oS)][(oE)](oD) 
10 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(crDEC/F)[(oF)](dsDE/C)[(oC)](scD/SE)(lmS/E)[1(oS)][(oE)](oD) 
11 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(dsDEC/F)[(oF)](crDE/C)[(oC)](scD/SE)(dsS/E)[1(oS)][(oE)](oD) 
12 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(dsDEC/F)[(oF)](crDE/C)[(oC)](scD/SE)(lmS/E)[1(oS)][(oE)](oD) 
13 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(dsDEC/F)[(oF)](dsDE/C)[(oC)](scD/SE)(dsS/E)[1(oS)][(oE)](oD) 
14 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(dsDEC/F)[(oF)](dsDE/C)[(oC)](scD/SE)(lmS/E)[1(oS)][(oE)](oD) 
 
Step C.3. Separation process selection 
Now, the analysis continues showing the main results of the process alternatives for all the three 
reactive steps. The first step in the selection of the process is to select the flowsheet with the 
minimum number of unit operations. 
Reaction step 1: The selected flowsheets for the Friedel-crafts acylation are listed in Table 5.16. 
After the reaction, the liquid-liquid separation between the IBB-rich phase and HF-rich phase 
is considered in all process alternatives. It can be seen from the list, that IBB has not been 
completely removed, as it is slightly soluble in HF. The sequence and the type of the remaining 
unit operations given in Table 5.16 are different.  
 
Table 5.16 Selected process alternatives with the minimum number of unit operations for the reaction 
step 1 (friedel-crafts acylation) where A: HF, B: IBB, C: IBAP, D: AcOH, E: AcF, F: Ac2O. 
 Generated SFILES 
1 (iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsAE/FBC)2[oFDBC](dsFDB/C) [oFDB][oC] 
2 (iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsAEFD/BC)2[oBC](dsB/C)[oB][oC] 
3 
(iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsA/BCDEF)2(dsEFD/BC)[oEFD] 
[oBC](dsB/C)[oB][oC] 
4 (iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsAEFD/BC)2[oBC](crB/C) [oB][oC] 
5 (iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsAEFD/BC)2[oBC](fB/C) [oB][oC] 
6 
(iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(prevA/BCDEF)2[oBCDEF](dsEFDB/C) 
[oEFDB][oC] 
 
The flowsheet number 3 is the one described by Lindley et al. [187], after the liquid-liquid 
phase separation where most of IBB is separated from HF phase. Then, the volatile compounds 
HF and AcF are removed, in the next step, which is a vapour-liquid separation. In the next 
separation step, the product is separated from the rest of the mixture in distillation columns.  
Reaction step 2: The selected process alternatives for the hydrogenation step are listed in Table 
5.17. The state-task network 1, which has been described by Elango et al. [182] is listed in 
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Table 5.17, where the hydrogen is removed after the reaction, the catalysts is filtrated and the 
impurities are removed by distillation from the main product. An extra separation unit might 
be required depending on the amount of the unreacted IBAP in the mixture.  
 
Table 5.17 Selected flowsheets with the minimum number of unit operations for the reaction step 2, 
where A: H2, B: IBAP, C: IBEP, D:water, E: IBEB. 
 Generated SFILES 
1 (iA)(iB)(rAB/pABCDE)(fA/DECB)(oDECB)(DE/CB)[oDE][oCB](C/B)[oC][oB] 
2 (iA)(iB)(rAB/pABCDE)(fA/DECB)(oDECB)(D/ECB)[oD][oECB](EC/B)[oB][oEC](E/C)[oC][oE] 
3 (iA)(iB)(rAB/pABCDE)(fA/DECB)(oDECB)(D/ECB)[oD][oECB](EC/B)[oB][oEC]crys(E/C)[oC][oE] 
4 (iA)(iB)(rAB/pABCDE) (fA/DECB)(oDECB)(DE/CB)[oDE][oCB](C/B)[oB][oC]crys(E/C)[oC][oE] 
5 (iA)(iB)(rAB/pABCDE (fA/DECB)(oDECB)(DEC/B)[oDEC](D/EC)[oD][oEC](E/C)[oC][oE] 
6 (iA)(iB)(rAB/pABCDE) (fA/DECB)(oDECB)(DEC/B)[oDEC](D/EC)[oD][oEC]crys(E/C)[oC][oE] 
7 (iA)(iB)(rAB/pABCDE) (fA/DECB)(oDECB)(DEC/B)[oDEC](DE/C)[oDE][oC] 
 
Reaction step 3: The selected process alternatives for the carbonylation step are listed in Table 
5.18. The state-task network 2, which has been described by Elango et al. [182] is listed in 
Table 5.18, where the carbon monoxide is removed after the reaction, the catalysts is removed 
with the aqueous phase during the liquid-liquid phase separation and a solvent is introduced for 
the crystallization of the main product. The solvent is then recovered in a solvent recovery unit.  
 
Table 5.18 Selected flowsheets with the minimum number of unit operations for the carbonylation 
step. The chemical species CO, water, IPBE, IBU, 3-IPPA and IBS are represnted with A-F 
respectively. 
 Process alternatives [SFILES] 
1 (rABCDEF)(fA/BCDEF)[(oA)](spB/CDEF)[(oB)](scD/SCEF)[(oD)](lmS/CEF)[1(oS)](oCEF) 
2 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(scD/SCEF)[(oD)](dsS/CEF)[1(oS)](oCEF) 
3 (rABCDEF)(fA/BCDEF)[(oA)](spB/CDEF)[(oB)](crDE/CF)[(oCF)](scD/SE)[(oC)](lmS/E)[1(oS)](oE) 
4 (rABCDEF)(fA/BCDEF)[(oA)](spB/CDEF)[(oB)](crDE/CF)[(oCF)](scD/SE)[(oD)](dcS/E)[1(oS)](oE) 
5 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(dsDE/CF)[(oCF)](scD/SE)(dsS/E)[1(oS)][(oE)](oD) 
6 (rABCDEF)(fA/BCDEF)[(oA)](spB/CDEF)[(oB)](dsDE/CF)[(oCF)](scD/SE)[(oD)](lmS/E)[1(oS)](oE) 
 
Step C.4. Specification of the unit operations 
The specification of the separation factors for each unit operations have been selected by 
analysing the phase equilibrium diagrams (VLE, LLE, and SLE) for the compounds to be 
separated. The equilibrium calculations are performed in ICAS platform using the original 
UNIFAC for VLE, LLE, and NRTL-SAC for SLE calculations. Table 5.19 lists the process 
specifications and the process conditions for the unit operations for Ibuprofen synthesis for 
selected process alternatives (alternative 3 for Friedel Crafts step, Table 5.16; alternative 1 from 
the hydrogenation step Table 5.17; and alternative 2 for the carbonylation step see Table 5.18). 
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Reaction step 3: The selected process alternatives for the carbonylation step are listed in Table 
5.18. The state-task network 2, which has been described by Elango et al. [181] is listed in 
Table 5.18, where the carbon monoxide is removed after the reaction, the catalysts is removed 
with the aqueous phase during the liquid-liquid phase separation and a solvent is introduced for 
the crystallization of the main product. The solvent is then recovered in a solvent recovery unit.  
Table 5.18). The specifications are presented in terms of separation factors (ξ) between the pair 
of the separation. For example, if CA/B is a distillation separation and ξ1=0.99 and ξ2=0.01 it 
means that 100% of C, 99% of A and 1% of B are recovered as top product. The remaining is 
recovered as bottom product.  
Table 5.19 Specifications of the different unit operation involved in Ibuprofen synthesis. Friedel-crafts 
acylation: alternative 1 see (Table 5.16), Hydrogentaion reaction: alternative 1 (see Table 5.17), 
carbonylation reaction: alternative 2 (see Table 5.18). 
Reaction Step Unit operation Process Conditions  
Separation 
factor Solvent 
Friedel-Crafts L-L separation (A/B) T = 348K, 7 atm ξ=0.88*; ξ=0 - 
 Distillation (E/F) T = 298 K, 1 atm ξ=0.99; ξ=0.01 - 
 Distillation ( T = 298 K, 1 atm ξ=0.99; ξ=0.01 - 
 Distillation T = 298 K, 1 atm ξ=0.97; ξ=0.03 - 
Hydrogenation  Flash T = 310 K, 1 atm ξ=1; ξ=0 - 
 Filtration T = 310 K, 1 atm ξ=1; ξ=0 - 
 Distillation  T = X K, X atm ξ=0.99; ξ=0.01 - 
Carbonylation  Flash T = 390 K, 1 atm ξ=1; ξ=0 - 
 Liquid phase separation T = 350 K, 1 atm ξ=0.92; ξ=0 - 
 filtration T = 350 K, 1 atm ξ=1; ξ=0 - 
 Solvent Crystallization T = 298 K, 1 atm Table 5.18 Table 5.18 
 Drying T =Tb.solvent, 1 atm ξ=1; ξ=0 - 
 Solvent Recovery Depends on the selected solvent ξ=0.999; ξ=0.001 - 
*The separation factor was calculated from data available in the patent [187] 
Solvent is required only for the final purification of ibuprofen in a solvent crystallization 
operation. The solvents, which have been found in literature, are listed in Table 5.20, 2-
ethoxyethyl acetate has been selected using computer-aided molecular design (CAMD) in 
ICAS platform and verified by experiments while the rest have been used in experimental 
studies first. As it is listed in Table 5.20, the values of potential product recovery (PR%) of the 
listed solvents are close to each other and the only mainly difference is on the crystal shape. 
Higher values of potential recovery are achieved when n-hexane or methanol are used and the 
lower PR value is obtained while the selected solvent through CAMD is used. However, even 
the slightly lower potential recovery, the overall process performance (consisting the next 
processing steps) might be improved because of the higher aspect ratio crystals obtained 
(experimentally verified by [130]) using the CAMD solvent. 
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Table 5.20 Maximum potential recovery, crystals shape and LC50 of Ibuprofen in different solvents, 
SLE equilibrium is illustrated in Figure 7.4 in Appendix A. 
Solvent PR% Crystal shape -log(LC 50) 
n-Hexane 96% Needle-like [128] 3.54 
n-Heptane 94% Needle-like 3.83 
n-pentane 93% Needle-like 3.25 
methanol 96% Plate-like [128] 1.68 
2-ethoxyethyl 
acetate 89% 
Needle-like (higher 
aspect ratio) [128] 3.28 
 
Step C.5. Batch or continuous? 
According to Table 5.19, 15 unit operations are involved in the production of ibuprofen through 
the BHC pathway with the recycle. The first reaction step is performed in continuous mode, the 
separation process consist of three distillation processes. Distillation operation is compatible 
with the continuous mode and as long as the reaction runs in a continuous mode, the separation 
can be in continuous mode. The unit operations used after the second and third batch reactive 
steps are mainly in batch mode. Despite the crystallization, filtration and drying steps the rest 
of the separation steps are compatible with continuous operation. In addition, using the unit 
operation database the crystallization process can be performed in mixed suspension mixed 
product removal.  
Table 5.21 Specifications of the different unit operation involved in Ibuprofen synthesis. 
Reaction Step Unit operation Batch or continuous?  
Friedel-Crafts  Distillation Semi-continuous 
 Distillation Semi-continuous 
 Distillation Semi-continuous 
Hydrogenation  Flash Batch 
 Filtration Batch 
 Distillation  Batch 
Carbonylation  Flash Batch 
 Liquid phase separation Batch 
 filtration Batch  
 Crystallization Batch 
 Drying Batch 
 Solvent Recovery Batch  
 
Step C.6. Design of separation unit 
In this case study, the step C.6 is not considered. 
5.1.5 Section D. Process analysis/simulation and analysis 
The process for the production of ibuprofen has now been obtained using the three first sections 
(A, B and C) of the developed framework. The next step is to validate the obtained process and 
perform process evaluation, identify optimization targets and define optimization objectives 
and finally propose the process operation.  
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The obtained flowsheet is illustrated in Figure 5.9. It consists of the continuous part for the 
synthesis and separation of the first intermediate and the state-task network for the 
hydrogenation, the carbonylation and the purification part. The continuous part, consists of the 
reactor and a liquid-liquid phase separation, the striping scetion to remove HF and AcF, the 
distillation to remove acetic acid and finally, a vacuum distillation to remove the impurities 
from the product. Then, the product of the first step is transferred to the second reactor, once 
the hydrogenation reaction is completed, the catalyst is separated from the mixture and the 
impurities are removed using a distillation under vaccuum. In the final step, the product of the 
second step reacts with carbon monoxide, then the CO is removed, the two liquid phases are 
separated and the product is purified (see Figure 5.9). 
(a)  
 
 
Figure 5.9 Obtained process for the production of ibuprofen through BHC pathway, (a) continuous 
friedel crafts acylation process; (b) state task network for the hydrogenation step and (c) is the state 
task network for the carbonylation step. 
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Step D.1. Process Simulation and Evaluation  
The validation of the obtained process has been performed using the ICAS simulation tool. The 
operational scenario considered for comparison of key performance criteria are listed in Table 
5.22. 
Table 5.22 Defined scenario for ibuprofen simulation. 
Scenario Objective  
Scenario A Evaluate the alternatives for the third carbonylation step with respect to energy required per kg of product 
Scenario B Evaluate the key performance criteria of the carbonylation  using different crystallization solvents  
 
Process Simulation: Scenario A 
The objective of the simulation scenario A, is to compare the process alternatives for the 
carbonylation and purification step in terms of energy. The results are given in Table 5.23, and 
as it can be seen that the process alternative “1” compared to the rest of generated process 
alternatives and it requires the least amount of energy per kg of pure product. For the process 
simulation, hexane was selected as a solvent for the crystallization step. The main difference of 
the first and the second alternative is that the solvent recovery step takes place in liquid-liquid 
membrane and not in a distillation.  
 
Table 5.23 Process alternatives, evaluated through process simulation to investigate the energy saving  
during the practices.  
Rank Process alternatives [SFILES] E 
1 (rABCDEF)(fA/BCDEF)[(oA)](spB/CDEF)[(oB)](scD/SCEF)[(oD)](lmS/CEF)[1(oS)](oCEF) 1.2 MJ/kg 
2 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(scD/SCEF)[(oD)](dsS/CEF)[1(oS)](oCEF) +5% 
3 (rABCDEF)(fA/BCDEF)[(oA)](spB/CDEF)[(oB)](crDE/CF)[(oCF)](scD/SE)[(oC)](lmS/E)[1(oS)](oE) +37% 
4 (rABCDEF)(fA/BCDEF)[(oA)](spB/CDEF)[(oB)](crDE/CF)[(oCF)](scD/SE)[(oD)](dcS/E)[1(oS)](oE) +44% 
5 (rABCDEF)(fA/BCDEF)[oA)](spB/CDEF)(CDEF)(dsDE/CF)[(oCF)](scD/SE)(dsS/E)[1(oS)][(oE)](oD) +125% 
6 (rABCDEF)(fA/BCDEF)[(oA)](spB/CDEF)[(oB)](dsDE/CF)[(oCF)](scD/SE)[(oD)](lmS/E)[1(oS)](oE) +124% 
 
The detailed mass and energy balances have been performed in ICAS simulation tool, the 
detailed mass and energy balances for alternative “2” are given in Appendix A (Table 7.8-Table 
7.10.). The process alternative “2” which is the current process has been selected for further 
evaluation. 
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Process Simulation: Scenario B 
In this scenario, different solvents for the crystallization step are evaluated based on the analysis 
of the simulation results. Performance criteria such as the energy required/kg of product, the 
total solvent use, solvent use per kg of product, and waste generated per kg of product are 
evaluated. The results are illustrated Figure 5.10, where it is shown the normalized 
improvement of the process alternatives using different crystallization solvents. It can be seen 
that using methanol as the crystallization solvent the energy requirements are reduced while 
using 2-ethoxyethyl acetate the energy requirements are high compared to hexane due to the 
energy intensive . The total solvent use, has been improved by using 2-ethoxyethyl acetate, kg 
solvent/kg product has been improved significantly and finally the generated waste has been 
significantly improved by using either methanol or 2-ethoxyethyl acetate. 
 
 
Figure 5.10 Perfomence criteria for the overall process to produce ibuprofen comparing four different 
crystallization solvents.  
 
Environmental analysis using the WAR algorithm implemented in ICAS, has also been 
performed for the four different solvent it can be seen in Figure 5.11 that significant 
improvements can be achieved using 2-ethoxyetyl acetate. The environmental impact 
calculated using the WAR algorithm, first the impact of the inlet streams and then the impact 
of the outlet stream was calculated which subtracted from the impact of the inlet streams. 
Therefore, negatives values of environmental impact show improvement. 
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Figure 5.11 Normalized comparison of the enironmental impact of the process to produce iburpofen 
for four different crystallization solvents. HTPI: human toxicity potential by ingestion, HTPE: human 
toxicity potential by exposure, ATP: aquatic toxicity potential, TTP: terrestial toxicity potential, GWP: 
global warming, ODP: ozone depletion potential, PCOP: Photochemical oxidation potential and AP: 
acidification potential.  
 
Considering the analysis for the crystallization solvents and that crystals with needle-like shape 
are preferred [128]–[130], 2-ethoxyethyl acetate is the best option as crystallization solvent. 
The weak point of using 2-ethoxyethyl acetate as a solvent is the energy requirements needed 
for the solvent recovery. The reduction of the energy required for solvent recovery can be 
subject of an optimization problem.  
Step D.2. Process Optimization, control, monitoring, and validation 
The section D, is not subject of this case study. 
Step D.3. Process Operation 
The process operation is not subject of this case study.   
5.1.6 Conclusions 
In this case study, the application of the overall framework was highlighted, all the section of 
except the Section D.2 and D.3 of the developed framework were verified. Reaction pathway 
was selected based on the evaluation of the proposed “green” metrics, reaction analysis was 
performed using model-based methods and experimental results, batch to continuous 
investigation was performed, process alternatives generated and process simulation and 
evaluation was performed comparing different process alternatives and crystallization solvents.   
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5.2 Case study 2: Solvent swap 
The objective of this case study is to highlight the applicability of the developed solvent swap 
methodology through the systematic framework. The application of the framework is given in 
a summarized way while the focus has been shifted in the solvent swap methodology. For the 
application of the solvent swap methodology, four examples have been selected where the 
production process to produce the desired product is known. In all the cases, a solvent swap 
operation is needed to switch solvents. The first two examples deal with swap solvent selection 
for a given original solvent. In the first example, the swap solvent is used for solute recovery 
following the reaction, while in the second example; it is used for another reaction. The third 
example deals with the selection of an original solvent that is suitable for reaction task and 
verifies if it can be swapped by known swap solvent that is the best for the crystallization task 
following the reaction. Finally, the fourth example deals with the selection of a swap solvent 
that should first enhance the liquid-liquid phase separation after the reaction task, then replace 
the original solvent in a batch distillation operation and finally, be a good solvent for the 
subsequent crystallization step. The detailed application of the framework and the methodology 
is highlighted for example A while for the other examples, only selected issues of the solvent 
swap methodology are highlighted. 
5.2.1 Example A. 6-Hydroxybuspirone Synthesis and purification 
6-Hydroybuspirone is synthesized in one-step conversion from buspirone in tetrahydrofuran 
(THF). After the completion of the reaction, MTBE is added in reaction mixture to enhance the 
phase split between the organic (API, impurities) and the aqueous phase (catalyst and 
promoters). Finally, crystallization is employed in another solvent to isolate and recover 6-
Hydroybuspirone from the organic mixture [190]. 
Problem Definition: 
a. Selection and evaluation the performance of solvents in solvent swap operation.  
b. Evaluation of the selected solvents performance in the crystallization unit.  
 
Section A: Reaction pathway identification  
Step A.1. Select API or intermediate: 6-Hydroybuspirone 
Step A.2. Reaction pathway identification: Using the reaction type database two pathways have 
been found, one is involving the oxidation of buspirone to 6-hydroxybuspirone [190] and the 
other one is involving the selective enzymatic reduction of buspirone to 6-hydroxybuspirone 
[191]. In this example, the process for the production of 6-hydroxybuspirone using the 
chemocatalytic way is fixed; therefore, the chemical synthesis is selected for further analysis. 
The reaction path is illustrated in Figure 5.12. 
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Figure 5.12 Reaction pathway from buspirone to 6-hydroxybuspirone [190]. 
 
Section B: Reaction analysis 
The process involves the enolation of buspirone in tetrahydrofuran at very low temperature 
range of -68oC to -75oC in presence of excess of triethylphosphite (3.0-3.5 eq.). Then oxygen 
in form of air is added in the system for the oxidation of the formed enolate and reaction 
completion. The selected solvent is THF due to its good solubility of buspirone and 6-
hydroxybuspirone during the reaction at low operating temperatures. The reaction temperature 
is low to ensure that the formed enolate will not be decomposed during the reaction. Enolate 
the thermally sensitive and due to the potential big temperature gradients (enolation step: 
exothermal reaction 41.9 kJ/mol, adiabatic temperature rise 4.2 oC; oxidation step: exothermal 
reaction 685 kJ/mol, adiabatic temperature rise 68 oC), every low temperature has been selected. 
Additionally, triethylphosphate low concentration leads to the formation of impurities, high 
concentrations of triethylphosphate lower the product recovery during the purification task. 
Regarding the process safety, at high concentrations of triethylphosphite, the consumption 
hazardous peroxides, which are formed as intermediate products, is ensured. Therefore, the 
build-up of these compounds in the reactor is minimized together with any potential risks [12], 
[190]. High concentration of the base and introduction of air, prior to complete enolation leads 
to the formation of diol by-product. Table 5.24 gives the summary of the reaction analysis 
section.  
Table 5.24 Reaction analysis for the oxidation of buspirone to 6-hydroxybuspirone. 
Reaction Step: Oxidation of buspirone  
Step B.1 Data collection Reactants: Buspirone; Oxygen 
 Main Product 6-hydroxybuspirone 
 Side Products 6,10-dihydroxybuspirone 
 Phases Organic phase  
 Solvent  THF 
 Solvent Role Dissolves reactant  
 Catalyst Triethylphosphite 
 Reaction conditions  T = -60oC; P = 1atm; t = 8-24 hr 
 Reaction data  Yield = 69-71% 
 Experimental data  Starting and end points 
 Scale kg-scale  
 Kinetic Models  Not available 
Step B.2 Kinetic Study Reaction Class Slow C  
 Mass Transfer  Mass Transfer Limitation 
 Heat Transfer  Heat transfer limitation 
 Equilibrium  No information  
 Control Mechanism  Mass Transfer  
 Kinetic model Not available 
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Step B.3 Process 
evaluation Temperature  -68
oC to -75oC 
 Mixing  Rigorous  
 Concentration   
 Stoichiometry  Excess of triethylphosphite, stoichiometric amount of base 
 Pressure  No information 
 pH  - 
 Solvent  THF 
 Process conditions T = -68oC; P = 1 atm, t= 8-24hr 
 Process performance C=82%; S:high 
Step B.4 Batch or 
continuous 
Potential benefits  
 
a. Improved mass and heat transfer,  
b. Improved process safety  
 Unit operation database  Microreactor or trickle bed reactor 
 Decision Batch reactor (Process is fixed) 
Step B.5 Reactor design  Not performed  
Step B.6 Separation 
objectives  
a. Purify product 
b. Remove triethyl phosphate 
c. Rremove sodium bis  
(trim- ethylsilyamide) 
 
Section C: Separation synthesis 
Steps C.1-C.3: The process for the separation of 6-hydroxybuspirone is fixed. Therefore, the 
steps C.1-C.3, to identify the type and the sequence of unit operations is not necessary to be 
performed.  A simple state-task network is illustrated in Figure 5.13 [190]. 
 
Figure 5.13 Processing tasks for case study 1: reaction in THF, phase separation assisted by MTBE 
addition, solvent swap, crystallization in the swap solvent. 
 
Step C.4 Specification of unit operation  
Table 5.25 lists the unit operations involved in the separation of the reaction mixture, the 
process conditions, the separation factors, and the solvent required for the separation. The 
conditions and the specifications for the solvent swap operation and the following 
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crystallization task depend on the selected swap solvent. For the swap solvent selection the 
developed solvent swap methodology is employed.  
Table 5.25 Specifications of the different unit operation involved in 6-Hydroxybuspirone synthesis. 
Reaction Step Unit operation Process 
Conditions  
Separation 
factor 
Solvent 
Oxidation Liquid-Liquid 
phase separation 
T = 298 K, P = 1 
atm 
ξ=0.99; ξ=0.01 MTBE, aq. HCl 
 Solvent swap 
operation 
T, P Depends on the 
selected solvent 
Swap Solvent 
 Crystallization T = 298 K, P = 1 
atm 
Depends on the 
selected solvent 
Swap solvent  
 
Solvent swap methodology 
Step 1. Problem definition: The objective of this case is to select a swap solvent to swap the 
original solvent (THF/MTBE) and maximize the product recovery in the crystallization task 
(see Figure 5.13). 
Step 2. Feasible swap solvents candidates 
The swap solvent needs to have higher boiling point than the original solvent, the relative 
volatility of the original solvent compared to the swap solvent needs to be high and preferably 
no azeotrope formation with the original solvent (Table 4.1). Using the swap solvent database 
(Figure 4.12 and Figure 4.13), the solvents satisfying these criteria are given in Table 5.26. 
Table 5.26 Generated feasible swap solvent candidates by the step 2.1 of the method (see Figure 4.6 ), 
considering the good solvent swap. 
Original 
solvent Swap solvent candidate Tb OS<< Tb SwapS Relative volatility Azeotrope 
THF 
Acetic Acid 65<<117.9 10.12 No 
2-propanol 65<<82.2 3.44 No 
Toluene 65<<110.6 5.61 No 
Isopropyl Acetate 65<<88.6 2.65 No 
Anisole 65<<153.7 43.02 No 
Methyl isobutyl ketone 65<<116.5 7.97 No 
Ethyl Acetate 65<<77.1 1.71 No 
2-Methyltetrahydrofuran  65<<78 1.46 No 
Acetonitrile 65<<81.6 1.76 Yes 
Water 65<<100 6.60 Yes 
N,N-Dimethylformamide 65<<152 38.38 No 
N-Methyl pyrrolidone 65<<202 445.27 No 
Ethanol 65<<78.2 2.65 Yes 
1-butanol 65<<117.7 22.04 No 
2-methyl-1-propanol 65<<107.8 13.12 No 
Note: subscript OS indicate original solvent; SwapS indicates swap solvent 
The identified solvents given in Table 5.26 are further analysed considering the vapour-liquid 
equilibria phase analysis and investigating the vacuum effect in the system (see Figure 4.14). 
The results of the analysis are given in Table 5.27. 
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Table 5.27 Generation feasible swap solvent candidates by the Step 2.2 of the solvent swap 
methodology, considering the VLE analysis. 
Original 
solvent Swap solvent candidate 
Solvent Swap Process 
Classification Vacuum effect 
THF 
Acetic Acid Very Easy Positive 
2-propanol Difficult Positive 
Toluene Easy No effect 
Isopropyl Acetate Difficult Weakly positive 
Anisole Very Easy Positive 
Methyl isobutyl ketone Very Easy Weakly positive 
Ethyl Acetate Very difficult Weakly positive 
2-Methyltetrahydrofuran Very difficult No effect 
Acetonitrile C10 No effect 
Water C16 No effect 
N,N-Dimethylformamide 
(DMF) Very Easy Positive 
N-Methyl pyrrolidone Very Easy No effect 
Ethanol C33 Positive 
1-butanol Very Easy Positive 
2-methyl-1-propanol Very Easy Positive 
 
Step 3. Candidate analysis 
The swap solvent must not only be able to replace the original solvent from the reactor effluent, 
but also must have very good performance during the next processing step, which is 
crystallization. Therefore, the aim here is to select a solvent from the list given in Table 5.27, 
which will lead to high product recovery from the crystallization task. 
Model development – parameter regression 
To evaluate the potential product recovery during crystallization in different solvents, a detailed 
analysis of solid solubility is required. Although ICAS-SolventPro can be employed to calculate 
the solid solubility, for the given API product, the model parameters for the NRTL-SAC model 
needs to be estimated first. As experimental solubility data of 6-hydroxybuspirone in 13 
solvents are available [190], they are used for the parameter regression, where 8 solvents out 
of the 13 are used as representatives of hydrophilic, polar, hydrophobic solvents (experimental 
data is given in Table 7.11). The regression has been performed in ICAS-SolventPro and the 
regressed NRTL-SAC molecular parameters for 6-hydroxybuspirone from its solubility data in 
eight solvents are given in Table 5.28. 
Table 5.28 Regressed NRTL-SAC parameters solute. 
Segment Parameters X Y- Y+ Z 
6-Hydroxybuspirone 0.411 0.255 1.761 0 
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Solute solubility analysis and swap solvent selection 
With the regressed parameters the NRTL-SAC model can be used to predict the solubility of 
6-hydroxybuspirone in the remaining and other solvents. The predictions are shown in Figure 
5.14 where the empty circles represent the solid solubility data in the eight pure solvents that 
were used for the regression step while the solid circles represent those that were not included. 
It is important to note that the model does quite well at the low solubility where the swap solvent 
should work and the high solubility where the original solvent should work. 
 
Figure 5.14 Regression of the NRTL-SAC parameters, empty circles indicate data used for regression 
and the filled ones are the predicted values. 
 
The identified model is also used to predict solid saturation curves in different solvents as a 
function of temperature, which are shown in Figure 5.15. According to the data in Figure 5.15, 
2-Propanol (IPA), Ethanol (EtOH) and 1-Butanol (n-BuOH) have the potential for high product 
recovery and are therefore, selected for further analysis. 
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Figure 5.15 Solid-Liquid equilibria (SLE) of the solute with respect to the temperature for different 
solvents. 
Identify operational limits for batch distillation 
Detailed solubility analysis is performed to identify the solubility limits during the distillation 
operation to avoid solute precipitation during batch distillation. The solute solubility in the 
solvents as a function of temperature and solvent mixture is shown in Figure 5.16 for the IPA-
THF solvent mixture. The results for the other two solvents (EtOH and n-BuOH) are included 
in Appendix B (see Figure 7.6 and Figure 7.8). Selecting a temperature below the saturation 
point guarantees that precipitation of the solute will not occur during the swap operation by 
batch distillation. The solid saturation curves help to establish the maximum potential recovery 
after each batch distillation run. 
 
Figure 5.16 Saturation solubility of the solute as a function of the solvent mixture composition (IPA-
THF) for different temperatures. 
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Section D. Process analysis/simulation and analysis 
In this section, the identified swap solvents are going to be evaluated through dynamic 
simulations. Detailed calculations are considered for the solvent swap operation, and simple 
mass balances, based on the solid-liquid equilibrium, are considered for the crystallization 
operation. The simulation were performed in ICAS using the dynamic batch distillation tool, 
the results of the simulations used to evaluated the process alternatives based on the predefined 
criteria.  
Step D.1 Process simulation/evaluation  
Swap operation 
The selected swap solvents are evaluated through rigorous dynamic simulations of batch 
distillation operations by using ICAS-still. The simulation results verify if feasible operational 
criteria such as operation time, swap solvent use, solvent water, and swap solvent charges can 
be obtained for the specified product recovery. Table 5.29 gives the details of the mixture 
(organic phase) after liquid-liquid extraction and before the swap operation. 
Table 5.29 Mixture composition of organic phase after the liquid-liquid extraction task. 
Compound Amount, kg 
MTBE 16.20 
THF 165.29 
Buspirone 2.65 
6-Hydroxybuspirone 7.35 
Diol traces 
 
Starting with the charge given in Table 5.29, 79 kg of fresh swap solvent are added to the batch 
distillation still. Dynamic simulations are performed for a boil-up flowrate of 1 kmol/hr and a 
still volume of 0.3 m3 at a reduced pressure of 0.1 atm. The obtained simulation results are 
presented in Figure 5.17 where the simulated volumetric compositions in the batch still during 
the batch distillation operation are shown. As expected, the total volume of the still and the 
compositions of the original solvent (THF & MTBE) decreases during the operation while 
composition of the swap solvent increases. The end of the operation, as batch distillation limit, 
(see Figure 5.17) is identified as the composition of the solvent that is not high enough to 
prevent solute precipitation - detailed solubility analysis from step 3 (this calculation procedure 
is explained in detail in section B-I.1 of the Appendix B). Therefore, to avoid precipitation 
during swap operation, the batch distillation should be stopped at the distillation limit or more 
swap solvent should be charged. The composition at the end of batch distillation is given in 
Table 5.30 
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Figure 5.17 Simulated transient responses of volumetric compositions and the still volume in a batch 
still (ICAS-Batch Still used for simulation).  The distillation limit represents the point where the 
operation has to stop in order to avoid solute precipitation. 
 
Table 5.30 Final composition of the mixture after the end of the batch distillation. 
 MTBE IPA THF Product 
Amount (kmoles) 0.0314 0.6787 0.6718 0.0204 
mol fraction (mol%) 0.0224 0.4840 0.4790 0.0146 
Mass fraction (wt%) 0.0272 0.3999 0.4749 0.0980 
 
Product recovery by crystallization 
The evaluation of the candidate swap solvents also need to consider the operational tasks after 
batch distillation. For example, if the product is to be recovered through crystallization, then 
the maximum potential for product recovery achievable through the swap solvent needs to be 
calculated apriori (see calculation example 1 in section B-I.2 in appendix B).   
Another issue with respect to use of crystallization for product recovery is how many times the 
operation needs to be repeated to achieve a desired product recovery amount.  
In Figure 5.18, t the initial (point 1), and the final (point 2) in terms of composition of the solute 
in the solvent mixture are shown as filled circles. The corresponding solute saturation curves 
for the initial and final compositions are also shown in Figure 5.18. It can be noted that by 
simply cooling from the final composition point to ambient temperature, no product can be 
recovered as solid. Only if the mixture is cooled further down to 285 K, around 30% of the 
product is recovered.  Therefore, in order to achieve higher product recovery, additional solvent 
swap charges are needed to replace completely the original solvent. Another option is run a 
sequence of crystallization operations at different solvent concentrations and/or temperatures. 
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Figure 5.18 Evaluation of the maximum potential product recovery during after the batch distillation. 
Figure shows the initial composition of the mixture and the corresponding saturation curve 
(IPA:THF=2:3) and the final composition when the distillation ends together with the corresponding 
saturation curve (IPA:THF=1:1). Performing the mass balances at the desired crystallization 
temperature, the potential recovery is evaluated. 
To investigate how much swap solvent needs to be charged to obtain a specified product 
recovery, three operational scenarios are considered. In base case scenario (Scenario 1), there 
is one swap solvent charge, and in Scenarios 2 and 3 there are two and three swap solvent 
charges, respectively. Note that Table 5.29 and Figure 5.17 and Figure 5.18 correspond to 
Scenario 1. The simulation results of the swap operations together with the distillation limits 
for Scenario 2 and the solid solubility analysis for scenario 2 are shown in Figure 5.19a and 
Figure 5.19b. After the end of the swap task the obtained mixture (point “2”, Figure 5.19) is 
cooled to ambient temperature and the potential product is calculated to be close to 86%.  
 
Figure 5.19 Simulation results for Scenario 2, (a) Volumetric composition in the batch still for two 
swap solvent charges and (b) calculation of the maximum potential product recovery based on the 
corresponding solid saturation curve. 
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The simulation results of the batch distillation operation during the second scenario where three 
swap solvent charges are considered and the corresponding saturation curves are presented in 
Figure 5.20. Similarly to the analysis before, given the final obtain composition (point “2”, 
Figure 5.20b) and cooling to ambient temperature (point “3”, Figure 5.20b), the potential 
recovery is calculated slightly higher than 89%. 
Figure 5.20 Simulation results for Scenario 3, (a) Volumetric composition in the batch still during the 
second run and (b) calculation of the maximum potential product recovery based on the corresponding 
solid saturation curve. 
 
The amount of the swap solvent added for every scenario and the calculated potential recoveries 
are given in Table 5.31. To summarize for the case where 2-propanol is used as a swap solvent, 
three swap solvent charges are needed to achieve maximum potential recovery by 
crystallization. The reason for this is that THF is completely removed from the system during 
the first and the second swap solvent charges. Taking also into account the high solute solubility 
in THF, lower temperatures are needed in order to recover higher amounts of the solute during 
crystallization. Therefore, a third swap charge is needed to remove almost the entire original 
solvent amount and to make the potential product recovery high when crystallization is 
performed at ambient operating temperatures. 
Table 5.31 Scenario description for swap solvent addition and maximum potential product recovery in 
the crystallization unit.   
Scenario Swap solvent added 
Max potential recover, 
crystallization at 298K 
Base case 79 kg 0.00% 
Scenario 1 79 kg 85.73% 
Scenario 2 79 kg 89.38% 
 
The results of similar analysis performed for the other two selected swap solvents, ethanol and 
n-butanol, are given as supplementary material (Figure 7.7 and Figure 7.9 and Table 7.12 and 
Table 7.13 in section B-I.4).The performance criteria are calculated using the simulation results 
and compared with the results given by Watson et al. [190]. The results are given in Table 5.32 
and it can be seen that one of the selected solvents (2-propanol) has also been used by Watson 
et al. [190], giving similar results with respect to the number of swap solvent charges and the 
total process yield calculated from experimental data [190]. Considering the performance 
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criteria and the selected swap solvents using the methodology, the overall process performance 
is better when n-BuOH is used as swap solvent (see Table 5.32). In case of ethanol, better 
performance is achieved during the solvent swap task, with respect to the solvent use, solvent 
losses and operation time, however, lower product recovery and lower overall process yield is 
achieved in comparison with 2-propanol. 
 
Table 5.32 Summarized results and comparison of results for case study 1.  
Solvent swap task This study Literature [190] 
Swap solvent IPA EtOH n-BuOH IPA 
Fresh swap charges 3 3 2 3 
Swap solvent use (kg) 237  207 148 237 
Solvent losses (kg) 350 320 172 n.i. 
Distillation operation time 
(hr) 5.5 5 3.92 n.i. 
Crystallization task     
Temperature (K) 298 298 298 298 
Max potential recovery 
(%) 89.38 81.97 91.63 n.i. 
Product loss (kg) 0.87 1.47 0.41 n.i. 
Total process      
Yield 70.1% 67% 75% 70-71% 
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5.2.2 Example B. Heck reaction 
Heck reactions with aryl triflates are very common reactions because they are found in a wide 
range of reaction paths and give access to regioisomeric products [192]. However, due to the 
lack of commercially available aryl triflates, they need to be produced prior to their use in Heck 
reactions. Triflates are commonly prepared from phenols and trifluromethanesulfonic 
anhydride in chlorinated solvents using stoichiometric amounts of amine bases. After the 
reaction is completed, the salt by-products and the excess of reagents are removed by liquid-
liquid extraction. The next reaction step usually needs to be carried out in another solvent, 
therefore the chlorinated solvent needs to be removed and replaced. 
Problem Definition: 
a. Selection and evaluation the performance of solvents in solvent swap operation  
b. Evaluation of the selected solvents performance for the reaction step 
 
Section A: Reaction pathway identification  
Step A.1. Select API or intermediate: Aryl triflates 
Step A.2. Reaction pathway identification: Searching in reaction type database for aryl triflates 
reactants utilized via Heck reactions, two reactive pathways were found. The overall reaction 
path is illustrated in Figure 5.21 
 
Figure 5.21 Synthesis of the aryl triflate in the first reaction step and utilization in Heck reaction. 
 
Section B: Reaction analysis 
In this example, the first reaction step 4-tert-butylphenyl tri-fluoromehtnaesulfonate is the aryl 
trilfate of interest, which is produced in dichloromenthane (CH2Cl2) from 4-tert-butylphenyl 
alcohol  and trifluromethanesulfonic anhydride using Diisopropylethylamine amine donor at 
20oC [192]. In the second step, the product from the first step is combined with alkene coupling 
partner, amine base, Pd catalyst, and ligand in a polar aprotic solvent at temperature higher than 
100oC. For the second reaction low temperature (below 100oC) and presence of 
dichloromenthane (above 5% v/v) decreases dramatically the reaction yield.  
After the first reaction step, salt by-products and excess of reagent need to be removed and 
solvent needs to be replaced with a polar aprotic solvent in order to improve the performance 
of the second reaction.  
 
Modeling and synthesis of pharmaceutical process: moving from batch to continuous 
 
120 
 
Section C: Separation synthesis 
The process for the separation of 6-hydroxybuspirone is fixed. Therefore, the steps C.1-C.3, to 
identify the type and the sequence of unit operations is not necessary to be performed. A simple 
process diagram with the synthesis of aryl triflates, the liquid-liquid separation by introducing 
aq. HCl, the solvent swap operation and the second reaction is illustrated in Figure 5.22 [192]. 
 
 
Figure 5.22 Processing task for the case study 2. Reaction in DCM, washing the impurities with aq. 
HCl, solvent swap, reaction in the swap solvent. 
For the selection of the swap solvent, the solvent swap methodology is employed.  
Solvent Swap methodology 
Step 1. Problem definition: The objective of this example is to remove the original solvent 
(dichloromethane, DCM) used for the synthesis of aryl triflate and replace it with a polar aprotic 
organic solvent (swap solvent) for the next processing task which is another reaction (see Figure 
5.22).  
Step 2.Feasible swap solvents candidates 
Dichloromethane has very low boiling point and it can be swapped with almost any solvent that 
present in the database (Table 4.5) and have a higher boiling point. Using the database (Figure 
4.12 and Figure 4.13), a list of feasible swap solvent candidates is identified and given in Table 
5.33.  
Table 5.33. Feasible swap solvent candidates that can replace DCM. Solvent classification: HBD: 
hydrogen bond donor, AP: aprotic polar, AALP: aromatic apolar or highly polar, EPD: electron pair 
donors, AAA: aliphatic aprotic apolar. 
Original 
solvent 
Swap solvent 
candidate 
Solvent Swap 
Process 
Classification 
Vacuum 
effect 
Tb 
(oC) 
Solvent 
Classification 
DCM Acetic Acid Very Easy No effect 117.9 HBD 
Acetone Very Difficult No effect 56.0 AP 
THF Easy Negative 65.0 AP 
2-methyl 
pentane Very difficult No effect 60.2 
No 
classification 
Methanol Easy No effect 64.8 HBD 
2-propanol Very easy Positive 82.3 HBD 
Toluene Very easy No effect 110.6 AP 
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Isopropyl 
Acetate Very easy Positive 88.6 
No 
classification 
Anisole Very Easy Weakly positive 153.7 AALP 
Methyl 
isobutyl 
ketone 
Very Easy Weakly positive 116.5 
No 
classification 
Ethyl Acetate Very easy Weakly positive 77.1 AP 
2-
Methyltetrahy
drofuran 
Easy Negative 78.0 No classification 
Acetonitrile Very easy No effect 81.6 AP 
Water Very easy No effect 100.0 HBD 
N,N-
Dimethylfor
mamide 
Very easy Weakly positive 152.0 AP 
MTBE Very Difficult Weakly positive 55.2 EPD 
N-Methyl 
pyrrolidone Very easy No effect 202.0 
No 
classification 
 
Step 3. Candidates Analysis 
In order to reduce the number of solvents identified in step 2, the swap solvent specifications 
for the next processing step are taken into account. According to experimental data [192], the 
swap solvent must be aprotic polar and the reaction usually takes place at temperature higher 
than 100oC. Therefore, the solvent must have a high boiling point (>100 oC) to assure that the 
solvent remains in the liquid phase during the swap operation [126] and to achieve  high product 
yield [192]. Toluene and DMF are the solvents which satisfy the solvent constrains for the 
reaction solvent (aprotic solvent and boiling point > 100oC). The selected solvents (toluene and 
DMF) are marked in bold in Table 5.33. It should be noted that Hartman et al. [192] also 
selected these two solvents.
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5.2.3 Example C. Synthesis and purification  
An API (unknown structure) is produced via hydrogenation reaction in an organic solvent, 
which can dissolve the reactants and the catalyst, increases the reactivity of the system and it is 
immiscible with water. After the production of the desired API, the salt impurities are extracted 
in the aqueous phase and a swap solvent that is suitable for the crystallization replaces the 
original solvent. For this case study the best performing solvent for the crystallization is toluene 
[64]. 
Step 1. Problem Definition 
The objective of this example is to identify the solvent that should be used for the reaction task, 
given that the swap solvent is toluene. The operational tasks needed for this process are shown 
in Figure 5.23.  
 
 
Figure 5.23 Processing tasks for the case study 3. Reaction in an original solvent, followed by washing 
step, solvent swap to toluene and crystallization in toluene.   
 
Step 2. Feasible solvents candidates 
The feasible solvent candidates are identified by looking for solvents that can be swapped by 
toluene using the swap solvent database (Figure 4.12, Figure 4.13 and Figure 4.14). The list of 
feasible original solvents are given in Table 5.34. 
Table 5.34 The generated feasible original solvents that toluene can swap. 
Original Solvent 
Candidate 
Swap 
solvent
Solvent Swap Process 
Classification Vacuum effect 
DCM Toluene Very Easy No effect 
MTBE Very Easy No effect 
Acetone Very Easy Positive 
2-methyl pentane Very Easy Positive 
Methanol Conditional Negative 
THF Very Easy No effect 
EtOAc Easy Weakly positive 
MeTHF Very Easy Weakly positive 
MEK Easy Weakly positive 
MeCN Conditional No effect 
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IPA Conditional Positive 
IPAc Very Difficult Weakly positive 
2-methyl-1-
propanol Conditional Negative 
water Conditional Weakly negative  
 
Step 3. Candidate Analysis 
To reduce the search space, concerns about the reaction step are considered. The solvent needs 
to have high API solubility and low water solubility. The API structure is not known but some 
experimental data is available, which shows that the API has very low solubility in toluene and 
high solubility in 2-methyl-1-propanol (i-BuOH) [64]. Therefore, the solubility parameter of 
the API should have a value close to 20 MPa½<SP<23 MPa½ (based on the value of i-BuOH). 
Considering the solubility parameters and the miscibility in water (retrieved from CAPEC 
database) the reduced list of the solvents is given in Table 5.35. Note that since the reaction 
temperature is not known, the boiling point and melting point temperatures are not considered 
in this analysis. 
Table 5.35 The selected original solvents based on the reaction concerns. 
Original Solvent Candidate SolPar (MPa½) Water Solubility 
DCM 20.4 Slightly soluble 
2-methyl-1-propanol 22.9 Slightly soluble 
 
Based on the analysis and the concerns for the reaction, two solvents are selected: DCM and i-
BuOH, where the selection of i-BuOH has also been reported by Hsieh et al. [64].  
Step 4. Process validation 
Further analysis cannot be performed in this example, as the molecular structure of the API is 
unknown. 
5.2.4 Example D. Ketone intermediate for the LY500307 synthesis 
A key intermediate for the production of API LY500307, is produced via the hydrogenation 
reaction in a solvent mixture of MeOH/EtOAc. After the reaction task has been completed, a 
swap solvent is added in the mixture to facilitate separation of the product from the reactor 
through liquid-liquid separation where the organic phase that contains ethyl acetate (EtOAc) 
and the API while the aqueous phase contains MeOH, water and water soluble impurities. From 
the organic phase, the original solvent is removed by batch distillation and the product is 
recovered through a subsequent crystallization task [193]. 
Step 1. Problem Definition 
The objective is to find a solvent that enhances the phase split between methanol and ethyl 
acetate after the reaction step and the selected solvent should be able to swap the original 
solvent (ethyl acetate) and should be suitable for the crystallization task.  
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Step 2. Feasible swap solvents candidates 
Using the database (see Figure 4.12 and Figure 4.13), the feasible solvent candidates are given 
in Table 5.36 
Table 5.36 List of generated swap solvents that can replace ethyl acetate. 
Original Solvent 
Candidate Swap solvent 
Solvent Swap 
Process 
Classification 
Vacuum effect SolPar (MPa½) 
EtOAc Acetic Acid Easy Weakly Positive 19 
 2-propanol Conditional Positive 23.4 
 Toluene  Easy Weakly Positive 18.3 
 Anisole  Very easy Weakly Positive 20.1 
 MIBK Easy  Weakly Negative 17.4 
 NMP Easy  No effect 23.2 
 Water Conditional No effect 47.8 
 DMF Very easy Weakly Positive 23.9 
 Ethanol  Difficult  Positive 26.1 
 1-butanol  Very easy  Weakly Positive 23.3 
 2-methyl-1-propanol Very easy No effect 22.9 
 
Step 3. Candidates Analysis 
The swap solvent needs to dissolve the API and it should not be miscible with a mixture of 
MeOH/water. Using ICAS-ProPred the solubility parameter of the API is calculated, SolPar = 
20.61 MPa½. Therefore, solvents that have solubility parameter values between 19 MPa½ ≤ 
SolPar ≤ 21 MPa½, are good candidates the selected solvents are given in Table 5.37. Based on 
the analysis, four possible swap solvents are identified. These solvents can be further analyzed 
for their performance in the liquid-liquid separation task and the crystallization task by 
performing LLE and SLE calculations, respectively. The use of toluene as the swap solvent has 
also been reported by Johnson et al. [193]. 
Table 5.37 The selected solvents for the case study 4. 
Original Solvent 
Candidate Swap solvent SolPar
½ 
EtOAc Acetic Acid 19 
 Toluene  18.3 
 Anisole  20.1 
 MIBK 17.4 
 
Based on the methodology four solvents have been selected as swap solvent, acetic acid, toluene 
(selected in the literature, Johnson et al., [193]), anisole and MIBK. 
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Step 4. Process validation 
Further analysis was not performed in this example. 
5.2.5 Conclusions 
The methodology has been applied to several case studies where it has been shown that it is 
possible to identify solvents that have higher potential for specific solvent swap tasks. The swap 
solvent selections are validated through dynamic simulations with rigorous models different 
use of solvents, operations and operation modes. One aspect not studied but could be interesting 
is to see how swapping of solvents could be avoided, for example, selecting the same solvents 
for more than one processing step or completely avoid the use of solvents.
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5.3 Case study 3: Production of L-2 Aminobutyric acid-Process 
intensification 
L-aminobutyric acid is an unnatural amino acid that it serves an intermediate for the synthesis 
of key chiral APIs such as Levetiracetam (anti-epileptic), Ethanmbutol (anti-tuberculotic) and 
Brivaracetam (anti-tuberculotic) [194]. 
5.3.1 Problem definition  
Objectives: 
 Investigation of the effect of solvent in reactionperformance. 
 Investigation of the advantages of process intensification and continuous operation  
 Process development  
5.3.2 Section A. Reaction pathway identification 
Step A.1. Select API or intermediate: L-2-aminobutyric acid 
Step A.2. Reaction pathway identification: Using the reaction database, several chemocatalytic 
and biocatalytic reactions have been suggested for the synthesis of unnatural amino acids. 
The selected reaction pathway is illustrated in Figure 5.24, 
 
Figure 5.24 The reaction pathway as it has been identified from the reaction type database. 
5.3.3 Section B. Reaction analysis 
The reaction takes places in the aqueous phase at mild conditions. 2-oxybutyric acid (OA) 
reacts with benzylamine (BA) which acts as amine donor to produce benzaldehyde (BD) and 
L-2-aminobutyric acid (AABA). The reaction is equilibrium controlled and catalysed using ω-
transamination (ω-TA) from Vibrio fluvialis. It exhibits amine donor inhibition when the 
concentration of benzylamine is above 100mM and it has shown severe product inhibition by 
benzaldehyde. To overcome the equilibrium limitations, the introduction of an organic solvent 
in the reaction mixture to create a second liquid phase and extract the inhibitory product has 
been used to increase the reaction rate and shift the equilibrium towards the product site (96% 
in biphasic system compared to 39% of the single phase system), with very high enantiomeric 
selectivity (ee%>99%) [151]. The reaction is a slow reaction (Type C) and it is operated in 
batch mode. However, according to the unit operation database, for this kind of operation, 
enzymatic reaction in two phase system with product removal, continuous operation might be 
beneficial for the system. Using the unit operation database, an enzyme multiphase continuous 
reactor is proposed (EMR) which has the advantage of completely separating the enzyme with 
the organic phase to avoid any potential contact of the enzyme with the organic phase.  
The summary of the reaction analysis step is given in Table 5.38. 
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Table 5.38 Reaction analysis for the oxidation of buspirone to 6-hydroxybuspirone. 
Reaction Step: Oxidation of buspirone  
Step B.1 Data collection Reactants: 2-Oxybtyric acid (OA); Benzylamine (BA) 
 Main Product L-Aminobutyric acid (LA) 
 Side Products Benzaldehyde (BD) 
 Phases Single (L) or Biphasic (L-L) 
 Solvent  Water or Water/Organic 
 Solvent Role 
Water: Reaction medium 
Organic: Create another phase to 
extract the by-product 
 Catalyst ω-Transamase 
 Reaction conditions  37oC; 1 atm 
 Reaction data  C= 39% (or 96%) ee(%) > 99% 
 Experimental data  Conversion vs. time 
 Scale mg scale (reaction volume ml scale) 
 Kinetic Model  Available  
Step B.2 Kinetic Study Reaction Class Type C 
 Mass Transfer  Mass Transfer Limitation  
 Heat Transfer  No information  
 Equilibrium  Yes 
 Control Mechanism  Equilibrium controlled  
 Kinetic model Fitted (see Figure 5.25) 
Step B.3 Process 
evaluation 
Temperature 37oC (higher temperature results in 
higher enzyme deactivation, lower 
temperature results in very low 
reaction rates) 
 Mixing  Gentle mixing 
 Concentration  CBA<100 mM  
 Stoichiometry  1:1.4 
 Pressure  1 atm 
 pH  7 
 Solvent  Table 5.40  
 Process conditions 37oC; 1 atm, t =5hr 
 Process performance C: 91%; ee: >99% 
Step B.4 Batch or 
continuous 
Potential benefits  Enzyme deactivation 
Lower amount of mass utilized 
Solvent recycle 
 Unit operation 
database  
Enzyme multiphase membrane 
reactor 
 Decision Batch, Section 5.3.3.2 
Step B.5 Reactor design  Not performed  
Step B.6 Separation 
Objectives 
 Separation of the phases 
Recover organic solvent 
Purify main product 
 
The kinetic model has been developed using the multiphase reaction modelling framework by 
Anantpinijwatna et al. [173]. Available experimental data [151] used for parameter estimation. 
The modelling fitting [25], [195] is illustrated in Figure 5.25. 
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Figure 5.25 Comparison between model prediction for biphasic and single phase: solid line) and 
experimental data (biphasic: open circles and single phase: Filled circles). Organic solvent: Hexane. 
5.3.3.1 Solvent selection for step B.3 
To create a second phase, the organic solvent should be selected that is immiscible with the 
aqueous phase and it selectively dissolves the inhibitory product. For the solvent selection the 
partition coefficient of the compounds involved in reaction are analysed and given in Table 
5.39. The partition coefficient of the compounds that are desired to remain in aqueous phase 
should be high, the compounds with low partition coefficients migrate in organic phase [195]. 
Table 5.39 Partition coefficient of the involved species in the long chain hydrocarbon solvents 
[25]. 
Partition orgi
aq
i
γ
γ
   
 Benzylamine  2OA  AABA  Benzaldehyde  
Hexane  1.014 1.20 x 105 2.22 x 105 1.24 x 10-4 
Heptane  0.849 1.85 x 105 2.81 x 105 1.20 x 10-4 
Isooctane  0.323 1.20 x 105 1.46 x 105 6.29 x 10-5 
Octane  0.338 2.68 x 103 8.40 x 103 7.69 x 10-5 
 
The evaluation of the reaction performance in terms of half-time, overall reaction rate, 
conversion and obtained product for the considered solvent is given in Table 5.40. Maximum 
conversion and reaction rates are achieved using isooctane and octane as solvent. However, the 
productivity of the system using octane and isooctane is lower compared to the productivity 
achieved when hexane or heptane is used [195]. 
 
Table 5.40 Predicted reaction information carried out in different solvents [195]. 
Solvents  Half-Life (hr.)  Overall 
Reaction Rate 
(μmol·h-1) 
Maximum 
Conversion  
Maximum 
Product (μmol)  
Hexane  0.425  0.980  0.950  46.075  
Heptane  0.475  0.977  0.947  45.930  
Isooctane  0.302  1.380  0.970  33.950  
Octane  0.311  1.340  0.970  33.950  
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Considering the results given in Table 5.40, selecting a solvent depends on the objectives of the 
study. Selecting, for example, octane as the extraction solvent, the product losses are high but 
at the same time, the separation of the phase containing the product might be less complicated. 
However, for the production of pharmaceutical product, the most important criterion is the 
product recovery. Therefore, here, hexane is used as the extraction solvent.  
5.3.3.2 Step B.4 Batch or continuous? 
According to unit operation database, the batch reactor can be converted into continuous 
enzyme multiphase reactor. In this section an evaluation between the two operation modes is 
performed. 
5.3.3.2.1 Comparison of the batch and the continuous reactive system.  
Here, the objective is to compare the batch operation and the proposed continuous operation 
(EMR). It is should be noted that the membrane which selectively separates the inhibitory 
product from the reaction mixture, to our knowledge, does not exist. However, the purpose here 
is to examine whether a continuous operation of the particular system is beneficial or not. In 
case, that process improvements can be achieved by converting, the batch process to 
continuous, further experimental verification is needed. Table 5.41 gives the description of the 
two scenarios of interest, the production target, the operation time, initial concentration, and 
required volume for the aqueous and organic phase. 
 
Table 5.41 Scenario of interest for the synthesis of L-2-aminobutyric acid.  
Scenario 1 2* 
Reactor  Batch  EMR 
Productivity  43 mmol 8.64 mmol/hr 
Operation time, hr 5  5 
Concentration, mM 50 70 
Aqueous phase volume, ml  1 0.17 
Organic phase volume 5 x Vaq 5 x Vaq 
*For the second scenario, an EMR reactor model has been developed based on the reaction model. The total reactor 
model; functional description (Figure 7.10), model construction (Table 7.17 and Table 7.18), model analysis (Table 
7.19)is given in Appendix C. 
 
The simulation results are given in Table 5.42, where the productivity per reaction volume has 
been calculated and compared. The use of continuous multiphase enzyme membrane reaction 
has demonstrated much higher productivity per reactor volume than the batch operation.  
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Table 5.42 Reaction productivity for the batch system. 
Scenario Conversion %  Ammount, mmol Productivity mmol/ reactor volume 
1 91% 43.2 mmol 7.2 
2 91.6% 43 mmol 38 
 
5.3.3.2.2 Simulation Results 
The developed model now is used to investigate the production at higher production rate 
(92mmol/hr, approximately 10 times higher than the productivity rate previously used in 
Section 5.3.3.2). The reaction conditions are given in Table 7.21 (Appendix C) where for all 
the variables identified from the degree of freedom analysis a value has been assigned. The 
results are illustrated in Figure 5.26, where in Figure 5.26a, the concentration of the reaction 
species in the aqueous phase is illustrated. The concentration of the inhibitory product (BD), as 
it was expected, has very low value, close to zero, which means that is efficiently separated in 
the organic phase (see Figure 5.26b). In Figure 5.26a, it can be seen that the concentration of 
the benzylamine during the reaction is not approaching the concentration limit (100 mΜ) where 
the BA starts to inhibit the enzyme. Finally, the conversion of the main substrate is illustrated 
in Figure 5.26c. 
(a) (b)
(c)  
Figure 5.26 Simualtion results of the EMR reactor, where A: OA, B: BA, C: BD and D: AABA. (a) 
concentration in aquesous phase, (b) concentration in organic phase, (c) conversion. 
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5.3.4 Section C. Separation synthesis 
Steps C.1-C.2: The alternatives for the separation process of L-2-aminobutyric acid has been 
generated using step C.1-C3. The pure compound properties for the compounds involved in the 
process are given in Table 7.24 (Appendix C). The pure compound properties used to generate 
the binary ratio matrix, to identify the separation tasks and generate separation alternatives.  
Step C.3. Separation process selection  
The generated list of the selected process alternatives to separate the organic phase with the by-
product and to recover the product from the aqueous phase are listed in Table 5.43. 
Table 5.43 Separation process alternatives for production of 2-Laminobutyric acid A: water, B: BA ,C: 
2OA, D: AABA, E: BD, F: Hexane. 
Rank Process alternatives [SFILES]
1 (rABCDEF)(spABCD/EF)(lmE/F)[[(oE)]1(pF)](crD/ABC)[(oD)](dsAB/C)[(oAB)] (oC) 
2 (rABCDEF)(spABCD/EF)(lmE/F)[[(oE)]1(pF)](crCD/AB)[(oAB)](scSC/D)[(oD)](scS/C)[2(oS)](oC) 
3 (rABCDEF)(spABCD/EF)(lmE/F)[[(oE)]1(pF)](scD/SABC)[(oD)](dsS/ABC)[(oS)](oABC) 
4 (rABCDEF)(spABCD/EF)(lmE/F)[[(oE)]1(pF)](dsAB/CD)[(oAB)](scSC/D)[(oD)](dsS/C)[2(oS)](oC) 
 
5.3.5 Section D. Process Simulation/Evaluation 
From section C, two state task networks (Figure 5.27) have chosen for further evaluation. 
1 
 
2 
 
Figure 5.27 The two selected state task networks  where A: water, B: BA ,C: 2OA, D: AABA, E: BD, 
F: Hexane. 
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Step D.1 Process simulation/evaluation 
Mass and energy balances calculation were performed for both cases using Hexane as the 
extraction solvent. Then, the state task network 1 is compared using two different extraction 
solvents, hexane and octane. The results of the simulation are given in Table 5.44, where it can 
be seen that the state task network 1 required much less energy than the state task network 2 
and it generates 6% less waste per kg of product. Comparing now the state-task network 1 using 
two different solvents, hexane and octane, it can be seen that the energy requirements are lower 
and the generated waste per kg of product using octane is higher than using hexane. These 
results verify the conclusions that made after the extraction solvent selection step where it was 
concluded that the product recovery is enhance when hexane is used, however the waste 
generation increases by 3% as bigger amounts of compounds involved in the reaction are 
extracted in the organic phase when octane is used. 
 
Table 5.44 Batch process performance of the process to produce 2-L-aminobutyric acid. State-task 
network 1 and 2 compared using hexane as extraction solvent and state-task network 1 compared for 
two diffrent extraction solvents.  
Performance criteria 
Extraction solvent 
Hexane Octane 
 State-task network 
State-task 
network 2 
State-task 
network 1 
Energy Requirements 
MJ/kg product 0.93 + 272% -8.53% 
Waste kg/kg product 1.26 +6% 3.17% 
 
Environmental impact analysis using the WAR algorithm in ICAS was performed for the state-
task network 1 and 2 using hexane as solvent. Figure 5.28, illustrates the results where it can 
be seen that this process contributes to ATP category where in the rest of the categories the 
impact is negative that is a positive for environmental point of view. It is expected that when 
octane is used as solvent, the environmental impact is going to be higher due to the increased 
waste generation. Nevertheless, octane is not selected for further analysis due to high product 
losses and not significant process improvements.  
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Figure 5.28 Normalized comparison of the enironmental impact of the process to produce L-2- 
aminobutyric acid for two different state task networks. HTPI: human toxicity potential by ingestion, 
HTPE: human toxicity potential by exposure, ATP: aquatic toxicity potential, TTP: terrestial toxicity 
potential, GWP: global warming, ODP: ozone depletion potential, PCOP: Photochemical oxidation 
potential and AP: acidification potential. 
 
5.3.6 Conclusions 
In this case study, a multiphase reactive system selected to demonstrate the use of a solvent to 
achieve reaction improvement in terms of performance. Here, the role of the solvent is to extract 
the inhibitory product (in this case the by-product) and shift the equilibrium towards the product 
side. In this study a kinetic model develop and evaluation of the different solvents was 
performed by Anantpinijwtna [195]. Based on the kinetic model, a continuous multiphase 
enzymatic membrane reactor model developed and compared with the batch reactor model 
showing higher productivity per reaction volume. Finally, process alternatives to separate the 
reaction mixture have been generated and evaluated through simulations. An experimental 
verification of this new design is needed.  
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5.4 Case study 4: Glucose isomerization 
Glucose isomerization is an important processing step for the food industry as the high fructose 
syrup (HFS) product it produces, is widely used for its ability to improve the sweetening and 
color of food products, is metabolized without the intervention of insulin and is absorbed slower 
than glucose. The GI-plant to produce high fructose syrup usually consists of a pre-treatment 
part, a reaction part where glucose is converted to fructose and a separation part where fructose 
is separated and recovered and the unreacted glucose is recycled back. The reaction is an 
equilibrium controlled enzyme reaction and it is usually carried out in fixed bed reactors where 
the enzyme is immobilized. Due to enzyme deactivation the reactors in typical GI plants are 
operated in parallel to keep a consistent reactor effluent. 
5.4.1 Problem definition 
The objective of this case study is to first develop and then use a multi-scale model that can 
accurately describe the behaviour of an industrial glucose isomerization reactor so that it can 
be used after validation, for the simulation-based analysis to identify efficient operational 
modes of a GI plant. In particular, the model must consider different phenomena that occur in 
the reacting system such as the reaction kinetics, the substrate diffusivity and the enzyme decay 
as a function of the temperature. 
5.4.2 Section A: Reaction pathway identification  
For the glucose isomerization process, the reaction scheme is known, glucose together with the 
free enzyme react to form the complex enzyme and then the product is released, and the reaction 
is an equilibrium-limited reaction. The reversible glucose-fructose enzymatic isomerization is 
given by the following expression: 
(1) 
 
Where S is the substrate (glucose), E is the free enzyme; SE the complex enzyme formed during 
the reaction and P the product (fructose). 
5.4.3 Section B: Reaction analysis 
The glucose isomerization reaction is catalyzed by isomerase, the reaction temperature is 
around 55-60oC and the feed concentration 45-50% w/w glucose. The reactors in the plant are 
fixed bed reactors operated in a semi-continuous mode which means that the reactor runs for 
certain period of time, when the enzyme is completely inactivated the operation stops and the 
operation restarts, when new enzyme is loaded in the reactor. During the operation, the reaction 
conversion is decreasing due to the enzyme inactivation. However, it is preferred to maintain 
the conversion constant and it can be achieved by reducing the substrate flowrate throughout 
the duration of the operation. 
5.4.3.1 Reactor Modelling  
Step I.1: Modelling objective  
Glucose isomerization to fructose is the process of interest and more specifically, a reactor plant 
where high fructose syrup (HFS) is produced by glucose isomerization using isomerase as the 
enzyme is to be studied. The objective here is to develop a multi-scale reactor model that 
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describes the reaction kinetics, the enzyme decay and the internal diffusivity of the substrate as 
function of temperature. Model analysis, model identification, model evaluation and validation 
are to be performed. The validated model is to be used for simulation of a typical glucose 
isomerization reactor to identify operational modes that maximize the productivity.  
Step I.2. System information and documentation 
Step I.2.1: Functional description/sketch of the system to be modelled.  
For this process the reaction scheme is given in equation(1), glucose together with the free 
enzyme react to form a complex enzyme and then the product is released. The reaction is an 
equilibrium-limited reaction. A typical GI reactor plant is illustrated in Figure 5.27. The reactor 
plant consists of NR (= 10-20) fixed-bed reactors, where the enzyme is immobilized in the 
reactor. The reaction is an equilibrium reaction where fructose is obtained as a product and the 
reaction takes place in the enzyme pellets where the glucose is diffused. The enzyme activity 
decreases during the operation due to enzyme inactivation. The output from reactor is desired 
to be consistent and operated at values of glucose conversion between 42-45%. To keep the 
conversion constant, the inlet flowrate is adjusted (decreased) as the enzyme activity decreases 
during the operation. The reaction usually takes place between 55-60 oC. Lower temperatures 
are usually avoided due to the risk of microbial contamination of the substrate and higher 
temperatures are usually avoided due to faster enzyme inactivation (Novozymes A/S).  
 
Figure 5.29 A typical glucose isomerization (IG) reactor plant with N fixed bed reactors. The 
operating temperature is between 55oC-60oC, the dry substance content is between 45-52% w/w and it 
depends on the operation temperature (the lower the temperature the higher the dry solids). 
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Step I.2.2: Phenomena in the system. 
The following phenomena are identified in the reactor system: 
 Enzymatic equilibrium reaction. 
 Enzyme decay. 
 Substrate diffusion in the enzymatic pellets. 
 Mass transfer between the substrate’s flows to the interface of the pellets. 
 Flow in fixed-bed reactor. 
Step I.2.3: Modelling information 
For the development of the reactor model, the phenomena described in Step I.2.2 have to be 
mathematically described and combined with other classes of model equations. The reaction 
kinetics, the reactor modelling, and the enzyme decay for different enzymes have been 
described in the literature (see Table 5.45). 
Table 5.45 Review of the GI modelling studies. 
Authors  Glucose Isomerase  Model types Available data  
[196]* Streptomyces sp. 
 Reaction kinetics 
 Batch reactor model  
 Enzyme decay 
a. Kinetic parameters 
estimation using 
experimental data from 
Takasaki et al., 1969 
b. Enzyme Inactivation 
parameters  
[197] Streptomyces sp. 
 Reaction Kinetics 
 Reactor Model  
o Including enzyme 
decay 
Enzyme decay 
Michaelis-Menden parameter 
estimation from initial reaction 
rate experiments  
[198] Bacillus sp.  Reaction Kinetics  
Michaelis-Menden parameter 
estimation from initial reaction 
rate experiments 
[199] n.i.  Diffusion resistance  Enzyme decay  
Investigation of enzyme decay 
upon diffusion limitations and 
different decay rates for reactions 
with Michaelis-Menden 
mechanism 
[200] n.i. 
 Reaction Kinetics 
 Reactor Model  
o Including enzyme 
decay 
Investigation of reaction 
conditions (T, pH, operation cost, 
particle size) 
[201] 
[202] Swetase  
 Reaction Kinetics 
 Reactor Model  
o Including enzyme 
decay 
Enyzme decay 
Michaelis-Menden parameter 
estimation from initial reaction 
rate experiments 
Enzyme inactivation kinetics 
[203] n.i.  Reactor model  Internal Diffusion  
Dynamic model for fluidized-bed 
reactor  
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[204]; [205], 
[206] 
Sweetzyme 
T 
 Reaction Kinetics 
 Reactor Model  
o Including enzyme 
decay 
Enzyme decay 
Michaelis-Menden parameter 
estimation from rom initial 
reaction rate experiments  
Enzyme inactivation kinetics 
 
[207]; 
[207];[208];
[209] 
Sweetzyme 
IT 
 Reaction Kinetics 
 Reactor Model  
 
Michaelis-Menden parameter 
estimation from initial reaction 
rate experiments 
Fixed bed reactor modelling 
without including enzyme decay 
and assuming reaction at the 
interface of the enzyme pellet 
Kinetics of a Three-Step 
Isomerization of Glucose to 
Fructose  
[210] Sweetzyme IT 
 Reaction Kinetics 
 Reactor Model  
Michaelis-Menden parameter 
estimation from initial reaction 
rate experiments 
Simulated moving bed reactor 
modelling 
  
The earlier studies have mainly aimed at process improvements by evaluating the reaction 
kinetics, enzyme inactivation and the effect of process variables such as the inlet flowrate, the 
temperature and the inlet glucose concentration. The objective in this project, however, is to 
combine all these effects in one multi-scale mathematical model that can describe the important 
phenomena related to increased product yield and design-analysis of an industrial GI plant.  
 
Step I.2.4: Assumptions: 
Reaction Kinetics: 
 By-products are formed in minor amounts so their formation can be neglected. 
 Briggs-Haldane approach is considered for the enzyme kinetics where the enzyme 
complex concentration is assumed to rapidly approach a steady state and after the initial 
phase its concentration will remain constant (
  0d SE
dt
  ). 
Fixed-bed reactor model: 
 Superficial velocity is high enough so that the external mass transfer resistance is not 
dependent on velocity. 
 Axial dispersion is considered. It has been shown that the effect of the axial dispersion 
is negligible when convection is higher than diffusion; high values of Peclet number 
[211]. In this model, the effect of axial dispersion is considered to make sure that it is 
taken into account when Peclet number is lower close to the end of the operation.  
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 The radial dispersion is neglected. It has been shown that for a small ratio of column 
diameter to column length and large values of fluid velocity the radial dispersion can 
be neglected [212], [213]. 
Particle diffusion model: 
 Enzyme is inside the catalytic pellets and there is no partitioning of the enzyme between 
the solid and the liquid. Therefore, the substrate is diffused inside the catalytic pellet 
where the reaction takes place. 
 The enzyme is uniformly immobilized in the pellet. Therefore, the enzyme deactivation 
through the particle is the same during the operation.  
 The enthalpy of the reaction is very low so no temperature gradient within the pellet. 
Enzyme decay 
 The enzyme decay follows first order inactivation  
Step I.2.5: System data. 
Experimental data is available from Novozymes A/S. Measure data for enzyme activity for the 
Sweetzyme T enzyme was measured, as a function of the time for a temperature range (55 oC-
90 oC) is available. 
5.4.3.2 Phase II. Model construction 
Step II.2: Model development 
The developed multi-scale reactor model consists of balance equations (Partial Differential 
Equations, PDEs) and constitutive equations (Algebraic Equations, AEs) and it describes the 
diffusion of the substrate in the enzyme, the reaction and the enzyme decay that are taking place 
in one scale (the enzymatic pellet) and the flow in the fixed bed reactor that is the second scale. 
The model equations are listed in Table 5.46-Table 5.48  and Table 5.50, and they are described 
in more detail in Appendix D. Table 5.46 gives the balance equations, the Eq. (2) describes the 
dimensionless concentration distribution of the substrate as function of the dimensionless 
reactor length with respect to time subject to the boundary and the initial conditions. The 
balance Eq. (3) in Table 5.46, describes the diffusion of the substrate in the enzymatic pellet 
and the reaction as a function of the dimensionless pellet radius and the dimensionless time 
subject to the boundaries and initial conditions. 
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Table 5.46 Mass balance equations for GI reactor model. Partial differential equations (PDEs). 
Description Equation Equation 
Number 
Number of 
Equations 
Balance 
Equations 
   
Fixed bed 
reactor  
2
*
2
1s s s
s s
y y y a y yτ Pe ξ ξ
         
(2) 1 
Two independent variables (1. dimensionless time: τ and 2. Dimensionless length z) 
Discretised variable: ξ (dimensionless reactor length), ODE solution with respect to τ 
Solution method: method of lines (number of points: 10) 
Subject to: : 0 0, 0
11: 1, 0, 0
2 : 0, 0, 1
s
s
s
s
IC y for τ ξ
yBC y for τ ξ
Pe ξ
yBC for τ ξξ
  
    
   
 
  
Diffusion in 
catalyst pellet  
** 2 * *
,
2 12
, 3
2
1
s s eqs s s
E
s s eq
y yy y yQ Q yτ λ λ λ y y Q
           
 (3) 1 
Subject to: *
*
0
*
,1
: 0 0, 0
1: 0, 0, 0
2: 0, 1
s
s
λ
s S bulkλ
IC y for τ λ
dyBC for τ λ
dλ
BC y y for τ λ


  
  
  
 
  
Two independent variables (1. dimensionless time: τ and 2. Dimensionless length z) 
Discretised variable: λ (dimensionless reactor length), ODE solution with respect to τ 
Solution method: method of lines (number of points: 10) 
Total number of PDEs  2 
 
The enzyme decay equations are given in Table 5.47, 
Table 5.47 Enzyme decay for GI reactor model. 
Description Equation Equation Number 
Number of 
Equations 
Enzyme decay  E d Edy k ydτ   (4) 1 
Subject to: 1 0 : ,EIC y τ    
Total Number of ODEs  1 
 
The partial differential equations (PDEs) have been converted to initial value problem (IVP) 
by discretizing them using the method of lines with respect to the reactor length and the particle 
radius respectively. Table 5.48 gives the balance equation describing the flow in the reactor and 
the balance equation describing the diffusion in the enzymatic pellet after the discretization. 
The discretization performed using the method of lines and considering 10 discretization points.  
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Table 5.48 Discretized partial differential equations for GI reactor model using the method of lines and 
converted to initial value problem. 
Description Equation Equation 
Number 
Number 
of 
Equatio
ns 
Balance 
Equations 
   
Fixed bed 
reactor  , , 1 , , 1 , 1 , 1 *,n ,021 Δ 2Δs n s n s n s n s n s n s sy y y y y y a y yτ Pe ξ ξ           (5) 10 
Subject to: ,
,2 ,0
,0
,10 ,8
: 0 0, 0
1
1 : 1, 0, 0
2Δ
2 : 0, 0, 1
2Δ
s n
s s
s
s s
IC y for τ ξ
y y
BC y for τ ξ
Pe ξ
y y
BC for τ ξξ
  
    
   
 
  
Diffusion 
in catalyst 
pellet 
 
* * * * * * *
, , 1 , , 1 , 1 , 1 , ,
2 12 *
, ,
2
Δ 2Δ 1
s n s n s n s n s n s n s n s eq
E
s n s eq
y y y y y y y y
Q Q yτ λ λ λ y y
               
 
(6) 10 
Subject to: *,
* *
,2 ,0
*
,10 ,
: 0 0, 0
1: 0, 0, 0
2Δ
2: 0, 1
s n
s s
s S bulk
IC y for τ λ
y y
BC for τ λλ
BC y y for τ λ
  
   
  
 
  
Total number equations  20 
 
Now, the problem has been converted to IVP and the total number of ordinary differential 
equations including the enzyme decay is 21, so the initial conditions, which are required, are 
21. Table 5.49 gives the dependent variables, the number of the dependent variables, the initial 
conditions needed and their initial values. 
Table 5.49 Initial values for the dependent variables for GI reactor model.  
Dependent variable Number of variables 
Initial 
conditions 
Initial 
Value 
ys 10 10 0  
ys* 10 10 0 
yE 1 1 1 
 
The constitutive equations needed for the solution of the balance equations are given in Table 
5.50. 
Table 5.50 Constitutive equations for GI reactor model. 
Description Equation Equation Number 
Number of 
Equations 
Temperature in K 273.15T     (7) 1 
Arrhenius Expression, kj exp
j
j j
E
k A
RT
      (8) 
5 (j: vmf, vmr, 
kmf, kmr,d) 
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Equilibrium constant, Keq 
mf mr
mr mf
v k
eq
v k
k k
K
k k
  (9) 1 
Equilibrium conversion, 
Xeq 1
eq
eq
eq
K
X
K
   (10) 1 
Equilibrium dimensionless 
concentration, yeq , 0
1
100
eq
eq s t
X
y y 
      (11) 1 
Maximum apparent 
reaction rate, Vm 
1
1 mr mf
mr mf
k v
m
eq k k
k k
V
K k k
        
(12) 1 
Apparent Michaelis-
Menden constant, Km ,0
1
1 eq mr mfm eq S
mf mr mr mf
K k k
K y c
k k k k
           
 (13) 1 
Cross Section, A 2
4 b
A d  (14) 1 
Superficial Velocity, U0 00
FU
A
   (15) 1 
Particle Reynolds Number, 
Rep 
0Re pp
d U    (16) 1 
Schmidt Number, Sc 
m
Sc
D

  (17) 1 
Dispersion Diffusivity, DL     1.20.65 0.5 ReL mD D Sm  (18) 1 
Reaction Rate, Rs 
  
  
**
0
*
,0 0
1 m S eqS
s
S m S eq
V y y SdyR
w c dt K y y S
       (19) 1 
Peclet Number, Pe  0
L
H UP e
D
 (20) 1 
Dimensionless variable, Q4 4
m
cat
m
VQ
K
  (21) 1 
Dimensionless variable, Q1 41
0
Q HQ
U
   (22) 1 
Effective Diffusivity 
correlation  
6 24000 1 17.6032 10
333s
D x
R T
        
  (23) 1 
Thiele Modulus, φ 43
p
s
R Q
D
  (24) 1 
Dimensionless variable Q2 2 2
0
s
p
HDQ
U R
   (25) 1 
Dimensionless variable Q3 
 0
3
m
S
Q
K
  (26) 1 
Mass transfer Wilson-
Geankoplis correlation, kL 
  2/3 2/301.09 ReL Uk Sc  (27) 1 
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Dimensionless mass 
transfer, α 
03
p
L
R Hk
U
  (28) 1 
Substrate conversion, Χ     
10 0
0
100%S
S y S
X x
S
    (29) 1 
Correction for DS   45 1 0 0014 45.DSk DS     (30) 1 
pH correction 1 0 3 7 5
2
. .in outpH
pH pHk            (31) 1 
Flowrate F  0 e xp dF F k t    (32) 1 
Activity, Act 
0 926
100
. ln eqeq DS pH
eq
XFρ DPAct X k k
w X
        
 
(33) 1 
Productivity, P 
 0 F S dtP
w  
(34) 1 
Total Number of Eq.   32 
    
*The Flowrate is the variable which is varied during the operation in order to keep the substrate conversion (Xs) 
constant and is calculated using Eq. (32). In that case it can be seen that all the variables in the Eq. (28) are constant 
except the flowrate and the activity, so in order to keep the conversion constant the flowrate needs to decay at the 
same rate as the activity decays. The enzyme activity decay is given in dimensionless form in the Eq. (3). 
 
For the model analysis the systematic procedure proposed by Gani et al. [214] has been used. 
The total number of equations (balance equations and constitutive equations) are listed in Table 
5.51. The model consists of 21 ODEs, 32 (explicit) AEs, the total number of variables is 82 and 
the number of the variables to be specified is 29. Table 5.51 gives the degree of freedom 
analysis.  
Table 5.51 Degree of Freedom analysis of the GI reactor model. 
Type of equation Number of equations 
ODEs  21 
Algebraic 32 
Total number of variables 82 
Degree of Freedom 29 
 
Table 5.52 lists all variables of the GI reactor model, the variables to be specified have been 
classified as system variables, system parameters and as known variables. The variables to be 
calculated have been classified as algebraic variables, which are the variables, needed for the 
calculation of the right-hand side of the differential equations in order to calculate the dependent 
variables. 
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Table 5.52 Variables classification of the glucose isomerization reactor model. 
 Variables Types Symbol Number of Variables 
Total 
Number 
To be 
specified 
System Variables 
w, θ, [S]0, dp, F0, ε, ρ, μ, 
db, H, Dm, ρcat, DS, pHin, 
pHout, DP, Rp, Xi, 
18  
 
System 
Parameters 
Akmf, Akmr, Avmf, Avmr, Ad, 
Ekmf, Ekmr, Evmf, Evmr, Ed, 
10  
 Known Variables R 1 29 
To be 
calculated 
Algebraic 
(explicit) 
T, vmf, vmr, kmf, kmr, kd, Keq, 
Xeq, Vm, Km, A, U0, Rep, 
Sc, DL, Rs, Pe, Q4, Q1, Ds, 
Q2, Q3, φ, kL, α, X, Act, 
yeq, P, F, kDS, kpH 
32  
 
Dependent 
Variables 
*, ,S s Ey y y  21 53 
 
Typical values of the variables listed in Table 5.52 are given in Table 7.33 in Appendix D. 
5.4.3.3 Phase III. Model Identification/Discrimination 
The values of the system parameters for the reactor model, have been obtained from the 
literature. The kinetic parameters (Akmf, Akmr, Avmf, Avmr, Ekmf, Ekmr, Evmf, Evm, Ad, Ed) have been 
taken from [205] and they are listed in TABLE the Appendix D. The parameters for the enzyme 
decay (Ad, Ed) found in published papers are given in Table 5.53, which are to be evaluated 
through experimental data provided by Novozymes A/S.  
 
Table 5.53. Different parameter sets found in the published literature for the enzyme inactivation 
kinetics. 
 [202]  [215] [216] [206] 
Enzyme Sweetase  Sweetase Sweetzyme T Sweetzyme T 
Parameter Set A Set B Set C Set D 
Ad (d-1) 1.82 x 1025 1.51 x 1025 3.26 x 1025 1.09 x 1026 
Ed(J mol-1) 170969.10 170867.75 174710.40 176464.65 
 
The experimental data is provided from Novozymes A/S, and shows the enzyme activity with 
respect to time for the different temperatures (55oC-90oC). However, because the data is not 
reliable for temperatures above 70oC, the model is to be evaluated considering the experimental 
data at temperature range 55-70oC. The process operation conditions are given in Table 7.34 in 
Appendix D and the experimental data is presented in Figure 5.28.  
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 Figure 5.30 Enzyme activity with respect to time for temperature range 55-70oC. Enzyme: Sweetzyme 
T. Experimental data is provided by Novozymes A/S. 
In Figure 5.29-Figure 5.32, the experimental data together with the model prediction for 
different parameter sets (listed in Table 5.53) for different temperatures are presented. In the 
beginning, the experimental data at 55oC is compared with the model prediction. The results 
are presented in Figure 5.29, and it can be seen that the model prediction using the parameter 
set A and B is in good agreement with the experimental data while the model calculation using 
the parameter set C and D are not in good agreement with the experimental data.  
 
Figure 5.31 Model prediction vs. experimental data at 55oC for parameters set A-Dgiven in Table 5.53. 
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The experimental data at 60oC is then compared with the model calculation for the different 
parameter sets. The results are presented in Figure 5.30, and it can be seen that the model 
calculation using the parameter set C is in good agreement with the experimental data while 
model calculation using the parameter set A, B and D are not in good agreement with the 
experimental data. 
 
 Figure 5.32 Model prediction vs. experimental data at 60oC for parameters set A-D given in Table 
5.53. 
 
The experimental data at 65oC is compared with the model prediction for the different 
parameter sets. The results are illustrated in Figure 5.31, and it can be seen that the model 
prediction using the parameter set C is in good agreement with the experimental data while 
model prediction using the parameter set A, B and D are not in good agreement. 
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Figure 5.33 Model prediction vs. experimental data at 65oC for parameters set A-D given in Table 
5.53. 
 
The experimental data at 70oC is compared with the model prediction for the different 
parameter sets. The results are illustrated Figure 6, and it can be seen that the model prediction 
using the parameter set C is in good agreement with the experimental data while model 
prediction using the parameter set A, B and D are not in good agreement. 
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Figure 5.34 Model prediction vs. experimental data at 70oC for parameters set A-D given in Table 5.53 
 
5.4.3.3.1 Fine tuning the parameters Ad and Ed. 
Figure 5.29-Figure 5.32 compare the model prediction to the experimental data for a 
temperature range 55oC-70 oC for different inactivation parameter sets (given in Table 5.53). 
From the analysis, it can be noticed that the different parameter set can provide better or worse 
matching with the experimental data, therefore it is essential to fine-tune the parameters Ad and 
Ed in order to have a set of parameters that provides acceptable model prediction for the certain 
temperature range (55-70oC). For the fine tuning six experimental data points (given in Table 
5.54), the initial enzyme activity and the half time activity for operating temperature 55oC, 60oC 
and 70oC, are going to be used. The experimental set for 65oC is going to be used as validation 
for the fine-tuned parameters.   
 
Table 5.54 Experimental data used in fine-tuning the inactivation parameters Ad and Ed. 
Operation  
Temperature 
Time  Amax  
(IGU/gr enzyme) 
t½ 
(hrs) 
A  
(IGU/gr enzyme)  
T = 55 oC  0  195  3750  97.5  
T = 60 oC 0  262  2200  131  
T = 70 oC   0  503  500  251.5  
 
Based on the data from Table 5.54 , the parameters have been fine-tuned their values are given 
inTable 5.55. 
 
Table 5.55 Enzyme deactivation parameters Ad and Ed found in literature and the fine-tuned 
parameters. 
 [202] [215] [216] [206] This project 
Enzyme Sweetase  Sweetase Sweetzyme T Sweetzyme T Sweetzyme T 
Parameter Set A Set B Set C Set D Fine-tuned 
Ad (d-1) 1.82 x 1025 1.51 x 1025 3.26 x 1025 1.09 x 1026 3.08x1016 
Ed(J mol-
1) 
170969.10 170867.75 174710.40 176464.65 118491 
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The fined-tuned parameters are evaluated against the experimental data and the results of the 
fine-tuning are presented in Figure 5.33. 
 
 
Figure 5.35 Model prediction vs. experimental data at temperatures 55, 60 and70oC using the fine-
tuned parameters. 
As it is illustrated in Figure 5.33, the model prediction fits very well the experimental data. The 
next step now is the model validation 
5.4.3.4 Model Evaluation/Validation 
The remaining set of experimental points (at operating temperature 65oC) is used now for the 
validation of the model using the fined-tuned parameters. Figure 5.34 illustrates the model 
prediction and the experimental data at 65oC and it can be seen that the model can sufficiently 
describe the experimental measurements. The model is now validated and it can be used for 
simulations in the operating temperature range 55-70oC.  
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Figure 5.36. Model prediction versus the experimental data at 65oC using the fine-tuned parameters. 
5.4.4 Section C: Separation synthesis 
The separation of fructose from the reaction mixture is fixed in this process. Therefore, Section 
C is not investigated.  
5.4.5 Section D: Process Simulation, Evaluation and Operation 
Step D.1. Process simulation and evaluation  
Simulation I. Reactor Performance vs. Temperature. The objective of this simulation-based 
study is to determine the range of the operation temperature of the reactor. The process 
operation conditions used in this simulation are given in Table 7.35 (in Appendix D). The 
simulation is performed for different operation temperatures while the substrate concentration 
is kept constant for all the simulations. The reactor is operated at constant substrate conversion 
of 42% for 1.5 yr. without temperature increase during the operation. 
  
Figure 5.37 Relative flowrate and productivity of the GI reactor for different operating temperatures. 
Constant substrate conversion 42%. The process conditions are given in Table 7.34 (in Appendix D).  
The reactor model provides qualitatively correct and consistent results for different operating 
temperatures as highlighted in Figure 5.35. It can be noted that the production rate is higher 
when the temperature increases but also the enzyme activity (it can be seen from the relative 
inlet flowrate plot) decreases rapidly at high temperatures resulting in much lower productivity. 
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Table 5.56 Model prediction for the maximum enzyme activity, enzyme half-life, 10% 15% and the 
productivity for different operating temperatures.  
Operation Amax (IGU/gr enzyme) t½ (days) t10% (days) t15% (days) 
P 
(kg/kg enzyme) 
T = 55oC 195 180 505 433 14356 
T = 57oC 215 137 385 329 13267 
T = 58oC 232 119.5 335 288 12766 
T = 60oC 261 91.5 256 220 11652 
 
Step D.2 Process Optimization/control/monitoring and validation 
During the operation, the initial operating temperature is kept constant until the time that the 
measured remaining activity is at 10-15% of the initial enzyme activity, then in order to burn-
out the remaining enzyme the temperature increases. In this step, the temperature change during 
the operation is done by considering a step change in the temperature profile. As it had been 
shown in Simulation I, the system is very sensitive to the operating temperature as it can affect 
the enzyme activity, the question now is whether the process performance can be improved 
when the temperature is increased  by (1-2oC) during the operation? 
Simulation II. Temperature profile during the operation 
To investigate the effect of the temperature profile during the operation, four operational 
scenarios have been defined and the results are compared with the base case scenario. The 
scenarios are given in Table 5.57. 
Table 5.57 Operational scenarios to test the effect of temperature during the reaction. 
 Initial temperature Temperature profile 
Base Case 55oC Constant, when remaining activity is at 15% temperature increases to 65oC 
Scenario 1 55oC 1
oC every 100 days, when remaining activity is at 15% 
temperature increases to 65oC 
Scenario 2 55oC 2
oC every 200 days, when remaining activity is at 15% 
temperature increases to 65oC 
Scenario 3 55oC 
Operation at 55oC for 200 days, temperature increase by 2oC 
every 100 days after 200 days, when remaining activity is at 15% 
temperature increases to 65oC 
Scenario 4  55oC 
temperature increase by 1oC every 100 days for the first 300 days, 
then temperature increase 2oC every 100 days, when remaining 
activity is at 15% temperature increases to 65oC 
 
Considering the operation scenario defined in Table 5.57, the simulations were performed 
considering one reactor and the process conditions are given in Table 7.34 (in Appendix D). 
The simulation results are highlighted in Figure 5.36-Figure 5.37, where the enzyme activity 
and the corresponding temperature change are presented. Looking at the enzyme activity plots 
in Figure 5.36-Figure 5.37, the enzyme decay during the operation can be observed. In all the 
scenarios the picks in the enzyme activity profiles can be noticed, these picks are because when 
the temperature increases at a specific operating time, it causes the increase in the enzyme 
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activity but also the enzyme decay is accelerated. The corresponding step-changes in operating 
temperature for each scenario are illustrated below each of the enzyme activity plots in Figure 
5.36-Figure 5.37. 
 
 
Figure 5.38 Enzyme activity as the function of time and the corresponding temperature change (Base 
case, scenario 1, scenario 2). 
 
  
 
Figure 5.39 Enzyme activity as the function of time and the corresponding temperature change 
(scenario 3 and scenario 4). 
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The productivity for the operational scenarios of Table 5.57 is shown in Figure 5.38 where it 
can be seen that the base case scenario is performing better than the rest and that scenario 2 is 
performing well but not better than the base case. It can also be noticed in Figure 5.38 that the 
productivity for all the scenarios is higher than the productivity in the base case at operating 
time between 130-400 days, this is because when the temperature increases, the activity 
increases and the productivity rate also increases. However, at the end of the operation, the 
productivity is higher in the base case scenario because the overall enzyme inactivation in the 
base case was slower compared to the enzyme inactivation in the rest of the scenarios.  
 
Figure 5.40 The productivity for the operational scenarios given in Table 5.57. 
 
Step D.3 Process Operation 
The validated reactor model is now used to simulate a typical GI reactor plant, which consist 
of 20 parallel fixed bed reactors. Due to the enzyme inactivation, the reactor productivity rate 
is allowed to gradually decrease until the complete depletion of the enzyme activity. In order 
to maintain a steady state operation, the reactors are started at different time; this time difference 
is called “age distribution”. Therefore, the first reactor starts at time 0, then the second reactor 
starts after time t (age distribution) and so on. 
Simulation III. Reactor Plant (20 reactors).  
The simulation considers 20 reactors where the age distribution between each reactor is 27 
days, each reactor operates for 1.5 year (540 days) from the starting point of each reactor, after 
the 540 days of operation the reactor stops and it is assumed that the reactor is restarted 2 days 
after its shutdown, finally, the total simulated operation of the plant is assumed for 4 years 
(1440 days). The reaction temperature is fixed at 55oC and as it has been explained before, 
when the remaining activity is 15% of the initial the temperature increases by a step change in 
the model to 65oC for the complete burn-out of the enzyme. The process conditions are given 
in Table 7.35 (in Appendix D). The results are highlighted in Figure 5.39, where the 
productivity per reactor and the total productivity of the reactor plant are presented. In Figure 
5.39 (plot on the left) the productivity of each reactor is shown, it can be seen the different 
starting point of each reactor, the increase in productivity rate when the temperature increases 
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and finally the reactor shut-down and its restart. On the plot on the right hand side, the total 
productivity of the reactor plant, which is the summation of the productivity of each reactor 
with respect to time, is shown.   
 
Figure 5.41 Productivity per reactor as a function of the time, the age distribution, the temperature 
increase and the reactor are presented (figure on the left). Total productivity of the reactor plant (figure 
on the right). 
Figure 5.40 illustrates the average daily productivity of the plant that is the difference of the 
productivity between two days (plot on the left-hand side), it can be seen that the system reaches 
the steady state when all the reactors are in operation. During the operation, the average daily 
productivity increases when a reactor starts and decreases because of the enzyme inactivation. 
Figure 5.40 also illustrates the average daily reactor productivity where it can also be seen that 
after 1.5 year of operation, the productivity of the plant has reached the steady state. The 
deviation in the average daily productivity when the reactor plant has reached the steady state 
is 11%. 
 
Figure 5.42 The average plant productivity (figure on the left) with maximum deviation of 11% and 
the average daily reactor productivity (figure on the right). 
5.4.6 Conclusions  
A multi-scale reactor model to describe the glucose isomerization process has been developed 
within a framework for systematic mathematical model development. In one scale the model 
takes into account the enzyme decay, the reaction kinetics and the substrate diffusion in the 
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enzymatic pellet as a function of the temperature and is connected with the other scale that is 
the flow in the fixed-bed reactor. To validate the model experimental data provided by 
Novozymes A/S for the enzyme activity of the Sweetzyme T A/S was used. Model-based 
analysis performed to determine the operating temperature and the temperature profile during 
the glucose isomerization operation. Finally, the reactor model was used to simulate a typical 
GI reactor plant where 20 reactors are operated in parallel. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
6.1 Conclusions  
In this project, an integrated framework consisted of systematic model-based methods for 
pharmaceutical process development during their early stage development focusing on the 
production of small molecule pharmaceutical active ingredients has been developed. The 
objective has been to generate the required process knowledge to enhance the process 
understanding, to assist with process improvements at the early process development stages 
and to investigate opportunities for continuous manufacturing. Process system engineering 
(PSE) methods and tools, which have been successfully applied to other industries, such as the 
chemical and the petrochemical industry, have been integrated in the framework and extended 
when necessary to include process concerns related to the pharmaceutical processes.  
6.2 Main contributions 
The main contributions of this project are discussed.  
6.2.1 Integrated Framework 
The framework is able to deal with the development of processes to produce small molecule 
APIs for completely new batch or continuous processes, and to retrofit already existing 
processes, with known or unknown state-task network or flowsheet. The framework is 
integrated with systematic model-based methods and tools such as databases, modelling 
libraries, process synthesis methods, solvent selection/design/analysis tool, mathematical 
modelling tools and process evaluation tools, which are used to generate data to assist the 
decision making process and evaluate different process alternatives. The framework has been 
divided into four main sections related to process development of pharmaceutical active 
ingredients starting with the reaction pathway identification, the reaction analysis, the 
separation synthesis and finally, process evaluation and optimization.   
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6.2.2 Reaction pathway identification 
A database based on organic reactions and biochemical reactions, which provides a data-rich 
environment, has been developed for reaction pathway identification, where knowledge can be 
collected, stored, and retrieved. The focus of this database is in pharmaceutical processes and 
multiphase reactions taking place within the pharmaceutical industry, which are associated with 
processing information. The reactions in this database have been categorized in terms of the 
reaction type, target product to be produced (when single-step or multistep reactions are 
considered), reaction product, and effect of the solvent use in the reacting system. Information 
that are contained in the database is reaction conditions (temperature, pressure etc.), reaction 
compound (reagents, catalysts etc.), reaction data (conversion, selectivity, dynamic data set, 
and kinetic models), scaling information and finally batch or continuous processing. For each 
reaction entry, a description of the process exists and the references are provided.  
6.2.3 Solvent Selection 
6.2.3.1 Solvent Swap methodology 
A systematic methodology for solvent swap problems in pharmaceutical processes has been 
developed and has been integrated with overall developed framework. Using this methodology 
a list of feasible solvent candidates suitable for the swap task is generated based on criteria for 
good solvent swap and phase equilibrium analysis. The generated solvents for the swap task 
are further analysed taking into account the desired solvent properties for the next processing 
task. Thus, the list of the feasible solvent candidates is reduced and consists of solvents that are 
suitable for the swap and the subsequent operational task. The selected solvents are validated 
for the swap task through rigorous dynamic simulation of batch distillation operations that 
perform the swap task. The final selection of the swap solvent is made by analysis of the 
simulation results that also help to establish operational criteria and to compare the performance 
of different candidates as the swap solvent.  
6.2.3.2 Solvent Swap database and computer-aided tool 
A solvent swap database consisting of 21 solvents that are commonly used in pharmaceutical 
processes has been created. The database provides the necessary property values, calculated 
apriori for us in the second step of the methodology. The database can also be used as a quick 
and reliable guide for fast solvent selection for the swap process. In addition, the solvent swap 
method and associated tools have been integrated in a computer-aided tool integrated with 
ICAS-SolventPro. 
6.2.4 Batch to continuous 
Opportunities of converting batch to continuous have been investigated in this project through 
the analysis of unit operations operated in batch mode. Crystallization and reaction are the unit 
operations that are commonly used in batch mode while the rest of unit operations such as 
distillation and liquid-liquid extraction are compatible in both continuous and batch mode. 
Through process analysis, the process limitations have been identified and designs, which can 
be used to overcome these limitations, have been proposed through an information-based 
system. In this project, a database with data on continuous and batch unit operations that are 
commonly used in pharmaceutical process has been developed. The database contains 
information such as the processing part, operation mode, types of unit operation, primary and 
secondary properties and finally operation and design properties. For a given set of processing 
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concerns, the database can be used to propose whether or not an operation can be performed in 
a continuous or batch operation. 
In this project, investigation of batch to continuous operation was performed for the production 
of ibuprofen (case study 1) and for the production of L-2-aminobutyric acid (case study 3). In 
the first case study, the continuous operation of the first reaction step was identified using the 
unit operation database. For the second and third reactive steps, the benefits of continuous 
reaction were identified and designs were proposed. In the third case study, a continuous 
multiphase enzymatic membrane reactor (EMR) identified to replace the batch operation. A 
mathematical model, based on reaction kinetics was developed to evaluate the EMR design 
compared to batch one. For the final verification of the suggested designs, model-based 
methods and/or experimental validation are required.  
6.2.5 Reaction analysis and process synthesis 
In this project, great emphasis was given on the reaction analysis and the process synthesis. 
Performing the reaction analysis, limitations related to the performance of the reaction can be 
identified and solutions to overcome these limitations are suggested, for example, 
implementation of different reactor technologies, solvent selection and/or reaction conditions 
optimization. The results of reaction analysis are used to make important decisions for the 
reactor design, for recycle streams, possibilities of reaction telescoping, possibilities of 
intensified reaction-separation, to identify needs for solvent swap and defining the separation 
needs when a separation is needed. 
Process synthesis methods and tools have used in this project to identify the type of unit 
operation and to generate process alternatives that satisfy the separation objectives. In the 
separation analysis, the efficiency of unit operation is determined by detailed equilibrium 
analysis or information from literature (for example membranes), solvent selection is also 
performed when is required and the need for solvent swap is identified.  
6.2.6 Model-based analysis, design and operational improvements  
In this project, systematic modelling approaches based on first principles were developed and 
applied in the case studies. Model-based methods were used in the ibuprofen case study to 
evaluate the reaction kinetics in terms of reaction performance in different reaction conditions. 
Model-based methods were also applied to evaluate feasibility of continuous the enzyme 
multiphase membrane reactor that applied for the reaction-separation system presented in the 
case study 3. Finally, model-based analysis through simulations was performed for the 
industrial case of glucose isomerization where the enzyme performance and operation planning 
were evaluated for different operational scenarios without the need of performing new 
experiments, which in this case is very time consuming. Therefore, model-based methods can 
be used to perform analysis and evaluation of the system of interest, to perform optimization 
studies to improve the process performance, to evaluate different design and to assist and 
improve the operation planning. 
6.2.7 Process evaluation 
Process evaluation to be used as a measure for the selection of different processing alternatives, 
process designs, and reaction pathways has been integrated in the overall framework. 
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Possibilities for improvements have been identified by the process evaluation analysis and can 
be translated to optimization targets.  
6.3 Future perspectives  
The efforts to improve the pharmaceutical processes have dramatically increased over the years. 
In this project, some key research areas related to pharmaceutical process development have 
been investigated. However, there are many research fields, which require further investigation 
and development. In this section some of the research areas where application and development 
of process systems engineering methods and tools are needed, are discussed. 
Framework limitations and challenges. The implementation of the framework requires the 
use of model-based methods and tools to generate data. During the application of the framework 
several limitations and challenges might be faced related to available data, data generation and 
the use of model-based tools. A first limitation appears during the application of the reaction 
analysis section (section B of the framework) where a kinetic model is important to evaluate 
the effect of different process variables on the reaction performance and perform reaction 
optimization. However, the reaction models need first to be developed and then validated using 
experimental dynamic reaction data, that might be time consuming or difficult to generate. 
Moreover, kinetic models are required as the basis of reactor models to be rapidly used to 
evaluate different scenarios of the reactive system such as different reactor configurations or 
reactor types. Other limitations are related on using model-based methods to predict the phase 
behaviour (VLE, LLE and SLE) of multicomponent mixtures containing molecules with 
complex functional groups such as to predict the solubility of API in different solvent mixtures. 
In addition, process evaluation in terms of sustainability and economics might be difficult to be 
implemented because the lack of sustainability data for pharmaceutical compounds and the lack 
of data to develop reliable cost models for the newly developed technologies. To conclude, the 
framework needs to adopt additional predictive model-based tools or to expand the already 
developed ones in order to reduce the time required to perform additional experiments and 
consequently the time required to implement the framework. In this section, different areas 
within the framework where data gaps do exist and the adoption of tools is required is discussed 
in detail.   
Reaction improvement and analysis. Advances in reaction synthesis can lead in significant 
advances in pharmaceutical processes, as the reactions are the core of these processes. 
Extension of the developed database, with many more reactions and processing information is 
required to create an even richer data environment at the early stage process development. This 
process knowledge can be used as an input to computer-aided tools that can perform the 
retrosynthesis, to investigate and evaluate different processing alternatives. Another aspect of 
the reaction synthesis is the selection of the substrates suitable for specific reaction types. The 
selection of the optimum substrate might lead in acceleration of pharmaceutical reactions to 
enable continuous synthesis, reduction of solvent required, increased process safety and 
improvement in separation process by reducing the number of steps resulting in greener, safer 
and high product quality processes.  
Mathematical models, which are predictive in nature and can be used to evaluate 
pharmaceutical processes during the development phases are required. Dynamic models to 
describe most of the unit operations already exist and they are coupled with predictive 
thermodynamic models. However, new models for newly developed technologies such as 
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microreactor technology might need to be developed, and stored in the framework for their easy 
retrieval and reuse. These dynamic models can be used to improve the process understanding 
of the processes and be applied for process optimization, for evaluation of different operational 
scenarios (e.g. start-ups and shutdowns) and finally for evaluation and implementation of 
different control strategies. A limitation here might be in the currently available thermodynamic 
models that might not able to describe the functional groups of some of the molecules. In this 
case, experimental data and parameter regression would be needed.  
Process analytical technology (PAT) is widely used to supplement process knowledge by 
collecting data in-line to enhance the process understanding in order to improve pharmaceutical 
processes development and minimize risks. The selection of the proper process analytical 
technology has been studied by Singh et al. [177] based on a knowledge-based system which 
has to be extended to include more pharmaceutical processes such as reaction (using different 
technologies) and continuous crystallizion. 
Process intensification in pharmaceutical processes can have a high impact on the process 
development as production volume, environmental impact, production cost and energy 
requirements might be decreased. However, the advantages of process intensification must be 
shown in many cases, as the introduction of complicated equipment, especially, in a production 
line, might be problematic due to high investments risks that are associated with the 
implementation of process intensification equipment. Other concerns are related to the short 
product life and the simplicity of the multipurpose pharmaceutical batch processing. 
LCA analysis. Emphasis should be given in the evaluation of the life cycle assessment (LCA), 
which can be used to evaluate the environmental impact from the extraction of the raw material 
to the final disposal of drug and to identify possibilities for process improvements. A major 
limitation here, is that the life cycle inventory (LCI) databases should be updated with data for 
pharmaceutical compounds. 
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NOMENCLATURE 
Symbols Description  Units 
ci or[i] Concentration of compound i kmol/m3 
t time time units 
Vij 
Stroichiometric coeffienet of the compound i in j 
reaction  
K Equilibrium constant  
kj Kinetic parameter of reaction j Depending on the reaction order 
P Pressure atm 
Pi Partial pressure of i atm 
He Henry constant kmol/m3/MPa 
Aj Preexponentation factor of the reaction j Depending on the reaction order 
Ea Activation energy J/mol 
R Universal gas constant 8.314 J/mol/K 
T Temperature K 
αi/j Relative volatility - 
αaver Average relative volatility - 
P Pressure atm 
ΔΗfus Enthalpy of fusion kJ/mol 
γ Activity coefficient - 
ξ Separation factor - 
ee%  Enantiomeric selectivity  
C conversion  
S selectivity  
V Volume  
F Flowrate Amount (moles. Vol., mass) /time 
J flux  
k Mass transfer coefficient  
π pi number 8.314 
Pi Partition coefficient  
MW Molecular weight  gr/mol 
SolPar Solubility parameter  MPa1/2 
yi 
Dimensionless concentration for enzyme and 
substrate - 
ys* 
Dimensionless concentration for the substrate in the 
pellet  - 
t Time min 
rj Reaction rates  mol m-3 min-1 
S Substrate, glucose - 
E Enzyme - 
SE Complex which is formed between the enzyme and the substrate - 
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P Product, fructose - 
w Catalyst load  grcat m-3 
Vm Maximum apparent reaction rate  mol grcat -1 min-1 
Km Apparent Michaelis-Menten constant mol m-3 
kmf 
Michaelis Constant for the forward reaction 
(glucose to fructose) mol m
-3 
kmr 
Michaelis Constant for the reserve reaction 
(fructose to glucose) mol m
-3 
vmf 
maximum reaction rates for the forward reaction 
(glucose to fructose) mol grcat 
-1 min-1 
vmr 
maximum reaction rates for the reserve reaction 
(fructose to glucose mol grcat
-1 min-1 
kd Deactivation constant min-1 
θ Temperature  oC 
keq Equilibrium constant  - 
X Conversion of the substrate - 
Xeq Equilibrium conversion - 
db Bed Diameter m 
U0 Superficial velocity m min-1 
A Reactor Cross section area m2 
Fk Inlet flowrate for the reactor k (= 1, 2, …NR) m3 hr-1 
Rep Particle Reynolds number  - 
Sc  Schmidt number  - 
Dm Molecular Diffusivity  m2 min-1 
DL Dispersion Coefficient  m2 min-1 
Pe Peclet Number  - 
r Pellet radius 0<r<Rp m 
τ Dimensionless time - 
Ds Molecular diffusivity m2 min-1 
Rp Particle radius m 
k1 Dimensionless variable - 
Qi Dimensionless variables (i=1, 2, 3, 4) - 
Greek Letters   
μ viscosity kg m min-1 
ε Bed porosity - 
ρ Density kg m-3 
λ Dimensionless pellet radius  - 
ξ Dimensionless reactor length  
Φ Thiele modulus - 
α Dimensionless mass transfer - 
Vol.% Volumetric composition % 
Subscripts   
m Melting point  
i Compound i  
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OS Original solvent  
SwapS Swap solvent  
S Solute  
tot Total   
t=0 Initial time  
eq At Equilibrium   
NR Total Number of Reactions  
p particle  
b Fixed bed  
S substrate  
cat Catalyst  
aq Aqueous  
Org Organic  
Abbreviations   
VLE Vapour-Liquid Equilibria  
PSE Process systems engineering  
PAT Process analytical technology  
QbD Quality by design   
NCE New chemical entities  
CSD Crystal size distribution  
MSMPR Mixed suspension mixed product removal  
PBE Population balance equations  
DEM Discrete element method  
PBM Population balance model  
LCA Life cycle assessment  
VOC Volatile organic compounds  
NR Number of reactions   
SFILES Simplified Flowsheet Input Line Entry System  
CSTR Continuous stirred tank reactor  
PFR Plug flow reactor  
ICAS Integrated computer aided system  
NSAID Nonsteroidal anti-inflammatory drugs  
IBB Isobutylbenzene  
4-IBAP 4-isobutyl acetophenone  
API Active pharmaceutical ingredient  
CAMD Computer-aided modelcular design   
ω-ΤΑ ω-transaminase   
ODE Ordinary differential equation  
AE Algebraic equation  
PDE Partial differential equation  
SLE Solid-Liquid Equilibria  
LLE Liquid-Liquid Equilibria  
DCM Dichloromethane  
MTBE Methyl tert-butyl ether  
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ACTN Acetone  
ANSL Anisole  
MeOH Methanol  
THF Tetrahydrofuran  
EtAC Ethyl acetate  
MeTHF Methyltetrahydrofuran  
MEK Methyl ethyl ketone  
MeCN Acetonitrile  
IPA 2-propanol  
IPAc Isopropylacetate  
MIBK Methyl-isobutyl-ketone  
DMF N,N-Dimethylformamide  
NMP N-Methyl pyrrolidone  
EtOH Ethanol  
n-BuOH 1-butanol  
i-BuOH 2-methyl-1-propanol (iso butanol)  
CXX Conditional swap number XX  
VE (or I) Very easy swap  
EA (or II) Easy swap  
DF (or III) Difficult swap  
VD (or IV) Very difficult swap  
IP (or V) Impossible swap  
AP Aprotic polar  
HBD Hydrogen bond donor  
AALP Aromatic apolar or highly polar  
EPD Electorn pair donor  
AAA Aliphatic aprotic apolar  
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7 APPENDIX 
 
 
M
od
el
in
g 
an
d 
sy
nt
he
si
s o
f p
ha
rm
ac
eu
tic
al
 p
ro
ce
ss
: m
ov
in
g 
fro
m
 b
at
ch
 to
 c
on
tin
uo
us
 
 
18
2 
 
A
. C
al
cu
la
tio
n 
re
la
te
d 
to
 C
as
e 
st
ud
y 
1 
A
-I
 S
ec
tio
n 
A
: R
ea
ct
io
n 
pa
th
w
ay
 
 
Fi
gu
re
 7
.1
 R
ea
ct
io
n 
ty
pe
 d
at
ab
as
e 
re
su
lts
 w
he
n 
it 
is
 se
ar
ch
 fo
r “
M
ai
n 
Pr
od
uc
t =
 Ib
up
ro
fe
n”
 
  
Modeling and synthesis of pharmaceutical process: moving from batch to continuous 
 
183  
 
Bogdan et al. Reaction pathway for ibuprofen synthesis 
 
 
Sneal et al. Reaction pathway for ibuprofen synthesis  
 
Figure 7.2. Recently published reaction pathway for ibuprofen synthesis as they have been retrieved using the reaction type 
database.  
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A-II  Section B. Reaction analysis 
Model for the carbonylation reaction 
Phase II: Model construction  
Table 7.1 Reaction mechanism considered for the development of the carbonylation model  
No of 
Reaction  
Reaction Comments 
1.    1 3kIPBE H IBS H O  Production of the intermediate IBS (D) 
from the substrate 
IPBE(B) 
2.     2
3
k
k
IBS H Cl IBPCl  Production of the active intermediate IBPCl (E) 
from B  
3.      2 3 12
42
3PdCl PPh CkIBPCl CO H O IBN IPPA H Cl
      
 
Production of Ibuprofen 
(IBN) and the main 
impurity 3-IPPA 
(P1+P2=P) from E  
 
Table 7.2 Mass balance equations for the carbonylation step  
Compound Mass balance 
IBPE (B)    1Bdc rdt   (35) 
IBS (D)    1 2 3Ddc r r rdt   (36) 
IBPCl (E)    2 3 4Edc r r rdt   (37) 
IBN+3-
IPPA(P) 
  4Pdc rdt   (38) 
 
Table 7.3 Constitutive equations for the carbonylation step 
No of 
Reaction Reaction Rate 
1 1 1 B Hr k c c   (39) 
2  2 2 D H Clr k c c c   (40) 
3 3 3 Er k c   (41) 
4  
2
*
4 1
4 1
m
E H O
E
k c c A c
r
Kc
  (42) 
5 
    
,exp a irefi i
K
E
k A
RT
                   (43) 
 
Table 7.4 Model anaylsis for the kinetic model of the carbonylation step 
Type of equation Number of equations Equation number 
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ODE equations 4 (35)-(38) 
Algebraic 9 (39)-(42)and 4x(43) 
Total number of variables 38  
Degree of Freedom 25  
 
Table 7.5 Variables values for the kinetic model of the carbonylation step 
Depedent variable Initial Value Source Comments 
cB 0.562-2.248kmol m-3 [37]  
cD 0 [37]  
cE 0 [37]  
cP 0 [37]  
 
System Parameters Value Source Comments 
k1 Table 7.7 [37] The kinetic parameters regressed 
for different temperatures and 
the pre exponential factor and 
activation energy will be 
calculated  
k2 Table 7.7 [37] 
k3 Table 7.7 [37] 
k4 Table 7.7 [37] 
 
System Variables Value Source Comments 
ccat 
1.121x10-3-4.482x10-3 
kmol m-3 [37] - 
cH+  0.224-0.896 kmol m-3 [37] - 
cH2O  [37] - 
cCL- 0.224-0.896 kmol m-3 [37] - 
t  60 min [37] - 
PCO  3.4-7.48 MPa [37] - 
He  
Table 7.6Error! 
Reference source not 
found. 
[37] - 
R  8.314 [37] - 
TK 378K-398K [37] - 
m 0.43 [37] - 
K 0.51 [37] - 
 
Table 7.6 The Henry coefficient values of CO in a mixture of IBPE/MEK [37]. 
Mixture of IBPE 
and MEK (w/w %) 
Hex103 (kmol/m3/MPa) 
378K 388K 398K 
11% of IBPE 6.131 6.444 6.735 
22% of IBPE 5.579 5.798 6.311 
33% of IBPE 5.051 5.479 5.906 
 
Table 7.7 Regressed parameters using ICAS-MoT, carbonylation step. 
Kinetic parameter 378K 388K 398K 
k1 x 102 [m3 kmol-1 sec-1] 1.30 ± 9.04 x 10-2 1.62 ± 1.60 x 10-1 1.80 ± 1.88 x 10-1 
k2 x 102 [(m3 kmol-1)2 sec-1] 7.64  ± 5.29 x 10-1 12.70 ± 1.25 10.40 ± 1.08 
K3 x 102 [m3 kmol-1 sec-1] 0.43  ± 2.98 x 10-2 0.89 ± 8.74 x 10-2 0.28 ± 2.90 x 10-2 
k4  [(m3 kmol-1)2.43sec-1] 1.03 ± 7.17 x 10-2 1.05 ± 0.104 1.82 ± 0.19 
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Figure 7.3 Model prediction against experimental data for different temperatures IBPE 1.123kmol m-3, 
TsOH/LiCl (1:1) 0.121 kmol m-3, PCO 5.4MPa, PdCl2(PPh3)2 1.121 x 10-3 kmol m-3, PPh3 2.242 x 10-3 
kmol m-3, water 2.67 kmol m-3, MEK 1.95 x 10-5 m3. 
A-III Section C. Separation process synthesis 
For the Friedel-Crafts acylation step, the compounds involved in reaction together with some 
of their pure compound properties are listed in Table 5.10.  
Table 7.8. Pure compound properties for the compound involved in reaction step 1 (Friedel crafts 
acylation).  
Compound Role Formula MW (gr mol-1) 
Sol.Par. 
[298K] Tb (K) Tm (K) Ref 
Isobutylbenzene 
(B) Reactant C10H14 134.22 17.27 445.94 221.70 
CAPEC 
database 
Acetic 
anhydride (F) Reactant C4H6O3 102.09 22.01 412.70 200.15 
CAPEC 
database 
Hydrofluoric 
acid (A) Cat/solvent HF 20.01 15.59 292.67 189.79 
CAPEC 
database 
Acetic acid (D) By-product C2H4O2 60.05 19.01 391.05 289.81 
CAPEC 
database 
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Acetyl fluoride 
(E) By-product C2H3FO 62.04 19.55 295.64 201.76 ProPred 
4-isobutyl 
acetophenone 
(C) 
Prod/react C13H18O 190.28 17.98 550.73 285.62 ProPred 
 
Azeotropic information are listed in Table 5.11, three azeotropes have been identified. 
Table 7.9 Binary azeotropes obtained from CAPEC database 
Binary Azeotropes Tb [K] P[atm] X1 X2 Method 
Acetic acid/isobutyl benzene 434.71 3.3 0.97 0.03 Predicted using UNIFAC 
 
Based on the pure compound properties the binary ratio matrix has been constructed (see Table 
5.12) 
Table 7.10 Binary ratio matrix (Friedel crafts acylation) 
Binary pair Mw Tb Tm SolPar HFus Pvap Hvap VdV DP RG Mv 
HF/IBB 6.71 1.52 1.17 1.11 2.73 461.74 6.44 9.92 5.84 22.66 7.55 
HF/4-IBAP 9.51 1.88 1.50 1.15 2.78 44944.25 8.17 20.66 1.18 ∞ 8.97 
HF/HoAc 3.00 1.34 1.53 1.22 2.56 58.76 3.03 3.66 1.05 12.99 2.75 
HF/AcF 3.10 1.01 1.06 1.25 -0.09 1.11 3.25 ∞ ∞ ∞ 3.07 
HF/Ac2O 5.10 1.41 1.05 1.41 2.29 185.45 6.30 5.98 1.53 17.81 4.53 
IBB/4-
IBAP 1.42 1.23 1.29 1.04 1.02 97.34 1.27 2.08 4.94 ∞ 1.19 
IBB/HoAc 2.24 1.14 1.31 1.10 1.07 7.86 2.13 2.71 5.58 1.75 2.74 
IBB/AcF 2.16 1.51 1.10 1.13 -0.03 415.53 1.98 ∞ ∞ ∞ 2.46 
IBB/ Ac2O 1.31 1.08 1.11 1.27 1.19 2.49 1.02 1.66 8.94 1.27 1.66 
4-IBAP 
/HoAc 3.17 1.41 1.01 1.06 1.08 764.84 2.70 5.64 1.13 ∞ 3.26 
4-IBAP 
/AcF 2.16 1.51 1.10 1.13 -0.03 415.53 1.98 ∞ ∞ ∞ 2.46 
4-IBAP 
/Ac2O 
1.86 1.33 1.43 1.22 1.21 242.35 1.30 3.45 1.81 ∞ 1.98 
HoAc /AcF 1.03 1.32 1.44 1.03 -0.04 52.88 1.07 ∞ ∞ ∞ 1.11 
HoAc / 
Ac2O 
1.70 1.06 1.45 1.16 1.12 3.16 2.08 1.63 1.60 1.37 1.65 
AcF / Ac2O 1.65 1.40 1.01 1.13 -24.26 166.89 1.94 ∞ ∞ ∞ 1.48 
 
Based on the listed possible separation task (see Table 7.4 identified using Table 7.3), the 
objectives of the separation and process conversations. For the reaction step 1, the first 
separation after the reaction, there are two phases, the IBB rich phase and the HF rich phase, 
which contains the product. In this way, the IBB rich phase can be recycled back in the reactor 
and azeotropic separations are avoided. 
 
Table 7.11 Feasible separation tasks for Friedel crafts acylation  
Task  Separation Technique 
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HF/IBB Flash, Distillation, Prevaporation, Liquid membranes, Ultrafiltration 
HF/4-IBAP Flash, Distillation, Crystallization, Ultrafiltration 
HF/HoAc Flash/Striping, Distillation, Crystallization, Liquid membranes, 
Ultrafiltration  
HF/AcF Distillation, Ultrafiltration 
IBB/4-IBAP Distillation, Flash, Crystallization 
IBB/HoAc Distillation, Crystallization, Liquid membranes, Ultrafiltration 
IBB/AcF Distillation, Flash operation, Ultrafiltration 
4-IBAP /HoAc Distillation, Flash operation, Ultrafiltration,  
4-IBAP /AcF Distillation, Flash operation, Ultrafiltration, 
HoAc /AcF Distillation, Flash operation, crystallization 
 
 By combining the separation tasks, the list of separation process alternatives is generated and 
listed in Table 5.13. 
 
Table 7.12 Generated process flowsheets (Firedel-Crafts reaction) where A: HF, B: IBB, C: IBAP, D: 
AcOH, E: AcF, F: Ac2O 
 Generated SFILES 
1 
(iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsAE/FBC)2[oFDBC](dsFDB/C) 
[oFDB][oC] 
2 (iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsAEFD/BC)2[oBC](dsB/C)[oB][oC] 
3 
(iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsA/BCDEF)2(dsEFD/BC)[oEFD] 
[oBC](dsB/C)[oB][oC] 
4 (iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsAEFD/BC)2[oBC](crB/C) [oB][oC] 
5 (iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(dsAEFD/BC)2[oBC](fB/C) [oB][oC] 
6 
(iB)(iAC)(rABC/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(prevA/BCDEF)2[oBCDEF](dsEFDB/C) 
[oEFDB][oC] 
7 (iB)(iAF)(rBFDE/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(prevA/BCDEFF)2[oBCDEF] 
(prevBCDEF/F)[oBCDEF](fE/DFBC)[oE][oFBC](D/FBC5[oFBC](FB/C)[oC](crysB/C)[oC][oB] 
8 (iB)(iAF)(rBFDE/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(prevA/BCDEFF)2[oBCDEFF] 
(prevBCDEF/F)[oBCDEF](fE/DFBC)4(D/FBC)5[oFBC](fFB/C)6[oC](fB/C)7[oC] 
9 (iB)(iAF)(rBFDE/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(prevA/BCDEFF)2[oBCDEFF] 
(prevBCDEF/F)[oBCDEF](fE/DFBC)4(DF/BC)5[oBC](B/C)6[oC] 
10 (iB)(iAF)(rBFDE/pABCDEF)<1<2(llspB/ABCDEF)1(oABCDEF)(prevA/BCDEFF)2[oBCDEFF] 
(prevBCDEF/F)[oBCDEF](fE/DFBC)4(DF/BC)5[oBC](crysB/C)6[oC] 
11 (iB)(iAF)(rBFDE/pABCDEF)<1<2 (llspB/ABCDEF)1(oABCDEF)(prevA/BCDEFF)2[oBCDEFF] 
(prevBCDEF/F)[oBCDEF](fE/DFBC)4(DF/BC)5[oBC](fB/C)6[oC] 
12 (iB)(iAF)(rBFDE/pABCDEF)<1<2 (llspB/ABCDEF)1(oABCDEF)(prevA/BCDEFF)2[oBCDEFF] 
(prevBCDEF/F)[oBCDEF](fE/DFBC)4(DFB/C)5[oC] 
13 (iB)(iAF)(rBFDE/pABCDEF)<1<2 (llspB/ABCDEF)1(oABCDEF)(prevA/BCDEFF)2[oBCDEFF] 
(prevBCDEF/F)[oBCDEF](fE/DFBC)4(fDFB/C)5[oC] 
13 (iB)(iAF)(rBFDE/pABCDEF)<1<2 (llspB/ABCDEF)1(oABCDEF)(prevABCDEF/F)[oABCDEF] 
(prevA/BCDEF)3[oBCDEF](fE/DFBC)4(D/FBC)5[oFBC](F/BC)6[oBC](B/C)7[oC] 
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Table 7.13 Generated SFILES for the sectond reactive step (Hydrogenation Step, solvent-free reaction) 
 Generated SFILES 
1 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(E/CB) [oCB](C/B)[oC] 
2 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(E/CB)[oFCB](C/B)[oB][oC] 
3 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(E/CB)[oFCB](C/B)[oB][oC] 
4 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(E/CB)[oE][oCB](C/B)[oC][oB] 
5 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(EC/B)[oEC](E/C)[oE][oC] 
6 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(EC/B)[oEC](E/C)[oE][oC] 
7 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(EC/B)[oEC](E/C)[oE][oC] 
8 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(EC/B)[oEC]crys(E/C)[oE][oC] 
9 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(EC/B)[oEC](prevE/C)[oE][oC] 
10 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(EC/B)[oEC](prevE/C)[oE][oC] 
11 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(EC/B)[oEC](prevE/C)[oE][oC] 
12 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(EC/B)[oEC](prevE/C)[oE][oC] 
13 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)(EC/B)[oEC](lmemE/C)[oE][oC] 
14 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)prevE/CB[oE][oCB](C/B)[oB][oC] 
15 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)prevE/CB[oE][oCB](C/B)[oB][oC] 
16 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)prevE/CB[oE][oCB](C/B)[oB][oC] 
17 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)lmemE/CB[oE] [oCB](C/B)[oB][oC] 
18 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)lmemE/CB[oE][oCB](C/B)[oB][oC] 
19 (iA)(iB)(rAB/pABCE)(fA/ECB)(oECB)lmemE/CB[oE][oCB](C/B)[oB][oC] 
 
 
 
 
Figure 7.4 Solid-liquid equilibrium of Ibuprofen and IPBE 
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Solvent evaluation for different crystallization solvent for ibuprofen crystallization is illustrated in Figure 7.5 
 
Figure 7.5 Solid-liquid equilibrium for Ibuprofen in different solvents. Calculated using ICAS-SolventPro 
 
A-IV Section D. Process evaluation/optimization 
The mass and energy balances for the carbonylation step, are given in Table 7.8-Table 7.10. 
Table 7.14 Mass and Energy balances for crabonylation step (Part A) 
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Table 7.15 Mass and Energy balances for crabonylation step (Part B) 
 
Table 7.16 Mass and Energy balances for crabonylation step (Part C) 
 
 
 
. 
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B. Calculations related to case study 2 
B-I Example A. 6-hydroxybuspiron 
B-I-1. Detailed calculation of solubility limits 
The solubility limits are calculated from solute solubility data as a function of temperature and 
solvent-swap solvent mixture composition (for example, see Figure 5.15 in the main text). This 
limit is important to avoid precipitation of the solute during the solvent swap operation. The 
calculation procedure is given below: 
Step 1. Select Temperature. 
The solubility of a solute in a solvent is function of the temperature, with solubility usually 
increasing with temperature. However, the effect of solvent mixture composition on the 
solubility of the solute at a fixed temperature needs to be established for each solvent pair so 
that the solubility limit (saturation point) need to be identified.  
Example: Let us assume that we have a mixture of solute S with an original solvent S2 and a 
swap solvent S1. Batch distillation is going to be used as the solvent swap operation. Select a 
temperature that is lower than the operating temperature, for example, 300K. 
Step 2. Collect or generate solid saturation data to determine a saturation correlation 
Collect data (or generate data through model-based SLE calculation tool) for solute solubility 
at a fixed temperature and at different solvent mixture compositions. Use the obtained data to 
find a correlation matching the data (see Figure 7.5). Now we have the equation that calculates 
the solubility of the solute as a function of the solvent mixture at a selected temperature that is 
lower than the operating temperature of the distillation operation.  
 
Figure 7.6 Solute solubility with respect the solvent mixture composition 
Step 3. Simulation  
erform simulations of the batch distillation operation for solvent swap. Use the concentration 
profiles obtained from simulation runs to retrieve the transient solute concentration responses. 
Also, use the correlation  obtained in Step 2 to calculate the solid saturation composition. If the 
solute concentration in the batch distillation is higher than the estimated solute saturation 
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composition then precipitation of the solid is likely to occur. Different solubility limits can be 
selected using this procedure.  
B-I.2 Recovery calculation 
The following equation is used for the calculation of the product recovery during crystallization 
 ( ) ( )Recovery 100%
( )
Initialamount kg amount in mother liquid kg x
Initialamount kg
   (44) 
Calculation Example 1 
Consider Figure 5.18 in the main text.  
Step 1. Calculate the initial amount of solute and solvents in kg 
Table 5.30 gives the composition and the amount of the component after the end of the swap 
operation. The amount of the product is 0.0204 kmol which corresponds to 8.2 kg 
(MWsolute=401.5 kg/kmol) and the total amount of solvents is 1.39 kmol (92 kg).  
Step 2. Calculate the amount of solute in the mother liquor 
When cooling at 285K, the composition of solute in the mother liquor is 0.010 mol% (see Figure 
5.18). Considering that the amount of the solvents has not changed, the amount of solute in the 
mother liquor is calculated to be 5.65 kg. 
Step 3. Calculate the maximum potential recovery 
Using the equation (44), the recovery is calculated  
8.2 5.65( ) 2.55
Recovery 100% 100% 31%
8.2( ) 8.2
kg x x
kg
    
B-I.3 Regression of NRTL-SAC parameters 
The parameter regression was performed through ICAS-Solvent Pro. The experimental data 
used for the parameter regression is given in Table 7.11 and retrieved from Watson et al. [190]. 
Table 7.17 Experimental solubility data in 13 solvents [190]. 
Solvent  Solubility (mg/ml) 6-hydroxybuspirone 
Solubility (mg/ml)  
Buspirone 
Solubility (mg/ml) 
Diol 
DCM 446 678 0.4 
Anisole 93 280 0.1 
THF 301 277 3.4 
DCE 260 242 0.2 
Toluene 32 189 0.0 
EthOAc 34 116 11 
Acetone 22 88 0.2 
MIBK 16 65 0.1 
nBuOH 23 59 0.3 
EtOH 27 54 0.2 
MeCN 14 49 0.1 
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MTBE 14 24 0.1 
IPA 11 21 0.2 
 
Then the identified parameters are used to predict the solubility of 6-hydroxybuspirone in the 
remaining solvents. The predictions are shown in Figure 5.14 where the empty circles represent 
the solid solubility data in the eight pure solvents that were used for the regression step and the 
solid circles represent the predicted solid solubility values in the remaining pure solvents. The 
results are used to predict the solid saturation curves in different solvents as a function of 
temperature as shown in Figure 5.15. 
B-I.4 Simulation results for ethanol and butanol  
Swap solvent: Ethanol (EtOH) 
Calculation of the solute saturation profile in different mixture composition at different 
temperatures. 
 
 
Figure 7.7 Saturation solubility of the solute as a function of the solvent mixture composition (EtOH-
THF) for different temperatures (l figure on the left). Saturation solubility of the solute as a function of 
the temperature for different solvent mixture (EtOH-THF) composition (figure on the right). 
 
The initial and final composition of the different charges during the operation is given in Table 
7.12. The amount of the original solvents and the solute is given in Table 7.12. Swap solvent 
(Ethanol) is added in amount of 69kg per charge.  
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Table 7.18 Composition table for the batch distillation operation considering Ethanol as the swap 
solvent. 
Compounds 
Composition 1st charge 
(mol %) 
Composition 2nd charge 
(mol %) 
Composition 3rd charge 
(mol %) 
Start End Start End Start End 
MTBE 0.049 0.02 0.010 0.000  0.000 0.00 
THF 0.571 0.471 0.218 0.109 0.069 0.030 
EtOH 0.374 0.490 0.764 0.879 0.922 0.957 
Solute 5.00 x 10-3 0.019 7.00 x 10-3 0.013 0.009 0.14 
Total amount in 
kmoles 4.04 1.05 2.79 1.56 2.31 1.50 
 
In Figure 7.7, the volumetric composition of the still during the total operation is presented as 
well as the corresponding saturation curves for the recovery calculation after the end of the 
operation. 
 
Figure 7.8 (a) Volumetric composition in the batch still during the second run and (b) calculation of 
the maximum potential recovery based on the corresponding SLE curve. 
 
Swap solvent: BuOH (BuOH) 
In Figure 7.8 the calculation of the solute saturation profile in different mixture composition at 
different temperatures is shown. 
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Figure 7.9 Saturation solubility of the solute as a function of the solvent mixture composition 
(n=BuOH-THF) for different temperatures (figure on the left). Saturation solubility of the solute as a 
function of the temperature for different solvent mixture (n-BuOH-THF) composition (figure on the 
right). 
 
The initial (start) and final (end) composition of the different charges during the operation are 
given in Table 7.13. The amount of the original solvents and the solute is given in Table 7.13. 
Swap solvent (Butanol) is added in amount of 74kg per charge. 
Table 7.19 Composition table for the batch operation considering BuOH as swap solvent. 
Compounds 
Composition 1st charge 
(mol %) 
Composition 2nd charge 
(mol %) 
Start End Start End 
MTBE 0.053 0.002 0.001 0.000  
THF 0.655 0.131 0.058 0.003 
n-BuOH 0.286 0.840 0.929 0.976 
Solute 6.00 x 10-3 0.026 0.011 0.021 
Total amount in 
kmoles 3.476 0.786 1.786 0.976 
 
In Figure 7.9, the volumetric composition of the still during the total operation is presented as 
well as the corresponding saturation curves for the recovery calculation after the end of the 
operation. 
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Figure 7.10 (a) Volumetric composition in the batch still during the second run and (b) calculation of 
the maximum potential recovery based on the corresponding SLE curve. 
 
In, the volumetric composition of the still during the total operation is presented as well as the 
corresponding saturation curves for the recovery calculation after the end of the operation. 
B-II Example B. Heck reaction 
Table 7.20 Feasible swap solvent candidates that can replace DCM 
Original solvent Swap solvent candidate Solvent Swap Process Classification Vacuum effect 
DCM 
Acetic Acid Very Easy No effect 
Acetone Very Difficult No effect 
THF Easy Negative  
iso-Hexane Very difficult No effect 
Methanol Easy  No effect 
2-propanol Very easy Positive 
Toluene Very easy No effect 
Isopropyl Acetate Very easy Positive  
Anisole Very Easy Weakly positive 
Methyl isobutyl ketone Very Easy Weakly positive 
Ethyl Acetate Very easy Weakly positive 
2-Methyltetrahydrofuran Easy  Negative 
Acetonitrile Very easy No effect 
Water Very easy No effect 
N,N-Dimethylformamide  Very easy Weakly positive 
MTBE Very Difficult Weakly positive 
N-Methyl pyrrolidone Very easy No effect 
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B-III Example C. Synthesis and separation 
Table 7.21. The generated feasible original solvents that toluene can swap. 
Original Solvent 
Candidate 
Swap 
solvent
Solvent Swap Process 
Classification Vacuum effect 
DCM Toluene Very Easy No effect 
MTBE Very Easy No effect 
Acetone Very Easy Positive 
iso-Hexane Very Easy Positive 
Methanol Conditional Negative 
THF Very Easy No effect 
EtOAc Easy Weakly positive 
MeTHF Very Easy Weakly positive 
MEK Easy Weakly positive 
MeCN Conditional  No effect 
IPA Conditional Positive 
IPAc Very Difficult Weakly positive 
water Conditional Weakly negative  
 
B-IV Example D. Ketone intermediate for the LY500307 synthesis 
Table 7.22. The generated swap solvents which can replace ethyl acetate. 
Original Solvent 
Candidate 
Swap solvent Solvent Swap Process 
Classification
Vacuum effect 
EtOAc Acetic Acid Easy Weakly Positive 
 2-propanol Conditional Positive 
 Toluene  Easy Weakly Positive 
 Anisole  Very easy Weakly Positive 
 MIBK Easy  Weakly Negative 
 NMP Easy  No effect 
 Water Conditional No effect 
 DMF Very easy Weakly Positive 
 Ethanol  Difficult  Positive 
 1-butanol  Very easy  Weakly Positive 
 2-methyl-1-
propanol 
Very easy No effect 
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C. Calculations related to case study 3 
C-I  Model development for reaction-separation equipment. 
Phase I: Functional Description 
 
Figure 7.11. System description for EMR, reaction-separration systems 
Phenomena: 
1. Equilibrium controlled reaction (by product enzyme inhibition) 
2. Mass transfer aqueous-organic phase 
3. Membrane separation  
 
Phase II: Model construction 
Table 7.23. Mass balance equation for EMR, reaction-separration systems 
Description Equation Number of equations 
Balance Equations   
Reaction in aqueous 
phase 
 ,0 ; ,B,C,Di i aqi i i
aq
c c Fdc v r J where i A
dt V
     4 
Initial conditions ,00 ; ,B,C,Di it c c where i A     
Extraction 
 ,org, 0 ,org, aqV ; ,B,C,Di i orgi org i
org org
c c Fdc
J where i A
dt V V
   4 
Initial conditions , , ,00 ; ,B,C,Di org i orgt c c where i A     
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Table 7.24 Constitutive equations for EMR, reaction-separration systems 
Description Equation  Number of equations 
Constitutive equations   
Reaction Rate  C DA B
eq
c cr k c c
K
       
  1 
Viscosity   46 10 exp ln μiEi μi μi μi μiμ x A B T C T D T       4 
Density      1 1 DρiρiT Ci i ρi ρiρ MW A B         4 
Log mean diameter   ln in outlm in out
d dd
d d
   1 
Mass transfer coefficient in 
the fiber  
1 2
1 3 3
3
, 1.62Re
i i
w i
i in
μ Dk ρL d
             
4 
Overall mass transfer 
coefficient , ,
1 1 i in i in
aq org i w i lm m out o
p d p d
K k d k d k
      
  4 
Alpha  
1
2 ; ,B,C,Dii aq org
in org
pα π r N K where i A
F F
           
  4 
Equilibrium concentration 
in the org. phase 
  *
i
1 exp1
c ; ,B,C,Daq ii
orgi
aq
i
F α L
c where i AFp F p
 

  4 
Mass transfer  
*
i
i aq org i
i
cJ k c
p
    
  4 
 
Table 7.25 Model analysis for EMR, reaction-separration systems 
Type of equation Number of equations 
ODEs  8 
Algebraic 30 
Total number of variables 112 
Degree of Freedom 74 
 
 
Table 7.26 Variables classification for EMR, reaction-separration systems 
 Variables Types Symbol Number of Variables 
Total 
Number 
To be specified System Variables ci,0, Faq, Vaq, vi, ci,0,org, Forg, 
Vorg, din, dout, Re, L, Di, pi, ko, 
r, N, Mwi, Aρi, Bρi, Cρi, Dρi, 
Aμi, Bμi, Cμi, Dμi, Eμi, T 
71  
 System Parameters k, Keq, 2  
 Known Variables π 1 74 
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To be predicted Algebraic (explicit) R, Ji, dlm, kw,i, Kaq-org,i, αi, 
ci*,ρi, μi 
30  
 Dependent 
Variables 
ci, ci,org 8 38 
 
Table 7.27 Variables values for EMR, reaction-separration systems 
  Specified Value Units 
Dependent variables    
ci  [0,0,0,0] mol/lt 
ci,org [0,0,0,0] mol/lt 
System Variables   
Faq 0.9 lt/hr 
Vaq 1 Lt 
ci ,0 [0.1,0.14,0,0] mol/lt 
ci,org,0 [0,0,0,0] mol/lt 
vi [-1, -1, 1, 1] - 
Vorg 5 Lt 
Forg 4.5 Lt/hr 
din 0.2 cm 
dout 0.6 cm 
L 1 cm 
Di [2x10-8, 2x10-8, 2x10-8, 2x10-8] cm2/hr 
pi [1.014, 1.20x105, 1.24x10-4, 2.22x105] - 
ko 0.0138 cm/hr 
km 0.324 cm/hr 
r 0.024 cm 
N 3600 - 
Re 0.02 - 
MWi [102.09, 107.15, 106.12, 103.12] gr/mol 
T 310 K 
[Aρi, Bρi, Cρi, Dρi] Table 7.29 - 
[Aμi, Bμi, Cμi, Dμi, Eμi] Table 7.29 - 
System parameters   
k 191 lt/(mol hr) 
Keq 0.434 - 
Known variables   
π 3.14 - 
 
Table 7.28. Coefficient for density calculation from ICAS 
 Aρi Bρi Cρi Dρi 
A 4.49602 0.56245 550 2 
B 0.7111 0.26525 683.5 0.13446 
C 1.11898 0.25625 688 0.4249 
D 0.79368 0.25711 695 0.2863 
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Table 7.29 Coefficient for viscosity calculation from ICAS 
 Aμi Bμi Cμi Dμi Eμi 
A -11.42 1702.18 -0.00011184 1.04x10-10 2 
B -12.192 1567.7 0.0883 0 0 
C -17.062 1609.3 0.0891 0 0 
D -11.42 1702.18 -0.00011184 1.04x10-10 2 
 
Section C. Separation Process synthesis 
Table 7.30 Pure compound properties for the compound involved in ω-transamination, where A: water, 
B: benzylamine, C: 2-oxybutyric acid, D: L-2-aminobutyric acid, BD: benzaldehyde, and F: hexane 
  MW (gr/mol) BP (K) MP (K) 
SP 
(MPa½) 
Mv 
(kmol/m3) VP RG(Å) 
A water 18 373.15 273.15 47.81 0.018  0.615 
B BA 107 458.15 227 21.7 0.109  3.837 
C OA 102.09 476.45 306.15 23.29 0.09 64.26 0 
D AABA 103.12 477.42 573.15 22.18 0.11  0 
E BD 106.12 452.15 247.15 21.6 0.102  3.751 
F Hexane 86.18 341.85 177.85 14.9 0.131  3.769 
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D. Calculation related to case study 4 
 
Table 7.31 Kinetic parameters for glucose isomerization as a function of the temperature adapted by 
[205]. 
T (K) vmf (mmol/min/lt) 
vmr  
(mmol/min/lt) 
kmf 
(mol/m3) 
kmr 
(mol/m3) Κeq Xeq 
333.15 4.75 3.11 700 450 0.98 0.49 
338.15 6.84 5.13 760 590 1.03 0.51 
343.15 9.14 7.93 850 840 1.14 0.53 
348.15 12.46 12.35 920 1110 1.22 0.55 
353.15 15.98 17.92 1020 1580 1.39 0.58 
 
Table 7.32 The Arrhenius parameters for glucose isomerization as they have been calculated from the 
data given in Table 7.32. 
j vmf vmr kmf kmr 
Aj 1.37 x 106  1.29 x 1017 5.46 x105 1.90 x 1012 
Ej 5.92 x104 8.58 x 104 1.85 x104 6.15 x 104 
 
Table 7.33 Systems Variables for the glucose isomerization reactor model 
System Variables Value Source 
w  560-3000kgrcat  Novo 
θ 55-60oC Novo 
wt%  45-52 Novo 
F0 3.6-6 m3 hr-1 Novo 
db 0.5-1.8 m Novo 
H 2.5-4.3m Novo 
ε 0.36 [211] 
Dm 1.38 x 10-4 m2 d-1 [211] 
dp 0.0002-0.0004 m [211] 
μ 0.12 kg m min-1 Correlation  
ρ 1100 kg m-3 [211] 
ρcat 1* [205] 
Rp 0.0001-0.0002 [211] 
DS 45 Novo 
DP 100 Novo 
Xi (%) 0-5 Novo 
pHout 7.4-7.6 Novo 
pHin 7.5 Novo 
R 8.314 J mol-1 K-1 - 
*included in reaction kinetics 
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Table 7.34 Process conditions for glucose isomerization 
Process Operation Variables Value Source 
Weight of Catalyst, W  560 kgrcat  Novo 
Temperature, T 55-70 oC Novo 
Inlet concentration [S]0 45-50% w/w Novo 
Initial Flowrate, F0 3.6 -17.5 m3 hr-1 Novo 
Bed Diameter, db 0.8 m Novo 
Bed length, H 3.3 m Novo 
 
 
Figure 7.12 Initial flowrate vs. temperature for the process variables for glucose isomerization given in 
Table 7.34. 
 
Table 7.35 Process conditions for glucose isomerization 
Process Operation Variables Value Source 
Weight of Catalyst, W  3000 kgrcat  Novo 
Temperature, T 55 oC Novo 
Inlet concentration [S]0 50% w/w Novo 
Initial Flowrate, F0 15.5 m3 hr-1 Novo 
Bed Diameter, db 1.6 m Novo 
Bed length, H 5 m Novo 
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